



Kent Academic Repository

Alexander, Stephen P. H., Fabbro, Dorian, Kelly, Eamonn, Mathie, Alistair A., Peters, John A., Veale, Emma L., Armstrong, Jane F., Faccenda, Elena, Harding, Simon D., Davies, Jamie A. and others (2023) *The Concise Guide to PHARMACOLOGY 2023/24: Transporters*. *British Journal of Pharmacology*, 180 (S2). S374-S469. ISSN 0007-1188.

Downloaded from

<https://kar.kent.ac.uk/114873/> The University of Kent's Academic Repository KAR

The version of record is available from

<https://doi.org/doi:10.1111/bph.16182>

This document version

Publisher pdf

DOI for this version

Licence for this version

CC BY (Attribution)

Additional information

Versions of research works

Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.


























Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in **Title of Journal**, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries

If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

The Concise Guide to PHARMACOLOGY 2023/24: Transporters

Stephen P. H. Alexander¹ , Dorian Fabbro² , Eamonn Kelly³, Alistair A. Mathie⁴ , John A. Peters⁵ ,
Emma L. Veale⁴ , Jane F. Armstrong⁶ , Elena Faccenda⁶ , Simon D. Harding⁶ , Jamie A. Davies⁶ , Laura Amarosi⁷,
Catriona M. H. Anderson⁸ , Philip M. Beart⁹ , Stefan Broer¹⁰ , Paul A. Dawson¹¹ , Gergely Gyimesi¹² ,
Bruno Hagenbuch¹³ , James R. Hammond¹⁴ , Jules C. Hancox¹⁵ , Michal Hershinkel¹⁶ , Ken-ichi Inui¹⁷ ,
Yoshikatsu Kanai¹⁸, Stephan Kemp¹⁹ , Edmund R. S. Kunji²⁰ , Gavin Stewart²¹ , Sotiria Tavoulari²⁰ ,
David T. Thwaites⁸  and Tiziano Verri⁷ 



¹School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, ²PIQUR Therapeutics, Basel, 4057, Switzerland, ³School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK, ⁴School of Allied Health Sciences, University of Suffolk, Ipswich, IP4 1QJ, UK, ⁵Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, ⁶Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK, ⁷University of Salento, Lecce, Italy, ⁸Newcastle University, Newcastle upon Tyne, UK, ⁹Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, ¹⁰Australian National University, Canberra, Australia, ¹¹Emory University, Atlanta, USA, ¹²University of Bern, Bern, Switzerland, ¹³University of Kansas, Kansas City, USA, ¹⁴University of Alberta, Edmonton, Canada, ¹⁵University of Bristol, Bristol, UK, ¹⁶Ben-Gurion University of the Negev, Beer Sheva, Israel, ¹⁷Kyoto Pharmaceutical University, Kyoto, Japan, ¹⁸Osaka University, Osaka, Japan, ¹⁹Amsterdam University, Amsterdam, The Netherlands, ²⁰University of Cambridge, Cambridge, UK, ²¹University College Dublin, Dublin, Ireland

Abstract

The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and over 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (<https://www.guidetopharmacology.org/>), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182>. Transporters are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors and enzymes. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

Conflict of interest

The authors state that there are no conflicts of interest to disclose.

© 2023 The Authors. *British Journal of Pharmacology* published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Overview: The majority of biological solutes are charged organic or inorganic molecules. Cellular membranes are hydrophobic and, therefore, effective barriers to separate them allowing the formation of gradients, which can be exploited, for example, in the generation of energy. Membrane transporters carry solutes across cell membranes, which would otherwise be impermeable to them. The energy required for active transport processes is obtained from ATP turnover or by exploiting ion gradients.

ATP-driven transporters can be divided into three major classes: P-type ATPases; F-type or V-type ATPases and ATP-binding cassette transporters. The first of these, P-type ATPases, are multimeric proteins, which transport (primarily) inorganic cations. The second, F-type or V-type ATPases, are proton-coupled motors, which can function either as transporters or as motors. Last, are ATP-binding cassette transporters, heavily involved in drug disposition as well as transporting endogenous solutes.

The second largest family of membrane proteins in the human genome, after the G protein-coupled receptors, are the SLC solute carrier family. Within the solute carrier family, there are a great variety of solutes transported, from simple inorganic ions to amino acids and sugars to relatively complex organic molecules like haem. The solute carrier family includes 65 families of almost 400 members. Many of these overlap in terms of the solutes that they carry. For example, amino acids accumulation is mediated by members of the SLC1, SLC3/7, SLC6, SLC15, SLC16, SLC17, SLC32, SLC36, SLC38 and SLC43 families. Further members of the SLC superfamily regulate ion fluxes at the plasma membrane, or solute transport into and out of cellular organelles. Some SLC family members remain orphan transporters, in as much as a physiological function has yet to be determined. Within the SLC superfamily, there is an abundance in diversity of structure. Two families (SLC3 and SLC7) only generate functional transporters as heteromeric partners, where

one partner is a single TM domain protein. Membrane topology predictions for other families suggest 3,4,6,7,8,9,10,11,12,13 or 14 TM domains. The SLC transporters include members which function as antiports, where solute movement in one direction is balanced by a solute moving in the reverse direction. Symports allow concentration gradients of one solute to allow co-transport of a second solute across a membrane. A third, relatively small group are equilibrative transporters, which allow solutes to travel across membranes down their concentration gradients. A more complex family of transporters, the SLC27 fatty acid transporters also exhibit enzymatic function. Many of the transporters also manifest electrogenic properties of ion channels.

Family structure

S376	ATP-binding cassette transporter family	S390	Proton-coupled inositol transporter	S406	SLC12 family of cation-coupled chloride transporters
S377	ABCA subfamily	S391	SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)	S407	SLC13 family of sodium-dependent sulphate/carboxylate transporters
S378	ABCB subfamily	S391	SLC3 family	S408	SLC14 family of facilitative urea transporters
S379	ABCC subfamily	S391	SLC7 family	S409	SLC15 family of peptide transporters
S380	ABCD subfamily of peroxisomal ABC transporters	S393	SLC4 family of bicarbonate transporters	S412	SLC16 family of monocarboxylate transporters
S381	ABCG subfamily	S393	Anion exchangers	S414	SLC17 phosphate and organic anion transporter family
S382	F-type and V-type ATPases	S394	Sodium-dependent HCO ₃ ⁻ transporters	S414	Type I sodium-phosphate co-transporters
S382	F-type ATPase	S394	SLC5 family of sodium-dependent glucose transporters	S414	Sialic acid transporter
S382	V-type ATPase	S395	Hexose transporter family	S415	Vesicular glutamate transporters (VGLUTs)
S383	P-type ATPases	S395	Choline transporter	S416	Vesicular nucleotide transporter
S383	P1B P-type ATPases: Cu ⁺ -ATPases	S396	Sodium iodide symporter, sodium-dependent multivitamin transporter and sodium-coupled monocarboxylate transporters	S416	SLC18 family of vesicular amine transporters
S383	P2A P-type ATPases: Ca ²⁺ -ATPases	S397	Sodium myo-inositol cotransporter transporters	S418	SLC19 family of vitamin transporters
–	P2B P-type ATPases: Ca ²⁺ -ATPases	S398	SLC6 neurotransmitter transporter family	S419	SLC20 family of sodium-dependent phosphate transporters
–	P2C P-type ATPases	S398	Monoamine transporter subfamily	S419	SLC22 family of organic cation and anion transporters
S384	Na ⁺ /K ⁺ -ATPases	S399	GABA transporter subfamily	S420	Organic cation transporters (OCT)
S384	H ⁺ /K ⁺ -ATPases	S399	Glycine transporter subfamily	S421	Organic zwitterions/cation transporters (OCTN)
S385	P4 P-type ATPases: Phospholipid-transporting ATPases	S400	Neutral amino acid transporter subfamily	S421	Organic anion transporters (OATs)
S385	P5 P-type ATPases: Mn ²⁺ -ATPases	S402	SLC8 family of sodium/calcium exchangers	S422	Urate transporter
S386	SLC superfamily of solute carriers	S403	SLC9 family of sodium/hydrogen exchangers	–	Orphan or poorly characterized SLC22 family members
S386	SLC1 family of amino acid transporters	S404	SLC10 family of sodium-bile acid co-transporters	S423	Atypical SLC22B subfamily
S386	Glutamate transporter subfamily	S404	SLC11 family of proton-coupled metal ion transporters	S424	SLC23 family of ascorbic acid transporters
S388	Alanine/serine/cysteine transporter subfamily	S405			
S389	SLC2 family of hexose and sugar alcohol transporters				
S389	Class I transporters				
S390	Class II transporters				

S425	SLC24 family of sodium/potassium/calcium exchangers	S438	SLC33 acetylCoA transporter	S451	SLC48 heme transporter
S425	SLC25 family of mitochondrial transporters	S438	SLC34 family of sodium phosphate co-transporters	S452	SLC49 family of FLVCR-related heme transporters
S426	Mitochondrial di- and tri-carboxylic acid transporter subfamily	S439	SLC35 family of nucleotide sugar transporters	S452	SLC50 sugar transporter
S426	Mitochondrial amino acid transporter subfamily	S440	SLC36 family of proton-coupled amino acid transporters	S453	SLC51 family of steroid-derived molecule transporters
S427	Mitochondrial phosphate transporters	S442	SLC37 family of phosphosugar/phosphate exchangers	S454	SLC52 family of riboflavin transporters
S428	Mitochondrial nucleotide transporter subfamily	S442	SLC38 family of sodium-dependent neutral amino acid transporters	S454	SLC53 Phosphate carriers
S429	Mitochondrial uncoupling proteins	S442	System A-like transporters	S455	SLC54 Mitochondrial pyruvate carriers
S429	Miscellaneous SLC25 mitochondrial transporters	S443	System N-like transporters	S456	SLC55 Mitochondrial cation/proton exchangers
S430	SLC26 family of anion exchangers	S443	Orphan SLC38 transporters	S456	SLC56 Sideroflexins
S430	Selective sulphate transporters	S444	SLC39 family of metal ion transporters	S457	SLC57 NiPA-like magnesium transporter family
S430	Chloride/bicarbonate exchangers	S444	SLC40 iron transporter	S457	SLC58 MagT-like magnesium transporter family
S431	Anion channels	S445	SLC41 family of divalent cation transporters	S458	SLC59 Sodium-dependent lysophosphatidylcholine symporter family
S431	Other SLC26 anion exchangers	S446	SLC42 family of Rhesus glycoprotein ammonium transporters	S458	SLC60 Glucose transporters
S432	SLC27 family of fatty acid transporters	S446	SLC43 family of large neutral amino acid transporters	S459	SLC61 Molybdate transporter family
S433	SLC28 and SLC29 families of nucleoside transporters	S447	SLC44 choline transporter-like family	S459	SLC62 Pyrophosphate transporters
S433	SLC28 family	S448	SLC45 family of putative sugar transporters	S460	SLC63 Sphingosine phosphate transporters
S434	SLC29 family	S449	SLC46 family of folate transporters	S460	SLC64 Golgi Ca ²⁺ /H ⁺ exchangers
S435	SLC30 zinc transporter family	S449	SLC47 family of multidrug and toxin extrusion transporters	S461	SLC65 NPC-type cholesterol transporters
S436	SLC31 family of copper transporters	S450		S461	SLC66 Lysosomal amino acid transporters
S437	SLC32 vesicular inhibitory amino acid transporter			S462	SLCO family of organic anion transporting polypeptides

ATP-binding cassette transporter family

Transporters → ATP-binding cassette transporter family

Overview: ATP-binding cassette transporters are ubiquitous membrane proteins characterized by active ATP-dependent movement of a range of substrates, including ions, lipids, peptides, steroids. Individual subunits are typically made up of two groups of 6TM-spanning domains, with two nucleotide-binding

domains (NBD). The majority of eukaryotic ABC transporters are 'full' transporters incorporating both TM and NBD entities. Some ABCs, notably the ABCD and ABCG families are half-transporters with only a single membrane spanning domain and one NBD, and are only functional as homo- or heterodimers.

Eukaryotic ABC transporters convey substrates from the cytoplasm, either out of the cell or into intracellular organelles. Their role in the efflux of exogenous compounds, notably chemotherapeutic agents, has led to considerable interest.

ABCA subfamily

Transporters → ATP-binding cassette transporter family → ABCA subfamily

Overview: To date, 12 members of the human ABCA subfamily are identified. They share a high degree of sequence conservation and have been mostly related with lipid trafficking in a wide range of body locations. Mutations in some of these genes have been described to cause severe hereditary diseases related with lipid transport, such as fatal surfactant deficiency or harlequin ichthyosis. In addition, most of them are hypothesized to participate in the subcellular sequestration of drugs, thereby being responsible for the resistance of several carcinoma cell lines against drug treatment [9, 11].

Nomenclature	ABCA1	ABCA3	ABCA4
Common abbreviation	ABC1, CERP	ABC3, ABCC	ABCR
HGNC, UniProt	ABCA1, O95477	ABCA3, Q99758	ABCA4, P78363
Selective ligands	bihelical apoA-I mimetic peptide 5A (Binding) [654]	–	–
Selective inhibitors	probucol [215, 798]	–	–
Comments	–	Loss-of-function mutations are associated with pulmonary surfactant deficiency	Retinal-specific transporter of N-retinylPE; loss-of-function mutations are associated with childhood-onset Stargardt disease, a juvenile onset macular degenerative disease. The earlier onset disease is often associated with the more severe and deleterious <i>ABCA4</i> variants [239]. <i>ABCA4</i> facilitates the clearance of all- <i>trans</i> -retinal from photoreceptor disc membranes following photoexcitation. <i>ABCA4</i> can also transport N-11- <i>cis</i> -retinylidene-phosphatidylethanolamine, the Schiff-base adduct of 11- <i>cis</i> -retinal; loss of function mutation cause a buildup of lipofuscin, atrophy of the central retina, and severe progressive loss in vision [593].

Nomenclature	ABCA5	ABCA6	ABCA7	ABCA12
HGNC, UniProt	ABCA5, Q8WWZ7	ABCA6, Q8N139	ABCA7, Q8IZY2	ABCA12, Q86UK0
Comments	<i>ABCA5</i> is a lysosomal protein whose loss of function compromises integrity of lysosomes and leads to intra-endolysosomal accumulation of cholesterol. It has recently been associated with Congenital Generalized Hypertrichosis Terminalis (CGHT), a hair overgrowth syndrome, in a patient with a mutation in <i>ABCA5</i> that significantly decreased its expression [164].	A recent genome wide association study identified an <i>ABCA6</i> variant associated with cholesterol levels [745].	Genome wide association studies identify <i>ABCA7</i> variants as associated with Alzheimer's Disease [339].	Reported to play a role in skin ceramide formation [861]. A recent study shows that <i>ABCA12</i> expression also impacts cholesterol efflux from macrophages. <i>ABCA12</i> is postulated to associate with <i>ABCA1</i> and LXR beta, and stabilize expression of <i>ABCA1</i> . <i>ABCA12</i> deficiency causes decreased expression of <i>Abca1</i> , <i>Abcg1</i> and <i>Nr1h2</i> [237].

Comments: A number of structural analogues are not found in man: *Abca14* ([ENSMUSG00000062017](#)); *Abca15* ([ENSMUSG00000054746](#)); *Abca16* ([ENSMUSG00000051900](#)) and *Abca17* ([ENSMUSG00000035435](#)).

ABCB subfamily

Transporters → ATP-binding cassette transporter family → ABCB subfamily

Overview: The ABCB subfamily is composed of four full transporters and two half transporters. This is the only human subfamily to have both half and full types of transporters. ABCB1 was discovered as a protein overexpressed in certain drug resistant tumor cells. It is expressed primarily in the blood brain barrier and liver and is thought to be involved in protecting cells from toxins. Cells that overexpress this protein exhibit multi-drug resistance [11, 159].

Nomenclature	ABCB1	ABCB2	ABCB3	ABCB4
Common abbreviation	MDR1, PGP1	TAP1	TAP2	PGY3
HGNC, UniProt	ABCB1 , P08183	TAP1 , Q03518	TAP2 , Q03519	ABCB4 , P21439
Comments	Responsible for the cellular export of many therapeutic drugs. The mouse and rat have two <i>Abcb1</i> genes (gene names; <i>Abcb1a</i> and <i>Abcb1b</i>) while the human has only the one gene, <i>ABCB1</i> .	Endoplasmic reticulum peptide transporter is a hetero-dimer composed of the two half-transporters, TAP1 (ABCB2) and TAP2 (ABCB3). The transporter shuttles peptides into the endoplasmic reticulum where they are loaded onto major histocompatibility complex class I (MHCI) molecules via the macromolecular peptide-loading complex and are eventually presented at the cell surface, attributing to TAP an important role in the adaptive immune response [655].	Endoplasmic reticulum peptide transporter is a hetero-dimer composed of the two half-transporters, TAP1 (ABCB2) and TAP2 (ABCB3). The transporter shuttles peptides into the endoplasmic reticulum where they are loaded onto major histocompatibility complex class I (MHCI) molecules via the macromolecular peptide-loading complex and are eventually presented at the cell surface, attributing to TAP an important role in the adaptive immune response [655].	Transports phosphatidylcholine from intracellular to extracellular face of the hepatocyte canalicular membrane [563]. Heterozygous <i>ABCB4</i> variants contribute to mild cholestatic phenotypes, while homozygous deficiency leads to Progressive Intrahepatic Familial Cholestasis (PFIC) Type 3, and increased risk of cholesterol gallstones [335].

Nomenclature	ABCB5	ABCB6	ABCB7
Common abbreviation	–	MTABC3	ABC7
HGNC, UniProt	ABCB5 , Q2M3G0	ABCB6 , Q9NP58	ABCB7 , O75027
Comments	A drug efflux transporter that has been shown to identify cancer stem-like cells in diverse human malignancies, and is also identified as a limbal stem cell that is required for corneal development and repair [429, 790].	Putative mitochondrial porphyrin transporter [426]; other subcellular localizations are possible, such as the plasma membrane, as a specific determinant of the Langereis blood group system [328]. Loss of <i>Abcb6</i> expression in mice leads to decreased expression and activity of CYP450 [116].	Mitochondrial; reportedly essential for haematopoiesis [583]. Deletion studies in mice demonstrate that <i>Abcb7</i> is essential in mammals and substantiate a role for mitochondria in cytosolic Fe-S cluster assembly [582].

Nomenclature	ABCB8	ABCB9	ABCB10	ABCB11
Common abbreviation	MABC1	TAPL	MTABC2	ABC16
HGNC, UniProt	ABCB8 , Q9NUT2	ABCB9 , Q9NP78	ABCB10 , Q9NRK6	ABCB11 , O95342
Ligands	–	–	–	glycochenodeoxycholic acid (Binding) (pK _i 5.2) [102]

Searchable database: <https://www.guidetopharmacology.org/>

Full Contents of ConciseGuide: <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182/full>

ABCB subfamily S378

Comments	Mitochondrial; suggested to play a role in chemoresistance of melanoma [196]. Cardiac specific deletion of <i>Abcb8</i> leads to cardiomyopathy and accumulation of mitochondrial iron, and is thus thought to modulate mitochondrial iron export [350].	A homodimeric transport complex that translocates cytosolic peptides into the lumen of lysosome for degradation [162].	Mitochondrial location; the first human ABC transporter to have a crystal structure reported [663]. ABCB10 is important in early steps of heme synthesis in the heart and is required for normal red blood cell development [53, 702].	Loss-of-function mutations are associated with progressive familial intrahepatic cholestasis type 2 [680]. ATP-dependent transport of bile acids into the confines of the canalicular space by ABCB11 (BSEP) generates an osmotic gradient and thereby, bile flow. Mutations in BSEP that decrease its function or expression cause Progressive Familial Cholestasis Type 2 (PFIC2), which in severe cases, can be fatal in the absence of a liver transplant. Drugs that inhibit BSEP function with IC ₅₀ values less than 25 μM [522] or decrease its expression [253] can cause Drug-Induced Liver Injury (DILI) in the form of cholestatic liver injury.
----------	--	--	--	---

ABCC subfamily

Transporters → ATP-binding cassette transporter family → ABCC subfamily

Overview: Subfamily ABCC contains thirteen members and nine of these transporters are referred to as the Multidrug Resistance Proteins (MRPs). The MRP proteins are found throughout nature and they mediate many important functions. They are known to be involved in ion transport, toxin secretion, and signal transduction [11, 159].

Nomenclature	ABCC1	ABCC2	ABCC3	ABCC4	ABCC5
Common abbreviation	MRP1	MRP2, cMOAT	MRP3	MRP4	MRP5
HGNC, UniProt	ABCC1, P33527	ABCC2, Q92887	ABCC3, O15438	ABCC4, O15439	ABCC5, O15440
Inhibitors	WP814 (pK _i 7.2) [588]	PAK-104P (pK _i 5.4) [124]	–	estradiol disulfate (pIC ₅₀ 6.7) [835]	compound 2 (pK _i 7.2) [627], sildenafil (pK _i 5.9) [627]
Comments	Exhibits a broad substrate specificity [44], including LTC ₄ (K _m 97 nM [451]) and estradiol-17β-glucuronide [687].	Loss-of-function mutations are associated with Dubin-Johnson syndrome, in which plasma levels of conjugated bilirubin are elevated (OMIM: 237500).	Transports conjugates of glutathione, sulfate or glucuronide [79]	Although reported to facilitate cellular cyclic nucleotide export, this role has been questioned [79]; reported to export prostaglandins in a manner sensitive to some cyclooxygenase inhibitors [604]	Although reported to facilitate cellular cyclic nucleotide export, this role has been questioned [79]

Nomenclature	ABCC6	ATP-binding cassette, sub-family C (CFTR/MRP), member 8	ABCC9	ABCC11
Systematic nomenclature	–	ABCC8	–	–
Common abbreviation	MRP6	SUR1	SUR2	MRP8
HGNC, UniProt	ABCC6, O95255	ABCC8, Q09428	ABCC9, O60706	ABCC11, Q96166
Selective inhibitors	–	repaglinide (pIC ₅₀ 7) [780]	–	–

Searchable database: <https://www.guidetopharmacology.org/>

Full Contents of ConciseGuide: <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182/full>

ABCC subfamily S379

Comments	Loss-of-function mutations in ABCC6 are associated with pseudoxanthoma elasticum (OMIM: 264800).	The sulfonyleurea drugs (acetohexamide, tolbutamide and glibenclamide) act through 'sulfonyleurea receptors'; tritiated glibenclamide can be used to identify a 140 kDa protein called SUR1 (now known as ABCC8) [603].	Associated with familial atrial fibrillation, Cantu syndrome and familial isolated dilated cardiomyopathy.	Single nucleotide polymorphisms distinguish wet vs. dry earwax (OMIM: 117800); an association between earwax allele and breast cancer risk is reported in Japanese but not European populations.
----------	--	---	--	--

Comments: ABCC7 (also known as CFTR, a 12TM ABC transporter-type protein, is a cAMP-regulated epithelial cell membrane Cl⁻ channel involved in normal fluid transport across various epithelia and can be viewed in the [Chloride channels](#)

section of the Guide. ABCC8 (ENSG0000006071, also known as SUR1, sulfonyleurea receptor 1) and ABCC9 (ENSG00000069431, also known as SUR2, sulfonyleurea receptor 2) are unusual in that they lack transport capacity but regulate the activity of

particular K⁺ channels (Kir6.1-6.2), conferring nucleotide sensitivity to these channels to generate the canonical K_{ATP} channels. ABCC13 (ENSG00000155288) is a possible pseudogene.

ABCD subfamily of peroxisomal ABC transporters

Transporters → ATP-binding cassette transporter family → ABCD subfamily of peroxisomal ABC transporters

Overview: Peroxisomes are indispensable organelles in higher eukaryotes. They are essential for the oxidation of a wide variety of metabolites, which include: saturated, monounsaturated and polyunsaturated fatty acids, branched-chain fatty acids, bile acids and dicarboxylic acids [397]. However, the peroxisomal membrane forms an impermeable barrier to these metabolites. The mammalian peroxisomal membrane harbours three ATP-binding cassette (ABC) half-transporters, named ABCD1, -2 and -3. The ABCD transporters predominantly act as homodimers to transport different acyl-CoAs.

Nomenclature	ABCD1	ABCD2	ABCD3
Common abbreviation	ALDP	ALDR	PMP70
HGNC, UniProt	ABCD1 , P33897	ABCD2 , Q9UBJ2	ABCD3 , P28288
Comments	Transports coenzyme A esters (CoA) of very long chain fatty acids (VLCFA) [746, 747]. Pathogenic variants in <i>ABCD1</i> (https://adrenoleukodystrophy.info/) result in adrenoleukodystrophy (OMIM: 300100) [396, 489].	<i>In vitro</i> experiments indicate that ABCD2 has overlapping substrate specificity with ABCD1 towards saturated and monounsaturated very long-chain fatty acids, albeit at much lower specificity. ABCD2 has affinity for the polyunsaturated fatty acids C22:6-CoA and C24:6-CoA. However, <i>in vivo</i> evidence for its true function is still lacking. No disease has yet been linked to a deficiency of ABCD2.	Transports long-chain dicarboxylic acids, branched-chain fatty acids and C27 bile acids DHC-CoA and THC-CoA [219]. In mitochondrial fatty acid deficient cells and mice, ABCD3 accepts medium and long-chain fatty acids

Comments: ABCD4 (ENSG00000119688, also known as PMP69, PXMP1-L or P70R) is located at the lysosome and is involved in the transport of vitamin B12 (cobalamin) from lysosomes into the cytosol [137].

ABCG subfamily

Transporters → ATP-binding cassette transporter family → ABCG subfamily

Overview: This family of 'half-transporters' act as homo- or heterodimers; particularly ABCG5 and ABCG8 are thought to be obligate heterodimers. The ABCG5/ABCG heterodimer sterol transporter structure has been determined [445], suggesting an extensive intracellular nucleotide binding domain linked to the transmembrane domains by a fold in the primary sequence. The functional ABCG2 transporter appears to be a homodimer with structural similarities to the ABCG5/ABCG8 heterodimer [11, 710].

Nomenclature	ABCG1	ABCG2	ABCG4	ABCG5	ABCG8
Common abbreviation	ABC8	ABCP	–	–	–
HGNC, UniProt	ABCG1 , P45844	ABCG2 , Q9UNQ0	ABCG4 , Q9H172	ABCG5 , Q9H222	ABCG8 , Q9H221
Inhibitors	–	cyclosporin A (pK _i 6.3) [565]	–	–	–
Comments	Transports sterols and choline phospholipids [400]	Exhibits a broad substrate specificity, including urate and haem, as well as multiple synthetic compounds [400].	Putative functional dependence on ABCG1	The ABCG5/ABCG8 heterodimer transports phytosterols and cholesterol [445]. Loss-of-function mutations in ABCG5 or ABCG8 are associated with sitosterolemia (OMIM: 210250).	The ABCG5/ABCG8 heterodimer transports phytosterols and cholesterol [445]. Loss-of-function mutations in ABCG5 or ABCG8 are associated with sitosterolemia (OMIM: 210250).

Comments on ATP-binding cassette transporter family: A further group of ABC transporter-like proteins have been identified to lack membrane spanning regions and are not believed to be functional transporters, but appear to have a role in protein translation [123, 569]: [ABCE1](#) (P61221, also known as OABP or 2'-5' oligoadenylate-binding protein); [ABCF1](#) (Q8NE71, also known as ABC50 or TNF- α -stimulated ABC protein); [ABCF2](#) (Q9UG63, also known as iron-inhibited ABC transporter 2) and [ABCF3](#) (Q9NUQ8).

Further reading on ATP-binding cassette transporter family

- Baker A *et al.* (2015) Peroxisomal ABC transporters: functions and mechanism. *Biochem Soc Trans* **43**: 959-65 [PMID:26517910]
- Beis K. (2015) Structural basis for the mechanism of ABC transporters. *Biochem Soc Trans* **43**: 889-93 [PMID:26517899]
- Chen Z *et al.* (2016) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. *Cancer Lett* **370**: 153-64 [PMID:26499806]
- Kemp S *et al.* (2011) Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance. *Br J Pharmacol* **164**: 1753-66 [PMID:21488864]
- Kerr ID *et al.* (2011) The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. *Br J Pharmacol* **164**: 1767-79 [PMID:21175590]
- Kloudova A *et al.* (2017) The Role of Oxysterols in Human Cancer. *Trends Endocrinol Metab* **28**: 485-496 [PMID:28410994]
- López-Marqués RL *et al.* (2015) Structure and mechanism of ATP-dependent phospholipid transporters. *Biochim Biophys Acta* **1850**: 461-475 [PMID:24746984]
- Neul C *et al.* (2016) Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. *Trends Pharmacol Sci* **37**: 904-932 [PMID:27659854]
- Peña-Solórzano D *et al.* (2017) ABCG2/BCRP: Specific and Nonspecific Modulators. *Med Res Rev* **37**: 987-1050 [PMID:28005280]
- Vauthier V *et al.* (2017) Targeted pharmacotherapies for defective ABC transporters. *Biochem Pharmacol* **136**: 1-11 [PMID:28245962]

F-type and V-type ATPases

Transporters → F-type and V-type ATPases

Overview: The F-type (ATP synthase) and the V-type (vacuolar or vesicular proton pump) ATPases, although having distinct subcellular locations and roles, exhibit marked similarities in subunit structure and mechanism. They are both composed of

a 'soluble' complex (termed F_1 or V_1) and a membrane complex (F_0 or V_0). Within each ATPase complex, the two individual sectors appear to function as connected opposing rotary motors, coupling catalysis of ATP synthesis or hydrolysis to proton trans-

port. Both the F-type and V-type ATPases have been assigned enzyme commission number [E.C. 3.6.3.14](#)

F-type ATPase

Transporters → F-type and V-type ATPases → F-type ATPase

Overview: The F-type ATPase, also known as ATP synthase or ATP phosphohydrolase (H^+ -transporting), is a mitochondrial membrane-associated multimeric complex consisting of two domains, an F_0 channel domain in the membrane and an F_1 domain extending into the lumen. Proton transport across the inner mitochondrial membrane is used to drive the synthesis of ATP, although it is also possible for the enzyme to function as an

ATPase. The ATP5O subunit (oligomycin sensitivity-conferring protein, [OSCP](#), [P48047](#)), acts as a connector between F_1 and F_0 motors.

The **F_1 motor**, responsible for ATP turnover, has the subunit composition $\alpha 3\beta 3\gamma\delta\epsilon$.

The **F_0 motor**, responsible for ion translocation, is complex in mammals, with probably nine subunits centring on A, B, and C subunits in the membrane, together with D, E, F2, F6, G2 and 8 subunits. Multiple pseudogenes for the F_0 motor proteins have been defined in the human genome.

Information on members of this family may be found in the [online database](#).

V-type ATPase

Transporters → F-type and V-type ATPases → V-type ATPase

Overview: The V-type ATPase is most prominently associated with lysosomes in mammals, but also appears to be expressed on the plasma membrane and neuronal synaptic vesicles.

The **V_1 motor**, responsible for ATP turnover, has eight subunits with a composition of A-H.

The **V_0 motor**, responsible for ion translocation, has six subunits (a-e).

Information on members of this family may be found in the [online database](#).

Further reading on V-type ATPase

Collins MP *et al.* (2020) Regulation and function of V-ATPases in physiology and disease. *Biochim Biophys Acta Biomembr* **1862**: 183341 [[PMID:32422136](#)]

Further reading on F-type and V-type ATPases

Brandt K *et al.* (2015) Hybrid rotors in F1F₀ ATP synthases: subunit composition, distribution, and physiological significance. *Biol Chem* **396**: 1031-42 [PMID:25838297]

Krah A. (2015) Linking structural features from mitochondrial and bacterial F-type ATP synthases to their distinct mechanisms of ATPase inhibition. *Prog Biophys Mol Biol* **119**: 94-102 [PMID:26140992]

Marshansky V *et al.* (2014) Eukaryotic V-ATPase: novel structural findings and functional insights.

Biochim Biophys Acta **1837**: 857-79 [PMID:24508215]

Noji H *et al.* (2017) Catalytic robustness and torque generation of the F₁-ATPase. *Biophys Rev* **9**: 103-118 [PMID:28424741]

Okuno D *et al.* (2013) Single-molecule analysis of the rotation of F₁-ATPase under high hydrostatic pressure. *Biophys J* **105**: 1635-42 [PMID:24094404]

P-type ATPases

Transporters → P-type ATPases

Overview: Phosphorylation-type ATPases (EC 3.6.3.-) are associated with membranes and the transport of ions or phospholipids. Characteristics of the family are the transient phosphorylation of the transporters at an aspartate residue and the interconversion between E1 and E2 conformations in the

activity cycle of the transporters, taken to represent 'half-channels' facing the cytoplasm and extracellular/luminal side of the membrane, respectively.

Sequence analysis across multiple species allows the definition of five subfamilies, P1-P5. The P1 subfamily includes heavy metal pumps, such as the copper ATPases. The P2 subfamily includes calcium, sodium/potassium and proton/potassium pumps. The P4 and P5 subfamilies include putative phospholipid flippases.

P1B P-type ATPases: Cu⁺-ATPases

Transporters → P-type ATPases → P1B P-type ATPases: Cu⁺-ATPases

Overview: Copper-transporting ATPases convey copper ions across cell-surface and intracellular membranes. They consist of eight TM domains and associate with multiple copper chaperone proteins (*e.g.* ATOX1, O00244).

Information on members of this family may be found in the [online database](#).

P2A P-type ATPases: Ca²⁺-ATPases

Transporters → P-type ATPases → P2A P-type ATPases: Ca²⁺-ATPases

Overview: The sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase (SERCA) is an intracellular membrane-associated pump for sequestering calcium from the cytosol into intracellular organelles, usually associated with the recovery phase following excitation of muscle and nerves.

The plasma membrane Ca²⁺-ATPase (PMCA) is a cell-surface pump for extruding calcium from the cytosol, usually associated with the recovery phase following excitation of cells. The active pump is a homodimer, each subunit of which is made up of ten

TM segments, with cytosolic C- and N-termini and two large intracellular loops.

Secretory pathway Ca²⁺-ATPases (SPCA) allow accumulation of calcium and manganese in the Golgi apparatus.

Information on members of this family may be found in the [online database](#).

Searchable database: <https://www.guidetopharmacology.org/>

Full Contents of ConciseGuide: <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182/full>

P-type ATPases S383

Comments: The fungal toxin [ochratoxin A](#) has been described to activate SERCA in kidney microsomes [131]. [Cyclopiazonic acid](#) [651], [thapsigargin](#) [478] and [BHQ](#) are widely employed to block SERCA. Thapsigargin has also been described to block the TRPV1 vanilloid receptor [726].

The stoichiometry of flux through the PMCA differs from SERCA, with the PMCA transporting 1 Ca²⁺ while SERCA transports 2 Ca²⁺.

Loss-of-function mutations in SPCA1 appear to underlie Hailey-Hailey disease [344].

Na⁺/K⁺-ATPases

[Transporters](#) → [P-type ATPases](#) → [P2C P-type ATPases](#) → [Na⁺/K⁺-ATPases](#)

Overview: The cell-surface Na⁺/K⁺-ATPase is an integral membrane protein which regulates the membrane potential of the cell by maintaining gradients of Na⁺ and K⁺ ions across the plasma membrane, also making a small, direct contribution to membrane potential, particularly in cardiac cells. For every mol-

ecule of ATP hydrolysed, the Na⁺/K⁺-ATPase extrudes three Na⁺ ions and imports two K⁺ ions. The active transporter is a heteromultimer with incompletely defined stoichiometry, possibly as tetramers of heterodimers, each consisting of one of four large, ten TM domain catalytic α subunits and one of three smaller,

single TM domain glycoprotein β -subunits. Additional protein partners known as FXYD proteins (*e.g.* [FXYD2](#), [P54710](#)) appear to associate with and regulate the activity of the pump.

Information on members of this family may be found in the [online database](#).

Comments: Na⁺/K⁺-ATPases are inhibited by [ouabain](#), and cardiac glycosides such as [digoxin](#), as well as potentially endogenous cardiotonic steroids [41].

H⁺/K⁺-ATPases

[Transporters](#) → [P-type ATPases](#) → [P2C P-type ATPases](#) → [H⁺/K⁺-ATPases](#)

Overview: The H⁺/K⁺ ATPase is a heterodimeric protein, made up of α and β subunits. The α subunit has 10 TM domains and exhibits catalytic and pore functions, while the β subunit has a single TM domain, which appears to be required for intracellular trafficking and stabilising the α subunit. The ATP4A and ATP4B subunits are expressed together, while the ATP12A subunit is suggested to be expressed with the $\beta 1$ (ATP1B1) subunit of the Na⁺/K⁺-ATPase [576].

Information on members of this family may be found in the [online database](#).

Comments: The gastric H⁺/K⁺-ATPase is inhibited by proton pump inhibitors (PPIs, *e.g.* [dexlansoprazole](#) and [esomeprazole](#)) which are used to treat excessive gastric acid secretion. PPIs have a gradual onset of action. More quickly acting potassium-competitive acid blockers (P-CABs; *e.g.* [vonoprazan](#), [revaprazan](#) and [tegoprazan](#)) have now entered the clinic. P-CABs are competitive and reversible H⁺/K⁺-ATPase blockers and their effect on acid suppression is stronger and more sustained compared to PPIs.

Further reading on H⁺/K⁺-ATPases

Tanaka S *et al.* (2022) Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump. *J Med Chem* [PMID:35604136]

P4 P-type ATPases: Phospholipid-transporting ATPases

Transporters → P-type ATPases → P4 P-type ATPases: Phospholipid-transporting ATPases

Overview: These transporters are thought to translocate the aminophospholipids phosphatidylserine and phosphatidylethanolamine from one side of the phospholipid bilayer to the other to generate asymmetric membranes. They are also proposed to be involved in the generation of vesicles from intracellular and cell-surface membranes.

Information on members of this family may be found in the [online database](#).

Comments: Loss-of-function mutations in ATP8B1 are associated with type I familial intrahepatic cholestasis.

P5 P-type ATPases: Mn²⁺-ATPases

Transporters → P-type ATPases → P5 P-type ATPases: Mn²⁺-ATPases

Overview: P5 subfamily P-type ATPases are cation and lipid pumps that transport inorganic cations and other substrates across cell membranes.

Nomenclature	ATPase 13A1	ATPase cation transporting 13A2	ATPase 13A3	ATPase 13A4	ATPase 13A5
HGNC, UniProt	ATP13A1 , Q9HD20	ATP13A2 , Q9NQ11	ATP13A3 , Q9H7F0	ATP13A4 , Q4VNC1	ATP13A5 , Q4VNC0
Comments	–	–	Identified as an important component of the mammalian polyamine transport system [319].	–	–

Further reading on P5 P-type ATPases: Mn²⁺-ATPases

Hamouda NN *et al.* (2020) ATP13A3 is a major component of the enigmatic mammalian polyamine transport system. *J Biol Chem* 296, 100182 [PMID:33310703]

Further reading on P-type ATPases

Aperia A *et al.* (2016) Na⁺-K⁺-ATPase, a new class of plasma membrane receptors. *Am J Physiol, Cell Physiol* 310: C491-5 [PMID:26791490]

Briani M *et al.* (2017) The plasma membrane calcium pumps: focus on the role in (neuro)pathology. *Biochem Biophys Res Commun* 483: 1116-1124 [PMID:27480928]

Bruce JIE. (2018) Metabolic regulation of the PMCA: Role in cell death and survival. *Cell Calcium* 69: 28-36 [PMID:28625348]

Diederich M *et al.* (2017) Cardiac glycosides: From molecular targets to immunogenic cell death. *Biochem Pharmacol* 125: 1-11 [PMID:27553475]

Dubois C *et al.* (2016) The calcium-signaling toolkit: Updates needed. *Biochim Biophys Acta* 1863: 1337-43 [PMID:26658643]

Dyla M *et al.* (2019) Structural dynamics of P-type ATPase ion pumps. *Biochem Soc Trans* 47: 1247-1257 [PMID:31671180]

Dyla M *et al.* (2020) Structure and Mechanism of P-Type ATPase Ion Pumps. *Annu Rev Biochem* 89: 583-603 [PMID:31874046]

Krebs J. (2015) The plethora of PMCA isoforms: Alternative splicing and differential expression. *Biochim Biophys Acta* 1853: 2018-24 [PMID:25535949]

Little R *et al.* (2016) Plasma membrane calcium ATPases (PMCAs) as potential targets for the treatment of essential hypertension. *Pharmacol Ther* 159: 23-34 [PMID:26820758]

López-Marqués RL *et al.* (2015) Structure and mechanism of ATP-dependent phospholipid transporters. *Biochim Biophys Acta* 1850: 461-475 [PMID:24746984]

Migocka M. (2015) Copper-transporting ATPases: The evolutionarily conserved machineries for balancing copper in living systems. *IUBMB Life* **67**: 737-45 [PMID:26422816]
Padányi R *et al.* (2016) Multifaceted plasma membrane Ca(2+) pumps: From structure to intracellular Ca(2+) handling and cancer. *Biochim Biophys Acta* **1863**: 1351-63 [PMID:26707182]
Pomorski TG *et al.* (2016) Lipid somersaults: Uncovering the mechanisms of protein-mediated lipid flipping. *Prog Lipid Res* **64**: 69-84 [PMID:27528189]

Retamales-Ortega R *et al.* (2016) P2C-Type ATPases and Their Regulation. *Mol Neurobiol* **53**: 1343-54 [PMID:25631710]
Tadini-Buoninsegni F *et al.* (2017) Mechanisms of charge transfer in human copper ATPases ATP7A and ATP7B. *IUBMB Life* **69**: 218-225 [PMID:28164426]

SLC superfamily of solute carriers

Transporters → SLC superfamily of solute carriers

Overview: The SLC superfamily of solute carriers is the second largest family of membrane proteins after G protein-coupled receptors, but with a great deal fewer therapeutic drugs that exploit them. As with the ABC transporters, however, they play a major role in drug disposition and so can be hugely influential in determining the clinical efficacy of particular drugs. 48 families are identified on the basis of sequence similarities, but many of them overlap in terms of the solutes that they carry. For example, amino acid accumulation is mediated by

members of the SLC1, SLC3/7, SLC6, SLC15, SLC16, SLC17, SLC32, SLC36, SLC38 and SLC43. Further members of the SLC superfamily regulate ion fluxes at the plasma membrane, or solute transport into and out of cellular organelles.

Within the SLC superfamily, there is an abundance in diversity of structure. Two families (SLC3 and SLC7) only generate functional transporters as heteromeric partners, where one partner is a single TM domain protein. Membrane topology predictions

for other families suggest 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, or 14 TM domains. Functionally, members may be divided into those dependent on gradients of ions (particularly sodium, chloride or protons), exchange of solutes or simple equilibrative gating. For many members, the stoichiometry of transport is not yet established. Furthermore, one family of transporters also possess enzymatic activity (SLC27), while many members function as ion channels (*e.g.* SLC1A7/EAAT5), which increases the complexity of function of the SLC superfamily.

SLC1 family of amino acid transporters

Transporters → SLC superfamily of solute carriers → SLC1 family of amino acid transporters

Overview: The SLC1 family of sodium dependent transporters includes the plasma membrane located glutamate transporters and the neutral amino acid transporters ASCT1 and ASCT2 [16, 54, 387, 388, 566].

Glutamate transporter subfamily

Transporters → SLC superfamily of solute carriers → SLC1 family of amino acid transporters → Glutamate transporter subfamily

Overview: Glutamate transporters present the unusual structural motif of 8TM segments and 2 re-entrant loops [299]. The crystal structure of a glutamate transporter homologue (GltPh) from *Pyrococcus horikoshii* supports this topology and indicates that the transporter assembles as a trimer, where each monomer is a functional unit capable of substrate permeation [81, 607, 828] reviewed by [375]). This structural data is in agreement with

the proposed quaternary structure for EAAT2 [259] and several functional studies that propose the monomer is the functional unit [292, 416, 441, 626]. Recent evidence suggests that EAAT3 and EAAT4 may assemble as heterotrimers [544]. The activity of glutamate transporters located upon both neurones (predominantly EAAT3, 4 and 5) and glia (predominantly EAAT 1 and 2) serves, dependent upon their location, to regulate excitatory

neurotransmission, maintain low ambient extracellular concentrations of glutamate (protecting against excitotoxicity) and provide glutamate for metabolism including the glutamate-glutamine cycle. The Na⁺/K⁺-ATPase that maintains the ion gradients that drive transport has been demonstrated to co-assemble with EAAT1 and EAAT2 [616]. Recent evidence supports altered glutamate transport and novel roles in brain for

splice variants of EAAT1 and EAAT2 [256, 442]. Three patients with dicarboxylic aminoaciduria (DA) were recently found to have loss-of-function mutations in EAAT3 [42]. DA is characterized by excessive excretion of the acidic amino acids glutamate and aspartate and EAAT3 is the predominant glutamate/aspartate transporter in the kidney. Enhanced expression of EAAT2 resulting from administration of β -lactam antibacterials

(*e.g.* ceftriaxone) is neuroprotective and occurs through NF- κ B-mediated EAAT2 promoter activation [250, 447, 620] reviewed by [402]). PPAR γ activation (*e.g.* by rosiglitazone) also leads to enhanced expression of EAAT though promoter activation [615]. In addition, several translational activators of EAAT2 have recently been described [140] along with treatments that increase the surface expression of EAAT2 (*e.g.* [440, 860]), or prevent its

down-regulation (*e.g.* [281]). A thermodynamically uncoupled Cl⁻ flux, activated by Na⁺ and glutamate [294, 387, 482] (Na⁺ and aspartate in the case of GlTPh [625]), is sufficiently large, in the instances of EAAT4 and EAAT5, to influence neuronal excitability [725, 759]. Indeed, it has recently been suggested that the primary function of EAAT5 is as a slow anion channel gated by glutamate, rather than a glutamate transporter [243].

Nomenclature	Excitatory amino acid transporter 1	Excitatory amino acid transporter 2	Excitatory amino acid transporter 3	Excitatory amino acid transporter 4	Excitatory amino acid transporter 5
Systematic nomenclature	SLC1A3	SLC1A2	SLC1A1	SLC1A6	SLC1A7
Common abbreviation	EAAT1	EAAT2	EAAT3	EAAT4	EAAT5
HGNC, UniProt	SLC1A3 , P43003	SLC1A2 , P43004	SLC1A1 , P43005	SLC1A6 , P48664	SLC1A7 , O00341
Substrates	L-trans-2,4-pyrrolidine dicarboxylate, DL-threo- β -hydroxyaspartate (K_m 5.8 \times 10 ⁻⁵ M) [659], D-aspartic acid	DL-threo- β -hydroxyaspartate, L-trans-2,4-pyrrolidine dicarboxylate [417], D-aspartic acid	DL-threo- β -hydroxyaspartate, L-trans-2,4-pyrrolidine dicarboxylate, D-aspartic acid	DL-threo- β -hydroxyaspartate, L-trans-2,4-pyrrolidine dicarboxylate, D-aspartic acid	DL-threo- β -hydroxyaspartate, L-trans-2,4-pyrrolidine dicarboxylate, D-aspartic acid
Endogenous substrates	L-glutamic acid, L-aspartic acid	L-glutamic acid, L-aspartic acid	L-cysteine [837], L-glutamic acid, L-aspartic acid	L-glutamic acid, L-aspartic acid	L-glutamic acid, L-aspartic acid
Stoichiometry	Probably 3 Na ⁺ : 1 H ⁺ : 1 glutamate (in): 1 K ⁺ (out)	3 Na ⁺ : 1 H ⁺ : 1 glutamate (in): 1 K ⁺ (out) [454]	3 Na ⁺ : 1 H ⁺ : 1 glutamate (in): 1 K ⁺ (out) [838]	Probably 3 Na ⁺ : 1 H ⁺ : 1 glutamate (in): 1 K ⁺ (out)	Probably 3 Na ⁺ : 1 H ⁺ : 1 glutamate (in): 1 K ⁺ (out)
Inhibitors	UCPH-101 (membrane potential assay) (pIC ₅₀ 6.9) [371], DL-TBOA (pK _B 5) [659]	WAY-213613 (pIC ₅₀ 7.1) [187], DL-TBOA (pK _B 6.9) [659], SYM2081 (pK _B 5.5) [749], dihydrokainate (pK _B 5), threo-3-methylglutamate (pK _B 4.7) [749]	NBI-59159 (pIC ₅₀ 7.1) [185], L- β -BA ([³ H]D-aspartate uptake assay) (pK _i 6.1) [206], DL-TBOA (pIC ₅₀ 5.1) [661]	DL-TBOA (pK _i 5.4) [658], threo-3-methylglutamate (pK _i 4.3) [195]	DL-TBOA (pK _i 5.5) [658]
Selective allosteric modulators	–	(R)-AS-1 (Positive) (pEC ₅₀ 8) [2]	–	–	–
Labelled ligands	[³ H]JETB-TBOA (Binding) (pK _d 7.8) [660] – Rat, [³ H]D-aspartic acid, [³ H]L-aspartic acid, [³ H]SYM2081	[³ H]JETB-TBOA (Binding) (pK _d 7.8) [660] – Rat, [³ H]D-aspartic acid, [³ H]L-aspartic acid, [³ H]SYM2081	[³ H]JETB-TBOA (Binding) (pK _d 6.5) [660] – Rat, [³ H]D-aspartic acid, [³ H]L-aspartic acid	[³ H]JETB-TBOA (Binding) (pK _d 7.9) [660] – Rat, [³ H]D-aspartic acid, [³ H]L-aspartic acid	[³ H]JETB-TBOA (Binding) (pK _d 7.6) [660] – Rat, [³ H]D-aspartic acid, [³ H]L-aspartic acid

Comments: The K_B (or K_i) values reported, unless indicated otherwise, are derived from transporter currents mediated by EAATs expressed in voltage-clamped *Xenopus laevis* oocytes [195, 658, 659, 749]. K_B (or K_i) values derived in uptake assays are generally higher (*e.g.* [659]). In addition to acting as a poorly transportable inhibitor of EAAT2, (2S,4R)-4-methylglutamate, also known as SYM2081, is a competitive substrate for EAAT1 ($K_M = 54 \mu\text{M}$; [346, 749]) and additionally is a potent kainate receptor agonist [849] which renders the compound unsuitable for autoradiographic localisation of EAATs [29]. Similarly, at concentrations that inhibit EAAT2, dihydrokainate binds to kainate receptors [659]. WAY-855 and WAY-213613 are both non-

substrate inhibitors with a preference for EAAT2 over EAAT3 and EAAT1 [186, 187]. NBI-59159 is a non-substrate inhibitor with modest selectivity for EAAT3 over EAAT1 (>10-fold) and EAAT2 (5-fold) [141, 184]. Analogously, L- β -threo-benzyl-aspartate (L- β -BA) is a competitive non-substrate inhibitor that preferentially blocks EAAT3 versus EAAT1, or EAAT2 [206]. [³H]SYM2081 demonstrates low affinity binding ($K_D \cong 6.0 \mu\text{M}$) to EAAT1 and EAAT2 in rat brain homogenates [31] and EAAT1 in murine astrocyte membranes [30], whereas [³H]JETB-TBOA binds with high affinity to all EAATs other than EAAT3 [660]. The novel isoxazole derivative (-)-HIP-A may interact at the same site as TBOA and preferentially inhibit reverse transport of glutamate

[139]. Threo-3-methylglutamate induces substrate-like currents at EAAT4, but does not elicit heteroexchange of [³H]-aspartate in synaptosome preparations, inconsistent with the behaviour of a substrate inhibitor [195]. Parawixin 1, a compound isolated from the venom from the spider *Parawixia bistriata* is a selective enhancer of the glutamate uptake through EAAT2 but not through EAAT1 or EAAT3 [229, 230]. In addition to the agents listed in the table, DL-threo- β -hydroxyaspartate and L-trans-2,4-pyrrolidine dicarboxylate act as non-selective competitive substrate inhibitors of all EAATs. Zn²⁺ and arachidonic acid are putative endogenous modulators of EAATs with actions that differ across transporter subtypes (reviewed by [748]).

Alanine/serine/cysteine transporter subfamily

Transporters → SLC superfamily of solute carriers → SLC1 family of amino acid transporters → Alanine/serine/cysteine transporter subfamily

Overview: ASC transporters mediate Na⁺-dependent exchange of small neutral amino acids such as Ala, Ser, Cys and Thr and their structure is predicted to be similar to that of the glutamate transporters [34, 743]. ASCT1 and ASCT2 also exhibit thermodynamically uncoupled chloride channel activity associated with substrate transport [11, 91, 839]. Whereas EAATs counter-transport K⁺ (see above) ASCTs do not and their function is independent of the intracellular concentration of K⁺ [11, 839].

Nomenclature	Alanine/serine/cysteine transporter 1	Alanine/serine/cysteine transporter 2
Systematic nomenclature	SLC1A4	SLC1A5
Common abbreviation	ASCT1	ASCT2
HGNC, UniProt	SLC1A4 , P43007	SLC1A5 , Q15758
Endogenous substrates	L-cysteine > L-alanine = L-serine > L-threonine	L-alanine = L-serine = L-cysteine (low V _{max}) = L-threonine = L-glutamine = L-asparagine ≫ L-methionine ≅ glycine ≅ L-leucine > L-valine > L-glutamic acid (enhanced at low pH)
Stoichiometry	1 Na ⁺ : 1 amino acid (in): 1 Na ⁺ : 1 amino acid (out); (homo-, or hetero-exchange; [838])	1 Na ⁺ : 1 amino acid (in): 1 Na ⁺ : 1 amino acid (out); (homo-, or hetero-exchange; [89])
Inhibitors	–	p-nitrophenyl glutamyl anilide (pK _i 4.3) [207] – Rat, benzylcysteine (pK _i 3.1) [293], benzylserine (pK _i 3) [293]

Comments: The substrate specificity of ASCT1 may extend to L-proline and trans-4-hydroxy-proline [580]. At low pH (~5.5) both ASCT1 and ASCT2 are able to exchange acidic amino acids such as L-cysteate and glutamate [700, 743]. In addition to the inhibitors tabulated above, HgCl₂, methylmercury and mersalyl, at low micromolar concentrations, non-competitively inhibit ASCT2 by covalent modification of cysteine residues [558].

Further reading on SLC1 family of amino acid transporters

- Beart PM *et al.* (2007) Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. *Br J Pharmacol* **150**: 5-17 [PMID:17088867]
- Bjørn-Yoshimoto WE *et al.* (2016) The importance of the excitatory amino acid transporter 3 (EAAT3). *Neurochem Int* **98**: 4-18 [PMID:27233497]
- Fahlke C *et al.* (2016) Molecular physiology of EAAT anion channels. *Pflugers Arch* **468**: 491-502 [PMID:26687113]
- Fontana AC. (2015) Current approaches to enhance glutamate transporter function and expression. *J Neurochem* **134**: 982-1007 [PMID:26096891]
- Freidman N *et al.* (2020) Amino Acid Transporters and Exchangers from the SLC1A Family: Structure, Mechanism and Roles in Physiology and Cancer. *Neurochem Res* **45**: 1268-1286 [PMID:31981058]
- Grewer C *et al.* (2014) SLC1 glutamate transporters. *Pflugers Arch* **466**: 3-24 [PMID:24240778]
- Jensen AA *et al.* (2015) Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities. *Curr Opin Pharmacol* **20**: 116-23 [PMID:25466154]
- Kanai Y *et al.* (2013) The SLC1 high-affinity glutamate and neutral amino acid transporter family. *Mol Aspects Med* **34**: 108-20 [PMID:23506861]
- Takahashi K *et al.* (2015) Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease. *Cell Mol Life Sci* **72**: 3489-506 [PMID:26033496]

SLC2 family of hexose and sugar alcohol transporters

Transporters → SLC superfamily of solute carriers → SLC2 family of hexose and sugar alcohol transporters

Overview: The SLC2 family transports **D-glucose**, **D-fructose**, inositol (*e.g.* **myo-inositol**) and related hexoses. Three classes of glucose transporter can be identified, separating GLUT1-4 and 14, GLUT6, 8, 10 and 12; and GLUT5, 7, 9 and 11. Modelling suggests a 12 TM membrane topology, with intracellular termini, with functional transporters acting as homodimers or homotetramers.

Class I transporters

Transporters → SLC superfamily of solute carriers → SLC2 family of hexose and sugar alcohol transporters → Class I transporters

Overview: Class I transporters are able to transport **D-glucose**, but not **D-fructose**, in the direction of the concentration gradient and may be inhibited non-selectively by **phloretin** and **cytochalasin B**. GLUT1 is the major glucose transporter in brain, placenta and erythrocytes, GLUT2 is found in the pancreas, liver and kidneys, GLUT3 is neuronal and placental, while GLUT4 is the insulin-responsive transporter found in skeletal muscle, heart and adipose tissue. GLUT14 appears to result from gene duplication of GLUT3 and is expressed in the testes [802].

Nomenclature	Glucose transporter 1	Glucose transporter 2	Glucose transporter 3	Glucose transporter 4	Glucose transporter 14
Systematic nomenclature	SLC2A1	SLC2A2	SLC2A3	SLC2A4	SLC2A14
Common abbreviation	GLUT1	GLUT2	GLUT3	GLUT4	GLUT14
HGNC, UniProt	SLC2A1 , P11166	SLC2A2 , P11168	SLC2A3 , P11169	SLC2A4 , P14672	SLC2A14 , Q8TDB8
Substrates	dehydroascorbic acid [65], D-glucosamine (D-glucose = D-glucosamine) [739], D-glucose (D-glucose = D-glucosamine) [739]	D-glucosamine (D-glucosamine > D-glucose) [739], D-glucose (D-glucosamine > D-glucose) [739]	D-glucose	D-glucosamine (D-glucosamine ≥ D-glucose) [739], D-glucose (D-glucosamine ≥ D-glucose) [739]	–
Labelled ligands	[³H]2-deoxyglucose	[³H]2-deoxyglucose	[³H]2-deoxyglucose	[³H]2-deoxyglucose	–
Comments	GLUT1 is a class I facilitative sugar transporter. GLUT1 functions to maintain basal glucose import which is required for cellular respiration.	–	–	–	–

Class II transporters

Transporters → SLC superfamily of solute carriers → SLC2 family of hexose and sugar alcohol transporters → Class II transporters

Overview: Class II transporters transport **D-fructose** and appear to be insensitive to **cytochalasin B**. Class II transporters appear to be predominantly intracellularly located.

Nomenclature	Glucose transporter 5	Glucose transporter 7	Glucose transporter 9
Systematic nomenclature	SLC2A5	SLC2A7	SLC2A9
Common abbreviation	GLUT5	GLUT7	GLUT9
HGNC, UniProt	SLC2A5 , P22732	SLC2A7 , Q6PXP3	SLC2A9 , Q9NRM0
Substrates	D-fructose (D-fructose > D-glucose) [96], D-glucose (D-fructose > D-glucose) [96]	D-glucose [117], D-fructose [117]	D-fructose [107], uric acid [107]

Nomenclature	Glucose transporter 11	Glucose transporter 6	Glucose transporter 8	Glucose transporter 10	Glucose transporter 12
Systematic nomenclature	SLC2A11	SLC2A6	SLC2A8	SLC2A10	SLC2A12
Common abbreviation	GLUT11	GLUT6	GLUT8	GLUT10	GLUT12
HGNC, UniProt	SLC2A11 , Q9BYW1	SLC2A6 , Q9UGQ3	SLC2A8 , Q9NY64	SLC2A10 , O95528	SLC2A12 , Q8TD20
Substrates	D-glucose [174], D-fructose [492]	–	D-glucose [348]	D-glucose [449], dehydroascorbic acid [449]	D-glucose [611]

Proton-coupled inositol transporter

Transporters → SLC superfamily of solute carriers → SLC2 family of hexose and sugar alcohol transporters → Proton-coupled inositol transporter

Overview: Proton-coupled inositol transporters are expressed predominantly in the brain and can be inhibited by **phloretin** and **cytochalasin B** [739].

Nomenclature	Proton <i>myo</i> -inositol cotransporter
Systematic nomenclature	SLC2A13
Common abbreviation	HMIT
HGNC, UniProt	SLC2A13 , Q96QE2
Substrates	myo-inositol [739], D-chiro-inositol [739], muco-inositol [739], scyllo-inositol [739]
Stoichiometry	1 H ⁺ : 1 inositol (in) [167]

Further reading on SLC2 family of hexose and sugar alcohol transporters

Augustin R. (2010) The protein family of glucose transport facilitators: It's not only about glucose after all. *IUBMB Life* **62**: 315-33 [PMID:20209635]
Holman GD. (2020) Structure, function and regulation of mammalian glucose transporters of the SLC2 family. *Pflugers Arch* **472**: 1155-1175 [PMID:32591905]
Klip A *et al.* (2014) Signal transduction meets vesicle traffic: the software and hardware of GLUT4 translocation. *Am J Physiol, Cell Physiol* **306**: C879-86 [PMID:24598362]

Leney SE *et al.* (2009) The molecular basis of insulin-stimulated glucose uptake: signalling, trafficking and potential drug targets. *J Endocrinol* **203**: 1-18 [PMID:19389739]
Mueckler M *et al.* (2013) The SLC2 (GLUT) family of membrane transporters. *Mol Aspects Med* **34**: 121-38 [PMID:23506862]

SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)

Transporters → SLC superfamily of solute carriers → SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)

Overview: The SLC3 and SLC7 families combine to generate functional transporters, where the subunit composition is a disulphide-linked combination of a heavy chain (SLC3 family) with a light chain (SLC7 family) [11].

SLC3 family

Transporters → SLC superfamily of solute carriers → SLC3 and SLC7 families of heteromeric amino acid transporters (HATs) → SLC3 family

Overview: SLC3 family members are single TM proteins with extensive glycosylation of the exterior C-terminus, which heterodimerize with SLC7 family members in the endoplasmic reticulum and assist in the plasma membrane localization of the transporter.

Information on members of this family may be found in the [online database](#).

SLC7 family

Transporters → SLC superfamily of solute carriers → SLC3 and SLC7 families of heteromeric amino acid transporters (HATs) → SLC7 family

Overview: SLC7 family members may be divided into two major groups: cationic amino acid transporters (CATs) and glycoprotein-associated amino acid transporters (gpaATs).

Cationic amino acid transporters are 14 TM proteins, which mediate pH- and sodium-independent transport of cationic amino acids (system γ^+), apparently as an exchange mechanism. These transporters are sensitive to inhibition by *N*-ethylmaleimide.

Nomenclature	High affinity cationic amino acid transporter 1	Low affinity cationic amino acid transporter 2	Cationic amino acid transporter 3	L-type amino acid transporter 1	L-type amino acid transporter 2
Systematic nomenclature	SLC7A1	SLC7A2	SLC7A3	SLC7A5	SLC7A8
Common abbreviation	CAT1	CAT2	CAT3	LAT1	LAT2
HGNC, UniProt	SLC7A1 , P30825	SLC7A2 , P52569	SLC7A3 , Q8WY07	SLC7A5 , Q01650	SLC7A8 , Q9UHI5
Substrates	L-arginine, L-lysine, L-ornithine, L-histidine	L-arginine, L-lysine, L-ornithine, L-histidine	L-arginine, L-lysine, L-ornithine	–	–
Selective inhibitors	–	–	–	KYT-0353 [552]	–

Nomenclature	y+L amino acid transporter 1	y+L amino acid transporter 2	b ^{0,+} -type amino acid transporter 1	Asc-type amino acid transporter 1	Cystine/glutamate transporter	AGT1
Systematic nomenclature	SLC7A7	SLC7A6	SLC7A9	SLC7A10	SLC7A11	SLC7A13
Common abbreviation	y+LAT1	y+LAT2	b ^{0,+} AT	Asc-1	xCT	–
HGNC, UniProt	SLC7A7 , Q9UM01	SLC7A6 , Q92536	SLC7A9 , P82251	SLC7A10 , Q9NS82	SLC7A11 , Q9UPY5	SLC7A13 , Q8TCU3
Inhibitors	–	–	–	–	quisqualate (pI _{C₅₀ 5.3) [208]}	–

Comments: CAT4 appears to be non-functional in heterologous expression [[792](#)], while SLC7A14 has yet to be characterized.

Glycoprotein-associated amino acid transporters are 12 TM proteins, which heterodimerize with members of the SLC3 family to act as cell-surface amino acid exchangers.

Heterodimers between 4F2hc and LAT1 or LAT2 generate sodium-independent system L transporters. LAT1 transports large neutral amino acids including branched-chain and aromatic amino acids as well as [miglustat](#), whereas LAT2 transports most of the neutral amino acids.

Further reading on SLC7 family

Colas C. (2020) Toward a Systematic Structural and Functional Annotation of Solute Carriers Transporters-Example of the SLC6 and SLC7 Families. *Front Pharmacol* **11**: 1229 [[PMID:32973497](#)]

Kanai Y. (2021) Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. *Pharmacol Ther* 107964 [[PMID:34390745](#)]

Heterodimers between 4F2hc and y⁺LAT1 or y⁺LAT2 generate transporters similar to the system y⁺L, which transport cationic (L-arginine, L-lysine, L-ornithine) amino acids independent of sodium and neutral (L-leucine, L-isoleucine, L-methionine, L-glutamine) amino acids in a partially sodium-dependent manner. These transporters are N-ethylmaleimide-insensitive. Heterodimers between rBAT and b^{0,+}AT appear to mediate sodium-independent system b^{0,+} transport of most of the neutral amino acids and cationic amino acids (L-arginine, L-lysine and L-ornithine).

Asc-1 appears to heterodimerize with 4F2hc to allow the transport of small neutral amino acids (such as L-alanine, L-serine,

L-threonine, L-glutamine and glycine), as well as D-serine, in a sodium-independent manner.

xCT generates a heterodimer with 4F2hc for a system x⁻_{e-c} transporter that mediates the sodium-independent exchange of L-cystine and L-glutamic acid.

AGT has been conjugated with SLC3 members as fusion proteins to generate functional transporters, but the identity of a native heterodimer has yet to be ascertained.

Koppula P *et al.* (2020) Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. *Protein Cell* [[PMID:33000412](#)]

Lin W *et al.* (2020) SLC7A11/xCT in cancer: biological functions and therapeutic implications. *Am J Cancer Res* **10**: 3106-3126 [[PMID:33163260](#)]

Further reading on SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)

Bhutia YD *et al.* (2015) Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. *Cancer Res* **75**: 1782-8 [PMID:25855379]
 Fotiadis D *et al.* (2013) The SLC3 and SLC7 families of amino acid transporters. *Mol Aspects Med* **34**: 139-58 [PMID:23506863]

Palacin M *et al.* (2004) The ancillary proteins of HATs: SLC3 family of amino acid transporters. *Pflugers Arch* **447**: 490-4 [PMID:14770309]
 Palacin M *et al.* (2005) The genetics of heteromeric amino acid transporters. *Physiology (Bethesda)* **20**: 112-24 [PMID:15772300]
 Verrey F *et al.* (2004) CATs and HATs: the SLC7 family of amino acid transporters. *Pflugers Arch* **447**: 532-42 [PMID:14770310]

SLC4 family of bicarbonate transporters

Transporters → SLC superfamily of solute carriers → SLC4 family of bicarbonate transporters

Overview: Together with the SLC26 family, the SLC4 family of transporters subserve anion exchange, principally of chloride and bicarbonate (HCO_3^-), but also carbonate and hydrogen sulphate (HSO_4^-). SLC4 family members regulate bicarbonate fluxes as part of carbon dioxide movement, chyme neutralization and reabsorption in the kidney.

Within the family, subgroups of transporters are identifiable: the electroneutral sodium-independent $\text{Cl}^-/\text{HCO}_3^-$ transporters (AE1, AE2 and AE3), the electrogenic sodium-dependent HCO_3^- transporters (NBCe1 and NBCe2) and the electroneutral HCO_3^- transporters (NBCn1 and NBCn2). Topographical information derives mainly from study of AE1, abundant in erythrocytes, which

suggests a dimeric or tetrameric arrangement, with subunits made up of 13 TM domains and re-entrant loops at TM9/10 and TM11/12. The N terminus exhibits sites for interaction with multiple proteins, including glycolytic enzymes, haemoglobin and cytoskeletal elements.

Anion exchangers

Transporters → SLC superfamily of solute carriers → SLC4 family of bicarbonate transporters → Anion exchangers

Nomenclature	Anion exchange protein 1	Anion exchange protein 2	Anion exchange protein 3	Anion exchange protein 4
Systematic nomenclature	SLC4A1	SLC4A2	SLC4A3	SLC4A9
Common abbreviation	AE1	AE2	AE3	AE4
HGNC, UniProt	SLC4A1 , P02730	SLC4A2 , P04920	SLC4A3 , P48751	SLC4A9 , Q96Q91
Endogenous substrates	Cl^- , HCO_3^-	Cl^- , HCO_3^-	Cl^- , HCO_3^-	–
Stoichiometry	1 Cl^- (in) : 1 HCO_3^- (out)	1 Cl^- (in) : 1 HCO_3^- (out)	1 Cl^- (in) : 1 HCO_3^- (out)	–

Sodium-dependent HCO₃⁻ transporters

Transporters → SLC superfamily of solute carriers → SLC4 family of bicarbonate transporters → Sodium-dependent HCO₃⁻ transporters

Nomenclature	Electrogenic sodium bicarbonate cotransporter 1	Electrogenic sodium bicarbonate cotransporter 4	Electroneutral sodium bicarbonate cotransporter 1	Electroneutral sodium bicarbonate cotransporter 2	NBCBE	NaBC1
Systematic nomenclature	SLC4A4	SLC4A5	SLC4A7	SLC4A10	SLC4A8	SLC4A11
Common abbreviation	NBCe1	NBCe2	NBCn1	NBCn2	NDCBE	BTR1
HGNC, UniProt	SLC4A4 , Q9Y6R1	SLC4A5 , Q9BY07	SLC4A7 , Q9Y6M7	SLC4A10 , Q6U841	SLC4A8 , Q2Y0W8	SLC4A11 , Q8NBS3
Endogenous substrates	NaHCO ₃	NaHCO ₃	NaHCO ₃	NaHCO ₃	Cl ⁻ , NaHCO ₃	Cl ⁻ , NaHCO ₃
Stoichiometry	1 Na ⁺ : 2/3 HCO ₃ ⁻ (out) or 1 Na ⁺ : CO ₃ ^{2*}	1 Na ⁺ : 2/3 HCO ₃ ⁻ (out) or 1 Na ⁺ : CO ₃ ^{2*}	1 Na ⁺ : 1 HCO ₃ ⁻ (out) or 1 Na ⁺ : CO ₃ ^{2*}	1 Na ⁺ : 1 HCO ₃ ⁻ (out) or 1 Na : CO ₃ ^{2*}	1 Na ⁺ : 2HCO ₃ ⁻ (in) : 1 Cl ⁻ (out)	—

Further reading on SLC4 family of bicarbonate transporters

- Majumdar D *et al.* (2010) Na-coupled bicarbonate transporters of the solute carrier 4 family in the nervous system: function, localization, and relevance to neurologic function. *Neuroscience* **171**: 951-72 [PMID:20884330]
- Parker MD *et al.* (2013) The divergence, actions, roles, and relatives of sodium-coupled bicarbonate transporters. *Physiol Rev* **93**: 803-959 [PMID:23589833]
- Reithmeier RA *et al.* (2016) Band 3, the human red cell chloride/bicarbonate anion exchanger (AE1, SLC4A1), in a structural context. *Biochim Biophys Acta* **1858**: 1507-32 [PMID:27058983]
- Romero MF *et al.* (2013) The SLC4 family of bicarbonate (HCO₃⁻) transporters. *Mol Aspects Med* **34**: 159-82 [PMID:23506864]
- Thornell IM *et al.* (2015) Regulators of Slc4 bicarbonate transporter activity. *Front Physiol* **6**: 166 [PMID:26124722]

SLC5 family of sodium-dependent glucose transporters

Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters

Overview: The SLC5 family of sodium-dependent glucose transporters includes, in mammals, the Na⁺/substrate co-transporters for glucose (*e.g.* choline), D-glucose, monocarboxylates, *myo*-inositol and I⁻ [221, 248, 795, 796]. Members of the SLC5 and SLC6 families, along with other unrelated Na⁺ cotransporters (*i.e.* Mhp1 and BetP), share a common structural core that contains an inverted repeat of 5TM α -helical domains [3].

Hexose transporter family

Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters → Hexose transporter family

Overview: Detailed characterisation of members of the hexose transporter family is limited to SGLT1, 2 and 3, which are all inhibited in a competitive manner by [phlorizin](#), a natural dihydrocholine glucoside, that exhibits modest selectivity towards SGLT2 (see [795] for an extensive review). SGLT1 is predomi-

nantly expressed in the small intestine, mediating the absorption of glucose (*e.g.* [D-glucose](#)), but also occurs in the brain, heart and in the late proximal straight tubule of the kidney. The expression of SGLT2 is almost exclusively restricted to the early proximal convoluted tubule of the kidney, where it is largely

responsible for the renal reabsorption of glucose. SGLT3 is not a transporter but instead acts as a glucosensor generating an inwardly directed flux of Na⁺ that causes membrane depolarization [170].

Nomenclature	Sodium/glucose cotransporter 1	Sodium/glucose cotransporter 2	Low affinity sodium-glucose cotransporter	Sodium/glucose cotransporter 4	Sodium/glucose cotransporter 5
Systematic nomenclature	SLC5A1	SLC5A2	SLC5A4	SLC5A9	SLC5A10
Common abbreviation	SGLT1	SGLT2	SGLT3	SGLT4	SGLT5
HGNC, UniProt	SLC5A1 , P13866	SLC5A2 , P31639	SLC5A4 , Q9NY91	SLC5A9 , Q2M3M2	SLC5A10 , A0PJK1
Substrates	D-glucose [764], D-galactose [764], α-MDG [764]	α-MDG , D-glucose	1-deoxynojirimycin-1-sulfonic acid [764], N-ethyl-1-deoxynojirimycin [764], 1-deoxynojirimycin [764], miglitol [764], miglustat [764], D-glucose [764]	D-glucose , α-MDG , D-mannose	D-glucose , D-galactose
Stoichiometry	2 Na ⁺ : 1 glucose [389]	1 Na ⁺ : 1 glucose [347]	–	–	–
Selective inhibitors	mizagliflozin (pK _i 7.6) [356]	dapagliflozin (pI _{C₅₀} 9.3) [392]	–	–	–
Comments	–	–	SGLT3 acts as a glucosensor.	–	–

Comments: Recognition and transport of substrate by SGLTs requires that the sugar is a pyranose. De-oxyglucose derivatives have reduced affinity for SGLT1, but the replacement of the sugar equatorial hydroxyl group by fluorine at some positions,

excepting C2 and C3, is tolerated (see [795] for a detailed quantification). Although SGLT1 and SGLT2 have been described as high- and low-affinity sodium glucose co-transporters, respectively, recent work suggests that they have a similar affinity for

glucose under physiological conditions [347]. Selective blockers of SGLT2, and thus blocking ~50% of renal glucose reabsorption, are in development for the treatment of diabetes (*e.g.* [113]).

Choline transporter

Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters → Choline transporter

Overview: The high affinity, hemicholinium-3-sensitive, choline transporter (CHT) is expressed mainly in cholinergic neurones on nerve cell terminals and synaptic vesicles (keratinocytes being an additional location). In autonomic neurones, expression of CHT requires an activity-dependent retrograde signal from postsynaptic neurones [427]. Through recapture of

choline generated by the hydrolysis of ACh by acetylcholinesterase, CHT serves to maintain [acetylcholine](#) synthesis within the presynaptic terminal [221]. Homozygous mice engineered to lack CHT die within one hour of birth as a result of hypoxia arising from failure of transmission at the neuromuscular junction of the skeletal muscles that support respiration [220]. A low

affinity choline uptake mechanism that remains to be identified at the molecular level may involve multiple transporters. In addition, a family of choline transporter-like (CTL) proteins, (which are members of the SLC44 family) with weak Na⁺ dependence have been described [728].

Nomenclature	CHT
Systematic nomenclature	SLC5A7
HGNC, UniProt	SLC5A7 , Q9GZV3
Substrates	triethylcholine
Endogenous substrates	choline
Stoichiometry	Na ⁺ : choline (variable stoichiometry); modulated by extracellular Cl ⁻ [367]
Selective inhibitors	hemicholinium-3 (pK _i 7–8) [555]
Labelled ligands	[³H]hemicholinium-3 (pK _d 8.2–8.4)

Comments: K_i and K_D values for [hemicholinium-3](#) listed in the table are for human CHT expressed in *Xenopus laevis* oocytes [556], or COS-7 cells [28]. [Hemicholinium mustard](#) is a substrate for CHT that causes covalent modification and irreversible inactivation of the transporter. Several exogenous substances (*e.g.* [triethylcholine](#)) that are substrates for CHT act as precursors to cholinergic false transmitters.

Sodium iodide symporter, sodium-dependent multivitamin transporter and sodium-coupled monocarboxylate transporters

Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters → Sodium iodide symporter, sodium-dependent multivitamin transporter and sodium-coupled monocarboxylate transporters

Overview: The sodium-iodide symporter (NIS) is an iodide transporter found principally in the thyroid gland where it mediates the accumulation of I⁻ within thyrocytes. Transport of I⁻ by NIS from the blood across the basolateral membrane followed by apical efflux into the colloidal lumen, mediated at least in part by pendrin (SLC22A4), and most likely not SMCT1 (SLC5A8) as once thought, provides the I⁻ required for the synthesis of the thyroid hormones triiodothyronine ([triiodothyronine](#)) and thyroxine (T₄) [69]. NIS is also expressed in the salivary glands, gastric mucosa, intestinal enterocytes and lactating breast. NIS mediates I⁻ absorption in the intestine and I⁻ secretion into the milk. SMVT is expressed on the apical membrane of intestinal enterocytes and colonocytes and is the main system responsible for [biotin](#) (vitamin H) and [pantothenic acid](#) (vitamin B₅) uptake in humans [630]. SMVT located in kidney proximal tubule epithelial cells mediates the reabsorption of [biotin](#) and [pantothenic acid](#). SMCT1 (SLC5A8), which transports

a wide range of monocarboxylates, is expressed in the apical membrane of epithelia of the small intestine, colon, kidney, brain neurones and the retinal pigment epithelium [248]. SMCT2 (SLC5A12) also localises to the apical membrane of kidney, intestine, and colon, but in the brain and retina is restricted to astrocytes and Müller cells, respectively [248]. SMCT1 is a high-affinity transporter whereas SMCT2 is a low-affinity transporter. The physiological substrates for SMCT1 and SMCT2 are lactate ([L-lactic acid](#) and [D-lactic acid](#)), [pyruvic acid](#), [propanoic acid](#), and [nicotinic acid](#) in non-colonic tissues such as the kidney. SMCT1 is also likely to be the principal transporter for the absorption of [nicotinic acid](#) (vitamin B₃) in the intestine and kidney [277]. In the small intestine and colon, the physiological substrates for these transporters are [nicotinic acid](#) and the short-chain fatty acids [acetic acid](#), [propanoic acid](#), and [butyric acid](#) that are produced by bacterial fermentation of dietary fiber [517]. In the kidney, SMCT2 is responsible for the bulk

absorption of lactate because of its low-affinity/high-capacity nature. Absence of both transporters in the kidney leads to massive excretion of lactate in urine and consequently drastic decrease in the circulating levels of lactate in blood [716]. SMCT1 also functions as a tumour suppressor in the colon as well as in various other non-colonic tissues [249]. The tumour-suppressive function of SMCT1 is based on its ability to transport [pyruvic acid](#), an inhibitor of histone deacetylases, into cells in non-colonic tissues [717]; in the colon, the ability of SMCT1 to transport [butyric acid](#) and [propanoic acid](#), also inhibitors of histone deacetylases, underlies the tumour-suppressive function of this transporter [248, 249, 309]. The ability of SMCT1 to promote histone acetylase inhibition through accumulation of [butyric acid](#) and [propanoic acid](#) in immune cells is also responsible for suppression of dendritic cell development in the colon [667].

Nomenclature	NIS	SMVT	SMCT1	SMCT2
Systematic nomenclature	SLC5A5	SLC5A6	SLC5A8	SLC5A12
HGNC, UniProt	SLC5A5 , Q92911	SLC5A6 , Q9Y289	SLC5A8 , Q8N695	SLC5A12 , Q1EHB4
Substrates	pertechnetate , ClO_4^- , SCN^- , I^- , NO_3^-	pantothenic acid [156], biotin [156], lipoic acid [156], I^- [156]	β -L-hydroxybutyric acid, acetic acid, butyric acid, propanoic acid, nicotinic acid, β -D-hydroxybutyric acid, L-lactic acid, D-lactic acid, salicylic acid, 3-bromopyruvate, dichloroacetate, 2-oxothiazolidine-4-carboxylate, acetoacetic acid, benzoate, 5-aminosalicylate, α -ketoisocaproate, pyroglutamic acid, γ -hydroxybutyric acid, pyruvic acid	nicotinic acid , L-lactic acid , pyruvic acid
Stoichiometry	$2\text{Na}^+ : 1\text{I}^-$ [205]; $1\text{Na}^+ : 1\text{ClO}_4^-$ [175]	$2\text{Na}^+ : 1$ biotin (or pantothenic acid) [587]	$2\text{Na}^+ : 1$ monocarboxylate [135]	–
Inhibitors	–	–	fenopropfen (pIC_{50} 4.6) [364], ibuprofen (pIC_{50} 4.2) [364], ketoprofen (pIC_{50} 3.9) [364]	–
Comments	–	–	–	Lactate/SLC5A12-induced reprogramming of CD4+ T cells (and the resulting induction of pro-inflammatory IL-17) has been shown to be amenable to pharmacological modulation in a mouse model of arthritis, and is proposed as a therapeutic target for chronic inflammatory disorders.

Comments: I^- , ClO_4^- , thiocyanate and NO_3^- are competitive substrate inhibitors of NIS [175]. [Lipoic acid](#) appears to act as a competitive substrate inhibitor of SMVT [769] and the anticonvulsant drugs [primidone](#) and [carbamazepine](#) competitively block the transport of [biotin](#) by brush border vesicles prepared from human intestine [631].

Sodium *myo*-inositol cotransporter transporters

Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters → Sodium *myo*-inositol cotransporter transporters

Overview: Three different mammalian *myo*-inositol cotransporters are currently known; two are the Na^+ -coupled SMIT1 and SMIT2 tabulated below and the third is proton-coupled HMIT (SLC2A13). SMIT1 and SMIT2 have a widespread and overlapping tissue location but in polarized cells, such as the Madin-

Darby canine kidney cell line, they segregate to the basolateral and apical membranes, respectively [68]. In the nephron, SMIT1 mediates *myo*-inositol uptake as a 'compatible osmolyte' when inner medullary tubules are exposed to increases in extracellular osmolality, whilst SMIT2 mediates the reabsorption of

myo-inositol from the filtrate. In some species (*e.g.* rat, but not rabbit) apically located SMIT2 is responsible for the uptake of *myo*-inositol from the intestinal lumen [27].

Nomenclature	SMIT	SGLT6
Systematic nomenclature	SLC5A3	SLC5A11
Common abbreviation	SMIT1	SMIT2
HGNC, UniProt	SLC5A3 , P53794	SLC5A11 , Q8WWX8
Substrates	myo-inositol , scyllo-inositol > L-fucose > L-xylose > L-glucose , D-glucose , α -MDG > D-galactose , D-fucose > D-xylose [312]	myo-inositol = D-chiro-inositol > D-glucose > D-xylose > L-xylose [136]
Stoichiometry	2 Na ⁺ :1 myo-inositol [312]	2 Na ⁺ :1 myo-inositol [83]
Inhibitors	phlorizin [136]	phlorizin (pK _i 4.1) [136]

Comments: The data tabulated are those for dog SMIT1 and rabbit SMIT2. SMIT2 transports [D-chiro-inositol](#), but SMIT1 does not. In addition, whereas SMIT1 transports both [D-xylose](#) and [L-xylose](#) and [D-fucose](#) and [L-fucose](#), SMIT2 transports only the D-isomers of these sugars [136, 312]. Thus the substrate specificities of SMIT1 (for [L-fucose](#)) and SMIT2 (for [D-chiro-inositol](#)) allow discrimination between the two SMITs. Human SMIT2 appears not to transport glucose [461].

Further reading on SLC5 family of sodium-dependent glucose transporters

- DeFronzo RA *et al.* (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. *Nat Rev Nephrol* **13**: 11-26 [PMID:27941935]
- Gyimesi G *et al.* (2020) Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. *Pflugers Arch* **472**: 1177-1206 [PMID:32767111]
- Koepsell H. (2017) The Na⁺-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. *Pharmacol Ther* **170**: 148-165 [PMID:27773781]
- Lehmann A *et al.* (2016) Intestinal SGLT1 in metabolic health and disease. *Am J Physiol Gastrointest Liver Physiol* **310**: G887-98 [PMID:27012770]
- Wright EM. (2013) Glucose transport families SLC5 and SLC50. *Mol Aspects Med* **34**: 183-96 [PMID:23506865]
- Wright EM *et al.* (2011) Biology of human sodium glucose transporters. *Physiol Rev* **91**: 733-94 [PMID:21527736]

SLC6 neurotransmitter transporter family

Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family

Overview: Members of the solute carrier family 6 (SLC6) of sodium- and (sometimes chloride-) dependent neurotransmitter transporters [11, 92, 119, 428] are primarily plasma membrane located and may be divided into four subfamilies that transport

monoamines, [GABA](#), [glycine](#) and neutral amino acids, plus the related bacterial NSS transporters [632]. The members of this superfamily share a structural motif of 10 TM segments that has been observed in crystal structures of the NSS bacterial homolog

LeuT_{AaT}, a Na⁺-dependent amino acid transporter from *Aquiflex aeolicus* [818] and in several other transporter families structurally related to LeuT [231].

Monoamine transporter subfamily

Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family → Monoamine transporter subfamily

Overview: Monoamine neurotransmission is limited by perisynaptic transporters. Presynaptic monoamine transporters allow recycling of synaptically released **noradrenaline**, **dopamine** and **5-hydroxytryptamine**.

Nomenclature	NET	DAT	SERT
Systematic nomenclature	SLC6A2	SLC6A3	SLC6A4
HGNC, UniProt	SLC6A2 , P23975	SLC6A3 , Q01959	SLC6A4 , P31645
Substrates	MPP ⁺ , methamphetamine, amphetamine	MPP ⁺ , amphetamine, methamphetamine	MDMA, p-chloroamphetamine
Endogenous substrates	(-)-noradrenaline, dopamine, (-)-adrenaline	(-)-noradrenaline, dopamine, (-)-adrenaline	5-hydroxytryptamine
Stoichiometry	1 noradrenaline: 1 Na ⁺ :1 Cl ⁻ [301]	1 dopamine: 1-2 Na ⁺ : 1 Cl ⁻ [300]	1 5-HT:1 Na ⁺ :1 Cl ⁻ (in), + 1 K ⁺ (out) [697]
Inhibitors	H05 (pK _i 8.2) [811] – Rat	–	H05 (pK _i 8.3) [811] – Rat
Sub/family-selective inhibitors	sibutramine (pK _i 5.2) [38]	sibutramine (pK _i 6.3) [38]	sibutramine (pK _i 6) [38]
Selective inhibitors	mazindol (pK _i 8.9), protriptyline (pI _{C₅₀ 8.8) [519], nisoxetine (pK_i 8.4), protriptyline (pK_i 8.2) [464], nomifensine (pK_i 8.1), reboxetine (pK_i 8) [793]}	mazindol (pK _i 8), WIN35428 (pK _i 7.9) [605], GBR12935 (pK _i 7.6), dexamethylphenidate (pK _i 7.6) [437], methylphenidate (pI _{C₅₀ 7.1) [236]}	clomipramine (pK _i 9.7) [707], paroxetine (pK _i 9.6) [707], clomipramine (pK _d 9.6) [707], sertraline (pK _i 9.1), escitalopram (pI _{C₅₀ 9) [619], dapoxetine (pI_{C₅₀ 8.9) [260], fluvoxamine (pK_d 8.7) [707], fluoxetine (pK_i 8.5) [707], citalopram (pK_i 8.4) [58]}}
Labelled ligands	[³ H]mazindol (Inhibitor) (pK _d 9.3) [595] – Rat, [³ H]nisoxetine (Inhibitor) (pK _d 8.4)	[³ H]GBR12935 (Inhibitor) (pK _d 8.5) [589], [³ H]WIN35428 (Inhibitor) (pK _d 8) [589]	[³ H]paroxetine (Inhibitor) (pK _d 9.7), [³ H]citalopram (Inhibitor) (pK _d 8.3)

Comments: [¹²⁵I]RTI55 labels all three monoamine transporters (NET, DAT and SERT) with affinities between 0.5 and 5 nM. Cocaine is an inhibitor of all three transporters with pK_i values between 6.5 and 7.2. Potential alternative splicing sites in non-coding regions of SERT and NET have been identified. A bacterial homologue of SERT shows allosteric modulation by selected anti-depressants [668].

GABA transporter subfamily

Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family → GABA transporter subfamily

Overview: The activity of GABA-transporters located predominantly upon neurones (GAT-1), glia (GAT-3) or both (GAT-2, BGT-1) serves to terminate phasic GABA-ergic transmission, maintain low ambient extracellular concentrations of GABA, and recycle GABA for reuse by neurones. Nonetheless, ambient concentrations of GABA are sufficient to sustain tonic inhibition mediated by high affinity GABA_A receptors in certain neuronal

populations [653]. GAT1 is the predominant GABA transporter in the brain and occurs primarily upon the terminals of presynaptic neurones and to a much lesser extent upon distal astrocytic processes that are in proximity to axons terminals. GAT3 resides predominantly on distal astrocytic terminals that are close to the GABAergic synapse. By contrast, BGT1 occupies an extrasynaptic location possibly along with GAT2 which has

limited expression in the brain [485]. TauT is a high affinity taurine transporter involved in osmotic balance that occurs in the brain and non-neuronal tissues, such as the kidney, brush border membrane of the intestine and blood brain barrier [119, 321]. CT1, which transports creatine, has a ubiquitous expression pattern, often co-localizing with creatine kinase [119].

Searchable database: <https://www.guidetopharmacology.org/>

Full Contents of ConciseGuide: <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182/full>

Monoamine transporter subfamily S399

Nomenclature	GAT1	GAT2	GAT3	BGT1	TauT	CT1
Systematic nomenclature	SLC6A1	SLC6A13	SLC6A11	SLC6A12	SLC6A6	SLC6A8
HGNC, UniProt	<i>SLC6A1</i> , P30531	<i>SLC6A13</i> , Q9NSDS	<i>SLC6A11</i> , P48066	<i>SLC6A12</i> , P48065	<i>SLC6A6</i> , P31641	<i>SLC6A8</i> , P48029
Substrates	nipecotic acid, guvacine	nipecotic acid, guvacine	nipecotic acid, guvacine	–	–	–
Endogenous substrates	GABA	GABA, β -alanine	GABA, β -alanine	GABA, betaine	GABA [21], β -alanine, taurine	creatine
Stoichiometry	2Na ⁺ : 1Cl ⁻ : 1GABA	2Na ⁺ : 1Cl ⁻ : 1GABA	≥ 2Na ⁺ : 2 Cl ⁻ : 1GABA	3Na ⁺ : 1 (or 2) Cl ⁻ : 1GABA	2Na ⁺ : 1Cl ⁻ : 1 taurine	Probably 2Na ⁺ : 1Cl ⁻ : 1 creatine
Selective inhibitors	NNC-711 (pIC ₅₀ 7.4) [78], tiagabine (pIC ₅₀ 7.2) [78], SKF89976A (pIC ₅₀ 6.9) [166], CI-966 (pIC ₅₀ 6.6) [78], (R/S) EF-1500 (pIC ₅₀ 4.9–5.7), (R)-EF-1520 (pIC ₅₀ 5.1–5.4), LU32-176B (pIC ₅₀ 5.4) [787] – Mouse, (S)-EF-1520 (pIC ₅₀ 3.6–3.9)	SNAP-5114 (pIC ₅₀ 4.7) [77] – Rat	SNAP-5114 (pIC ₅₀ 5.2) [77]	NNC052090 (pK _i 5.9) [721] – Mouse, (R/S) EF-1500 (pIC ₅₀ 4.9), (R)-EF-1520 (pIC ₅₀ 3.7–4.7), (S)-EF-1520 (pIC ₅₀ 3.6–4.5), LU32-176B (pIC ₅₀ 4) [787] – Mouse	–	–
Labelled ligands	[³ H]tiagabine (Inhibitor)	–	–	–	–	–

Comments: The IC₅₀ values for GAT1-4 reported in the table reflect the range reported in the literature from studies of both human and mouse transporters. There is a tendency towards lower IC₅₀ values for the human orthologue [433]. SNAP-5114 is only weakly selective for GAT 2 and GAT3, with IC₅₀ values in the range 22 to >30 μ M at GAT1 and BGT1, whereas NNC052090 has at least an order of magnitude selectivity for BGT1 [see [134, 649] for reviews]. Compound (R)-4d is a recently described compound that displays 20-fold selectivity for GAT3 over GAT1

[241]. In addition to the inhibitors listed, deramciclane is a moderately potent, though non-selective, inhibitor of all cloned GABA transporters (IC₅₀ = 26–46 μ M; [165]). Diaryloxime and diarylvinyl ether derivatives of nipecotic acid and guvacine that potently inhibit the uptake of [³H]GABA into rat synaptosomes have been described [409]. Several derivatives of exo-THPO (e.g. N-methyl-exo-THPO and N-acetyloxyethyl-exo-THPO) demonstrate selectivity as blockers of astroglial, versus neuronal, uptake of GABA [see [134, 648] for reviews]. GAT3 is inhibited by phys-

iologically relevant concentrations of Zn²⁺ [138]. Taut transports GABA, but with low affinity, but CT1 does not, although it can be engineered to do so by mutagenesis guided by LeuT as a structural template [173]. Although inhibitors of creatine transport by CT1 (e.g. β -guanidinopropionic acid, cyclocreatine, guanidinoethane sulfonic acid) are known (e.g. [148]) they insufficiently characterized to be included in the table.

Glycine transporter subfamily

Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family → Glycine transporter subfamily

Overview: Two gene products, GlyT1 and GlyT2, are known that give rise to transporters that are predominantly located on glia and neurones, respectively. Five variants of GlyT1 (a,b,c,d & e) differing in their N- and C-termini are generated by alternative promoter usage and splicing, and three splice variants of GlyT2 (a,b & c) have also been identified (see [61, 209, 272, 686] for reviews). GlyT1 transporter isoforms expressed in glia surrounding glutamatergic synapses regulate synaptic glycine concentrations influencing NMDA receptor-mediated neurotransmission [59, 242], but also are important, in early neonatal life, for regulating glycine concentrations at inhibitory glycinergic

synapses [273]. Homozygous mice engineered to totally lack GlyT1 exhibit severe respiratory and motor deficiencies due to hyperactive glycinergic signalling and die within the first postnatal day [273, 730]. Disruption of GlyT1 restricted to forebrain neurones is associated with enhancement of EPSCs mediated by NMDA receptors and behaviours that are suggestive of a promnesic action [827]. GlyT2 transporters localised on the axons and boutons of glycinergic neurones appear crucial for efficient transmitter loading of synaptic vesicles but may not be essential for the termination of inhibitory neurotransmission [274, 621]. Mice in which GlyT2 has been deleted develop a fatal hyperk-

plexia phenotype during the second postnatal week [274] and mutations in the human gene encoding GlyT2 (SLC6A5) have been identified in patients with hyperkplexia (reviewed by [323]). ATB⁰⁺ (SLC6A14) is a transporter for numerous dipolar and cationic amino acids and thus has a much broader substrate specificity than the glycine transporters alongside which it is grouped on the basis of structural similarity [119]. ATB⁰⁺ is expressed in various peripheral tissues [119]. By contrast PROT (SLC6A7), which is expressed only in brain in association with a subset of excitatory nerve terminals, shows specificity for the transport of L-proline.

Nomenclature	GlyT1	GlyT2	ATB^{0,+}	PROT
Systematic nomenclature	SLC6A9	SLC6A5	SLC6A14	SLC6A7
HGNC, UniProt	SLC6A9 , P48067	SLC6A5 , Q9Y345	SLC6A14 , Q9UN76	SLC6A7 , Q99884
Substrates	–	–	zwitterionic or cationic NOS inhibitors [326], val-ganciclovir [740], 1-methyltryptophan [394], BCH	–
Endogenous substrates	glycine , sarcosine	glycine	β-alanine [19, 21] L-isoleucine > L-leucine , L-methionine > L-phenyl-alanine > L-tryptophan > L-valine > L-serine [669]	L-proline
Stoichiometry	2 Na ⁺ : 1 Cl ⁻ : 1 glycine	3 Na ⁺ : 1 Cl ⁻ : 1 glycine	2-3 Na ⁺ : 1 Cl ⁻ : 1 amino acid [669]	Probably 2 Na ⁺ : 1 Cl ⁻ : 1 L-proline
Inhibitors	PF-03463275 (pK _i 7.9) [474]	GT-0198 (pIC ₅₀ 8.8) [557], opi-ranserin (pIC ₅₀ 6.1) [553], bitopertin (pEC ₅₀ <4.5) [579]	–	–
Selective inhibitors	(R)-NFPS (pIC ₅₀ 8.5–9.1) [575], SSR-103800 (pIC ₅₀ 8.7) [82], N-methyl-SSR504734 (pIC ₅₀ 8.6), LY2365109 (pIC ₅₀ 7.8) [575], GSK931145 (pIC ₅₀ 7.6), bitopertin (pEC ₅₀ 7.5) [579]	Org 25543 (pIC ₅₀ 7.8) [108], ALX 1393 (pIC ₅₀ 7) [509], ALX 1405	α-methyl-D,L-tryptophan (pIC ₅₀ 3.6) [394]	compound 58 (pIC ₅₀ 7.7) [858], LP-403812 (pIC ₅₀ 7) [830]
Labelled ligands	[³H](R)-NPTS (Binding) (pK _d 9) [473], [³H]GSK931145 (Binding) (pK _d 8.8) [331], [³⁵S]ACPPB (Binding) (pK _d 8.7) [836], [³H]SB-733993 (Binding) (pK _d 8.7) [331], [³H]N-methyl-SSR504734 (pK _d 8.1–8.5), [³H]NFPS (pK _d 7.7–8.2)	–	–	–
Comments	–	N-Oleoyl-L-carnitine (0.3 μM, [104]) and N-arachidonoylglycine (IC ₅₀ 5–8 μM, [788]) have been described as potential endogenous selective GlyT2 inhibitors	–	–

Comments: [Sarcosine](#) is a selective transportable inhibitor of GlyT1 and also a weak agonist at the [glycine](#) binding site of the NMDA receptor [840], but has no effect on GlyT2. This difference has been attributed to a single glycine residue in TM6 (serine residue in GlyT2) [750]. Inhibition of GLYT1 by the sarcosine derivatives [NFPS](#), [NPTS](#) and [Org 24598](#) is non-competitive [490, 503]. IC₅₀ values for [Org 24598](#) reported in the literature vary,

most likely due to differences in assay conditions [95, 490]. The tricyclic antidepressant [amoxapine](#) weakly inhibits GlyT2 (IC₅₀ 92 μM) with approximately 10-fold selectivity over GlyT1 [549]. The endogenous lipids [arachidonic acid](#) and [anandamide](#) exert opposing effects upon GlyT1a, inhibiting (IC₅₀ ~ 2 μM) and potentiating (EC₅₀ ~ 13 μM) transport currents, respectively [570]. [N-arachidonoylglycine](#), [N-arachidonoyl-γ-aminobutyric acid](#) and

[N-arachidonoyl-D-alanine](#) have been described as endogenous non-competitive inhibitors of GlyT2a, but not GlyT1b [189, 372, 788]. Protons [37] and Zn²⁺ [380] act as non-competitive inhibitors of GlyT1b, with IC₅₀ values of ~100 nM and ~10 μM respectively, but neither ion affects GlyT2 (reviewed by [748]). Glycine transport by GLYT1 is inhibited by Li⁺, whereas GLYT2 transport is stimulated (both in the presence of Na⁺) [571].

Neutral amino acid transporter subfamily

Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family → Neutral amino acid transporter subfamily

Overview: Certain members of neutral amino acid transport family are expressed upon the apical surface of epithelial cells and are important for the absorption of amino acids from the duodenum, jejunum and ileum and their reabsorption within the proximal tubule of the nephron (*i.e.* B⁰AT1 (SLC6A19), SLC6A18, SLC6A20). Others may function as transporters for neurotransmitters or their precursors (*i.e.* B⁰AT2, SLC6A17) [93]. B⁰AT1 has been proposed as a drug target to treat phenylketonuria [56].

Nomenclature	B ⁰ AT1	B ⁰ AT2	B ⁰ AT3	NTT5	NTT4	SIT1
Systematic nomenclature	SLC6A19	SLC6A15	SLC6A18	SLC6A16	SLC6A17	SLC6A20
HGNC, UniProt	SLC6A19 , Q695T7	SLC6A15 , Q9H2J7	SLC6A18 , Q96N87	SLC6A16 , Q9GZN6	SLC6A17 , Q9H1V8	SLC6A20 , Q9NP91
Endogenous substrates	L-leucine, L-methionine, L-isoleucine, L-valine > L-asparagine, L-phenylalanine, L-alanine, L-serine > L-threonine, glycine, L-proline [92]	L-proline > L-alanine, L-valine, L-methionine, L-leucine > L-isoleucine, L-threonine, L-asparagine, L-serine, L-phenylalanine > glycine [92]	L-alanine, glycine > L-methionine, L-phenylalanine, L-leucine, L-histidine, L-glutamine [753]	–	L-leucine, L-methionine, L-proline > L-cysteine, L-alanine, L-glutamine, L-serine > L-histidine, glycine [833]	L-proline
Stoichiometry	1 Na ⁺ : 1 amino acid [76]	1 Na ⁺ : 1 amino acid [90]	Na ⁺ - and Cl ⁻ -dependent transport [666]	–	Na ⁺ -dependent, Cl ⁻ -independent transport [833]	2 Na ⁺ : 1 Cl ⁻ : 1 imino acid [88]
Inhibitors	cinromide (pIC ₅₀ 6.4) [151], inhibitor E18 (pIC ₅₀ 5.5) [813], inhibitor CB3 (pIC ₅₀ 5.3) [813], inhibitor E4 (pIC ₅₀ 5.1) [813], nimesulide (pIC ₅₀ 4.6) [581] – Rat, benzatropine (pIC ₅₀ 4.4) [126]	–	–	–	–	–
Selective inhibitors	–	loratadine (pIC ₅₀ 5.4) [145]	–	–	–	–
Comments	Mutations in B ⁰ AT1 are associated with Hartnup disorder	–	SLC6A18 is a functional transporter in mouse, but not in humans.	–	–	–

Further reading on SLC6 neurotransmitter transporter family

- Birmingham DP *et al.* (2016) Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters. *Pharmacol Rev* **68**: 888-953 [PMID:27591044]
- Bröer S *et al.* (2012) The solute carrier 6 family of transporters. *Br J Pharmacol* **167**: 256-78 [PMID:22519513]
- Colas C. (2020) Toward a Systematic Structural and Functional Annotation of Solute Carriers Transporters-Example of the SLC6 and SLC7 Families. *Front Pharmacol* **11**: 1229 [PMID:32973497]

- Joncquel-Chevalier Curt M *et al.* (2015) Creatine biosynthesis and transport in health and disease. *Biochimie* **119**: 146-65 [PMID:26542286]
- Lohr KM *et al.* (2017) Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. *Eur J Neurosci* **45**: 20-33 [PMID:27520881]
- Schumann-Gillett A *et al.* (2019) Is protein structure enough? A review of the role of lipids in SLC6 transporter function. *Neurosci Lett* **700**: 64-69 [PMID:29758303]

SLC8 family of sodium/calcium exchangers

Transporters → SLC superfamily of solute carriers → SLC8 family of sodium/calcium exchangers

Overview: The sodium/calcium exchangers (NCX) use the extracellular sodium concentration to facilitate the extrusion of calcium out of the cell. Alongside the plasma membrane Ca²⁺-ATPase (PMCA) and sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase (SERCA), as well as the sodium/potassium/calci-

um exchangers (NKCX, SLC24 family), NCX allow recovery of intracellular calcium back to basal levels after cellular stimulation. When intracellular sodium ion levels rise, for example, following depolarisation, these transporters can operate in the reverse direction to allow calcium influx and sodium efflux,

as an electrogenic mechanism. Structural modelling suggests the presence of 9 TM segments, with a large intracellular loop between the fifth and sixth TM segments [11].

Nomenclature	Sodium/calcium exchanger 1	Sodium/calcium exchanger 2	Sodium/calcium exchanger 3
Systematic nomenclature	SLC8A1	SLC8A2	SLC8A3
Common abbreviation	NCX1	NCX2	NCX3
HGNC, UniProt	SLC8A1, P32418	SLC8A2, Q9UPR5	SLC8A3, P57103
Stoichiometry	3 Na ⁺ (in) : 1 Ca ²⁺ (out) or 4 Na ⁺ (in) : 1 Ca ²⁺ (out) [176]; Reverse mode 1 Ca ²⁺ (in): 1 Na ⁺ (out)	–	–
Activators	neurounina-1 (pEC ₅₀ 8.9) [520] – Dog	neurounina-1 (pEC ₅₀ 8.8) [520] – Rat	–
Selective inhibitors	–	–	YM-244769 (pIC ₅₀ 7.7) [368]

Comments: Although subtype-selective inhibitors of NCX function are not widely available, 3,4-dichlorobenzamil and CBDMB act as non-selective NCX inhibitors, while SEA0400, KB-R7943, SN6, ORM-10103 [379] and ORM-10962 [419] act

to inhibit NCX function with varying degrees of selectivity. BED is a preferential NCX3 inhibitor. It inhibits both modes of NCX3 operation, but only the reverse mode of NCX2 (and with reduced potency compared to NCX3) [650]. YM-244769

inhibits NCX3 preferentially over other isoforms [368, 819]. Neurounina-1 stimulates NCX1 and NCX2 activity but not that of NCX3 [520].

Further reading on SLC8 family of sodium/calcium exchangers

- Giladi M *et al.* (2016) Structure-Functional Basis of Ion Transport in Sodium-Calcium Exchanger (NCX) Proteins. *Int J Mol Sci* **17**: [PMID:27879668]
- Khananshvili D. (2013) The SLC8 gene family of sodium-calcium exchangers (NCX) - structure, function, and regulation in health and disease. *Mol Aspects Med* **34**: 220-35 [PMID:23506867]
- Sekler I. (2015) Standing of giants shoulders the story of the mitochondrial Na(+)/Ca(2+) exchanger. *Biochem Biophys Res Commun* **460**: 50-2 [PMID:25998733]

SLC9 family of sodium/hydrogen exchangers

Transporters → SLC superfamily of solute carriers → SLC9 family of sodium/hydrogen exchangers

Overview: Sodium/hydrogen exchangers or sodium/proton antiports are a family of transporters that maintain cellular pH by utilising the sodium gradient across the plasma membrane to extrude protons produced by metabolism, in a stoichiometry of 1 Na⁺ (in) : 1 H⁺ (out). Several isoforms, NHE6, NHE7, NHE8 and

NHE9 appear to locate on intracellular membranes [518, 530, 548]. Li⁺ and NH₄⁺, but not K⁺, ions may also be transported by some isoforms. Modelling of the topology of these transporters indicates 12 TM regions with an extended intracellular C-terminus containing multiple regulatory sites.

NHE1 is considered to be a ubiquitously-expressed 'house-keeping' transporter. NHE3 is highly expressed in the intestine and kidneys and regulate sodium movements in those tissues. NHE10 is present in sperm [768] and osteoclasts [448]; gene disruption results in infertile male mice [768].

Information on members of this family may be found in the [online database](#).

Comments: Analogues of the non-selective cation transport inhibitor amiloride appear to inhibit NHE function through competitive inhibition of the extracellular Na⁺ binding site. The more selective amiloride analogues [MPA](#) and [ethylisopropylamiloride](#) exhibit a rank order of affinity of inhibition of NHE1 > NHE2 > NHE3 [142, 731, 732].

Further reading on SLC9 family of sodium/hydrogen exchangers

Donowitz M *et al.* (2013) SLC9/NHE gene family, a plasma membrane and organellar family of Na⁺/H⁺ exchangers. *Mol Aspects Med* **34**: 236-51 [PMID:23506868]

Kato A *et al.* (2011) Regulation of electroneutral NaCl absorption by the small intestine. *Annu Rev Physiol* **73**: 261-81 [PMID:21054167]

Ohgaki R *et al.* (2011) Organellar Na⁺/H⁺ exchangers: novel players in organelle pH regulation and their emerging functions. *Biochemistry* **50**: 443-50 [PMID:21171650]

Parker MD *et al.* (2015) Na⁺-H⁺ exchanger-1 (NHE1) regulation in kidney proximal tubule. *Cell Mol Life Sci* **72**: 2061-74 [PMID:25680790]

Ruffin VA *et al.* (2014) Intracellular pH regulation by acid-base transporters in mammalian neurons. *Front Physiol* **5**: 43 [PMID:24592239]

SLC10 family of sodium-bile acid co-transporters

Transporters → SLC superfamily of solute carriers → SLC10 family of sodium-bile acid co-transporters

Overview: The SLC10 family transport bile acids, sulphated solutes, and other xenobiotics in a sodium-dependent manner. The founding members, SLC10A1 (NTCP) and SLC10A2 (ASBT) function, along with members of the ABC transporter family (MDR1/ABCB1, BSEP/ABCB11 and MRP2/ABCC2) and the organic solute transporter obligate heterodimer OST α :OST β (SLC51), to

maintain the enterohepatic circulation of bile acids [155, 407]. SLC10A6 (SOAT) functions as a sodium-dependent transporter of sulphated solutes including sulphated steroids and bile acids [261, 263]. Transport function has not yet been demonstrated for the 4 remaining members of the SLC10 family, SLC10A3 (P3), SLC10A4 (P4), SLC10A5 (P5), and SLC10A7 (P7), and the

identity of their endogenous substrates remain unknown [222, 263, 271, 762]. Members of the SLC10 family are predicted to have seven transmembrane domains with an extracellular N-terminus and cytoplasmic C-terminus [49, 315].

Nomenclature	Sodium/bile acid and sulphated solute cotransporter 1	Sodium/bile acid and sulphated solute cotransporter 2	Sodium/bile acid and sulphated solute cotransporter 6
Systematic nomenclature	SLC10A1	SLC10A2	SLC10A6
Common abbreviation	NTCP	ASBT	SOAT
HGNC, UniProt	SLC10A1 , Q14973	SLC10A2 , Q12908	SLC10A6 , Q3KNW5
Substrates	–	glycodeoxycholic acid > glyoursodeoxycholic acid, glycochenodeoxycholic acid > taurocholic acid > cholic acid [144]	dehydroepiandrosterone sulphate [263], pregnenolone sulphate [261], tauroolithocholic acid-3-sulphate, estrone-3-sulphate
Endogenous substrates	estrone-3-sulphate, dehydroepiandrosterone sulphate [144, 222, 497], iodothyronine sulphates [762] tauroursodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid > glycocholic acid > cholic acid [497]	–	–
Stoichiometry	2 Na ⁺ : 1 bile acid [49, 261]	>1 Na ⁺ : 1 bile acid [144, 782]	–
Inhibitors	(-)-propranolol (pIC ₅₀ 8.2) [404], cyclosporin A (pIC ₅₀ 6) [404], ursodeoxycholic acid (pIC ₅₀ 5.4) [404], (+)-propranolol (pIC ₅₀ 5.3) [404], cyclosporin A (pK _i 5.1) [177], irbesartan (pK _i 4.9) [177]	odevixibat (pIC ₅₀ 9.8) [264], maralixibat (pIC ₅₀ 9.6) [345], elobixibat (pIC ₅₀ 8.9) [265], SC-435 (pIC ₅₀ 8.8) [64], 264W94 (pIC ₅₀ 7.3) [724, 803]	–
Labelled ligands	–	[³ H]taurocholic acid [144]	–
Comments	–	Chenodeoxycholyl-Ne-nitrobenzoxadiazol-lysine is a fluorescent bile acid analogue used as a probe [782].	–

Comments: Heterologously expressed SLC10A4 [262] or SLC10A7 [271] failed to exhibit significant transport of taurocholic acid, pregnenolone sulphate, dehydroepiandrosterone sulphate or choline. SLC10A4 has recently been suggested to associate with neuronal vesicles [97].

Further reading on SLC10 family of sodium-bile acid co-transporters

Anwer MS *et al.* (2014) Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. *Pflugers Arch* **466**: 77-89 [PMID:24196564]

Claro da Silva T *et al.* (2013) The solute carrier family 10 (SLC10): beyond bile acid transport. *Mol Aspects Med* **34**: 252-69 [PMID:23506869]

Dawson PA. (2017) Roles of Ileal ASBT and OST α -OST β in Regulating Bile Acid Signaling. *Dig Dis* **35**: 261-266 [PMID:28249269]

Zwicker BL *et al.* (2013) Transport and biological activities of bile acids. *Int J Biochem Cell Biol* **45**: 1389-98 [PMID:23603607]

SLC11 family of proton-coupled metal ion transporters

Transporters → SLC superfamily of solute carriers → SLC11 family of proton-coupled metal ion transporters

Overview: The family of proton-coupled metal ion transporters are responsible for movements of divalent cations, particularly ferrous and manganese ions, across the cell membrane (SLC11A2/DMT1) and across endosomal (SLC11A2/DMT1) or lysosomal/phagosomal membranes (SLC11A1/NRAMP1), depen-

dent on proton transport. Both proteins appear to have 12 TM regions and cytoplasmic N- and C- termini. NRAMP1 is involved in antimicrobial action in macrophages, although its precise mechanism is undefined. Facilitated diffusion of divalent cations into phagosomes may increase intravesicular free radicals to

damage the pathogen. Alternatively, export of divalent cations from the phagosome may deprive the pathogen of essential enzyme cofactors. SLC11A2/DMT1 is more widely expressed and appears to assist in divalent cation assimilation from the diet, as well as in phagocytotic cells.

Searchable database: <https://www.guidetopharmacology.org/>

Full Contents of ConciseGuide: <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182/full>

SLC11 family of proton-coupled metal ion transporters S405

Nomenclature	NRAMP1	DMT1
Systematic nomenclature	SLC11A1	SLC11A2
HGNC, UniProt	SLC11A1 , P49279	SLC11A2 , P49281
Endogenous substrates	Mn ²⁺ , Fe ²⁺	Cd²⁺ , Co²⁺ , Cu²⁺ , Mn ²⁺ , Fe ²⁺
Stoichiometry	1 H ⁺ : 1 Fe ²⁺ (out) or 1 Fe ²⁺ (in) : 1 H ⁺ (out)	1 H ⁺ : 1 Fe ²⁺ (out) [306]
Inhibitors	–	compound 6b (pIC ₅₀ 7.1) [843]

Comments: Loss-of-function mutations in NRAMP1 are associated with increased susceptibility to microbial infection (OMIM: 607948). Loss-of-function mutations in DMT1 are associated with microcytic anemia (OMIM: 206100).

Further reading on SLC11 family of proton-coupled metal ion transporters

- Codazzi F *et al.* (2015) Iron entry in neurons and astrocytes: a link with synaptic activity. *Front Mol Neurosci* **8**: 18 [PMID:26089776]
- Montalbetti N *et al.* (2013) Mammalian iron transporters: families SLC11 and SLC40. *Mol Aspects Med* **34**: 270-87 [PMID:23506870]
- Wessling-Resnick M. (2015) Nramp1 and Other Transporters Involved in Metal Withholding during Infection. *J Biol Chem* **290**: 18984-90 [PMID:26055722]
- Zheng W *et al.* (2012) Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. *Pharmacol Ther* **133**: 177-88 [PMID:22115751]

SLC12 family of cation-coupled chloride transporters

Transporters → SLC superfamily of solute carriers → SLC12 family of cation-coupled chloride transporters

Overview: The SLC12 family of chloride transporters contribute to ion fluxes across a variety of tissues, particularly in the kidney and choroid plexus of the brain. Within this family, further subfamilies are identifiable: NKCC1, NKCC2 and NCC constitute a group of therapeutically-relevant transporters,

targets for loop and thiazide diuretics. These 12 TM proteins exhibit cytoplasmic termini and an extended extracellular loop at TM7/8 and are kidney-specific (NKCC2 and NCC) or show a more widespread distribution (NKCC1). A second family, the K-Cl co-transporters are also 12 TM domain proteins with

cytoplasmic termini, but with an extended extracellular loop at TM 5/6. CCC6 exhibits structural similarities with the K-Cl co-transporters, while CCC9 is divergent, with 11 TM domains and a cytoplasmic N-terminus and extracellular C-terminus.

Nomenclature	Kidney-specific Na-K-Cl symporter	Basolateral Na-K-Cl symporter	Na-Cl symporter	K-Cl cotransporter 1	K-Cl cotransporter 2
Systematic nomenclature	SLC12A1	SLC12A2	SLC12A3	SLC12A4	SLC12A5
Common abbreviation	NKCC2	NKCC1	NCC	KCC1	KCC2
HGNC, UniProt	SLC12A1 , Q13621	SLC12A2 , P55011	SLC12A3 , P55017	SLC12A4 , Q9UP95	SLC12A5 , Q9H2X9
Stoichiometry	1 Na ⁺ : 1 K ⁺ : 2 Cl ⁻ (in)	1 Na ⁺ : 1 K ⁺ : 2 Cl ⁻ (in)	1 Na ⁺ : 1 Cl ⁻ (in)	1 K ⁺ : 1 Cl ⁻ (out)	1 K ⁺ : 1 Cl ⁻ (out)
Inhibitors	bumetanide (pIC ₅₀ 6.5) [322], piretanide (pIC ₅₀ 6) [322], furosemide (pIC ₅₀ 5.2) [322]	piretanide (pIC ₅₀ 5.6) [322], bumetanide (pIC ₅₀ 5.6) [322], furosemide (pIC ₅₀ 5.1) [322]	chlorothiazide , cyclothiazide , hydrochlorothiazide , metolazone	DIOA	VU0240551 (pIC ₅₀ 6.2) [160], DIOA

Nomenclature	K-Cl cotransporter 3	K-Cl cotransporter 4	Cation-chloride cotransporter 9
Systematic nomenclature	SLC12A6	SLC12A7	SLC12A8
Common abbreviation	KCC3	KCC4	CCC9
HGNC, UniProt	SLC12A6, Q9UHW9	SLC12A7, Q9Y666	SLC12A8, A0AV02
Substrates	–	–	spermine, L-glutamic acid, spermidine, L-aspartic acid
Stoichiometry	1 K ⁺ : 1 Cl ⁻ (out)	1 K ⁺ : 1 Cl ⁻ (out)	Unknown
Inhibitors	DIOA	DIOA	–
Comments	–	–	In mouse studies Slc12a8 has been shown to transport the nicotinamide adenine dinucleotide (NAD ⁺) precursor, nicotinamide mononucleotide (NMN) in to cells, and administration of NMN produces anti-ageing effects <i>in vivo</i> [296].

Comments: [DIOA](#) is able to differentiate KCC isoforms from NKCC and NCC transporters, but also inhibits CFTR [366].

Further reading on SLC12 family of cation-coupled chloride transporters

Arroyo JP *et al.* (2013) The SLC12 family of electroneutral cation-coupled chloride cotransporters.

Mol Aspects Med **34**: 288-98 [PMID:23506871]

Bachmann S *et al.* (2017) Regulation of renal Na-(K)-Cl cotransporters by vasopressin. *Pflugers Arch* **469**: 889-897 [PMID:28577072]

Bazúa-Valenti S *et al.* (2016) Physiological role of SLC12 family members in the kidney. *Am J Physiol Renal Physiol* **311**: F131-44 [PMID:27097893]

Huang X *et al.* (2016) Everything we always wanted to know about furosemide but were afraid to ask. *Am J Physiol Renal Physiol* **310**: F958-71 [PMID:26911852]

Kahle KT *et al.* (2015) K-Cl cotransporters, cell volume homeostasis, and neurological disease. *Trends Mol Med* **21**: 513-23 [PMID:26142773]

Martín-Aragón Baudel MA *et al.* (2017) Chloride co-transporters as possible therapeutic targets for stroke. *J Neurochem* **140**: 195-209 [PMID:27861901]

SLC13 family of sodium-dependent sulphate/carboxylate transporters

Transporters → SLC superfamily of solute carriers → SLC13 family of sodium-dependent sulphate/carboxylate transporters

Overview: Within the SLC13 family, two groups of transporters may be differentiated on the basis of the substrates transported: NaS1 and NaS2 convey sulphate, while NaC1-3 transport carboxylates. NaS1 and NaS2 transporters are made up of 13 TM domains, with an intracellular N terminus and are electrogenic with physiological roles in the intestine, kidney and placenta. NaC1, NaC2 and NaC3 are made up of 11 TM domains with an intracellular N terminus and are electrogenic, with physiological roles in the kidney and liver.

Nomenclature	Na ⁺ /sulfate cotransporter	Na ⁺ /dicarboxylate cotransporter 1	Na ⁺ /dicarboxylate cotransporter 3	Na ⁺ /sulfate cotransporter	Na ⁺ /citrate cotransporter
Systematic nomenclature	SLC13A1	SLC13A2	SLC13A3	SLC13A4	SLC13A5
Common abbreviation	NaS1	NaC1	NaC3	NaS2	NaC2
HGNC, UniProt	SLC13A1 , Q9BZW2	SLC13A2 , Q13183	SLC13A3 , Q8WWT9	SLC13A4 , Q9UKG4	SLC13A5 , Q86YT5
Endogenous substrates	SO ₄ ²⁻ , S ₂ O ₃ ²⁻ , SeO ₄ ²⁻	citric acid, succinic acid	citric acid, succinic acid	SO ₄ ²⁻	citric acid, pyruvic acid
Stoichiometry	3 Na ⁺ : 1 SO ₄ ²⁻ (in)	3 Na ⁺ : 1 dicarboxylate ²⁻ (in)	Unknown	3 Na ⁺ : SO ₄ ²⁻ (in)	Unknown
Selective inhibitors	–	–	–	–	BI01383298 (pIC ₅₀ 7.2) [75]
Comments	–	–	–	–	Expressed in hepatocytes where it is involved in the synthesis of sterols and fatty acids. Potential drug target for obesity and diabetes.

Further reading on SLC13 family of sodium-dependent sulphate/carboxylate transporters

- Bergeron MJ *et al.* (2013) SLC13 family of Na⁺-coupled di- and tri-carboxylate/sulfate transporters. *Mol Aspects Med* **34**: 299-312 [PMID:23506872]
- Markovich D. (2014) Na⁺-sulfate cotransporter SLC13A1. *Pflugers Arch* **466**: 131-7 [PMID:24193406]
- Pajor AM. (2014) Sodium-coupled dicarboxylate and citrate transporters from the SLC13 family. *Pflugers Arch* **466**: 119-30 [PMID:24114175]

SLC14 family of facilitative urea transporters

Transporters → SLC superfamily of solute carriers → SLC14 family of facilitative urea transporters

Overview: As a product of protein catabolism, urea is moved around the body and through the kidneys for excretion. Although there is experimental evidence for concentrative urea transporters, these have not been defined at the molecular level. The SLC14 family are facilitative transporters, allowing urea

movement down its concentration gradient. Multiple splice variants of these transporters have been identified; for UT-A transporters, in particular, there is evidence for cell-specific expression of these variants with functional impact [11, 679]. Topographical modelling suggests that the majority of the

variants of SLC14 transporters have 10 TM domains, with a glycosylated extracellular loop at TM5/6, and intracellular C- and N-termini. The UT-A1 splice variant, exceptionally, has 20 TM domains, equivalent to a combination of the UT-A2 and UT-A3 splice variants.

Nomenclature	Erythrocyte urea transporter	Kidney urea transporter
Systematic nomenclature	SLC14A1	SLC14A2
Common abbreviation	UT-B	UT-A
HGNC, UniProt	SLC14A1 , Q13336	SLC14A2 , Q15849
Substrates	acrylamide [845], acetamide [845], methylurea [845]	–
Endogenous substrates	ammonium carbonate [845], urea [845], formamide [845]	urea [483]
Stoichiometry	Equilibrative	Equilibrative
Inhibitors	compound 1a (pIC ₅₀ ~8) [466], compound 1a (pIC ₅₀ 7.6) [466] – Mouse, compound 8ay (pIC ₅₀ ~5.7) [446] – Rat	compound 8ay (pIC ₅₀ ~6.8) [446] – Rat

Further reading on SLC14 family of facilitative urea transporters

- Esteva-Font C *et al.* (2015) Urea transporter proteins as targets for small-molecule diuretics. *Nat Rev Nephrol* **11**: 113-23 [PMID:25488859]
- LeMoine CM *et al.* (2015) Evolution of urea transporters in vertebrates: adaptation to urea's multiple roles and metabolic sources. *J Exp Biol* **218**: 1936-1945 [PMID:26085670]
- Pannabecker TL. (2013) Comparative physiology and architecture associated with the mammalian urine concentrating mechanism: role of inner medullary water and urea transport pathways in the rodent medulla. *Am J Physiol Regul Integr Comp Physiol* **304**: R488-503 [PMID:23364530]
- Shayakul C *et al.* (2013) The urea transporter family (SLC14): physiological, pathological and structural aspects. *Mol Aspects Med* **34**: 313-22 [PMID:23506873]
- Stewart G. (2011) The emerging physiological roles of the SLC14A family of urea transporters. *Br J Pharmacol* **164**: 1780-92 [PMID:21449978]

SLC15 family of peptide transporters

Transporters → SLC superfamily of solute carriers → SLC15 family of peptide transporters

Overview: The Solute Carrier 15 (SLC15) family of peptide transporters, alias H⁺-coupled oligopeptide cotransporter family, is a group of membrane transporters known for their key role in the cellular uptake of di- and tripeptides (di/tripeptides). Of its members, SLC15A1 (PEPT1) chiefly mediates intestinal absorption of luminal di/tripeptides from overall dietary

protein digestion, SLC15A2 (PEPT2) mainly allows renal tubular reuptake of di/tripeptides from ultrafiltration and brain-to-blood efflux of di/tripeptides in the choroid plexus, SLC15A3 (PHT2) and SLC15A4 (PHT1) interact with both di/tripeptides and histidine, e.g. in certain immune cells, and SLC15A5 has unknown physiological function. In addition, the SLC15 family of peptide

transporters variably interacts with a very large number of peptidomimetics and peptide-like drugs. It is conceivable, based on the currently acknowledged structural and functional differences, to divide the SLC15 family of peptide transporters into two subfamilies [11].

Nomenclature	Peptide transporter 1	Peptide transporter 2
Systematic nomenclature	SLC15A1	SLC15A2
Common abbreviation	PEPT1	PEPT2
HGNC, UniProt	SLC15A1 , P46059	SLC15A2 , Q16348
Substrates	cefadroxil [476, 698, 784], valacyclovir [46, 47, 246, 307, 510], fMet-Leu-Phe [101, 115, 499, 500, 801], muramyl dipeptide [363, 430, 479, 756], D-Ala-Lys-AMCA [276, 295, 423, 691], His-Leu-lopinavir [491], alafosfalin [536], cephalexin [18, 143, 238, 245, 476, 713, 714], valganciclovir [681, 741], mirogabalin [817], β-Ala-Lys-AMCA [4, 13, 369, 423]	muramyl dipeptide [342, 683], D-Ala-Lys-AMCA [423, 691, 783], γ-iE-DAP [683, 689], β-Ala-Lys-AMCA [4, 12, 13, 169, 423, 614, 623, 683, 694, 856, 857], alafosfalin [536], javamide-I(N-coumaroyltryptophan)-II(N-caffeoyltryptophan) esters (javamide-I-O-methyl ester and javamide-II-O-methyl ester), acetylated prolyl-glycyl-proline (Ac-PGP) ; the acetylated form of the collagen-derived matrikine PGP [610], mirogabalin [817]
Endogenous substrates	5-aminolevulinic acid [22, 63, 179, 357, 406, 434, 535, 635], di/tripeptides including peptides with high intrinsic hydrolysis resistance such as carnosine , anserine and γ-glutamyl-dipeptides [4, 179, 258, 303, 332, 612, 613, 760, 806]	5-aminolevulinic acid [179, 357, 806], di/tripeptides including peptides with high intrinsic hydrolysis resistance such as carnosine and anserine [4, 258, 471, 559, 683, 806, 844]
Stoichiometry	Transport is electrogenic and involves a variable proton-to-substrate stoichiometry for uptake of neutral and mono- or polyvalently charged peptides, as well as the other substrates tested to date.	Transport is electrogenic and involves a variable proton-to-substrate stoichiometry for uptake of neutral and mono- or polyvalently charged peptides, as well as the other substrates tested to date.
Inhibitors	Lys[Z(NO₂)]-Val (pK _i 5.7) [410, 677], Lys[Z(NO₂)]-Pro (pK _i 5–5.3) [412], Lys[Z(NO₂)]-Lys[Z(NO₂)] (pK _i 4.9) [67], 4-AMBA (pK _i 2.3) [22, 152, 498]	Lys[Z(NO₂)]-Lys[Z(NO₂)] (pK _i 8) [67, 719], Lys[Z(NO₂)]-Val (pK _i 7) [67, 719], Lys[Z(NO₂)]-Pro (pK _i 6.2) [67, 719], 4-AMBA (pK _i 2.5) [67, 719]
Labelled ligands	(3,5)-[¹⁹F]₂-Phe-ψ-Ala [32], [¹¹C]GlySar [512], [¹⁴C]GlySar [7, 47, 66, 245, 246, 247, 357, 411, 412, 413, 476, 491, 642, 698, 713, 714, 715], [¹⁸F]FEPPG [521], [³H]-IPP [269, 270], [³H]-LKP [269, 270], [³H]GlySar [18, 100, 133, 143, 320, 370, 457, 562, 635, 691], [³H]mirogabalin [817], glycyl-[¹³C₃]-sarcosine [763]	(3,5)-[¹⁹F]₂-Phe-ψ-Ala [32], Ac-[¹³C,¹⁵N]PGP [610], [¹¹C]GlySar [526], [¹⁴C]GlySar [240, 245, 246, 247, 343, 357, 411, 413, 465, 476, 642, 713, 715], [¹⁸F]FEPPG [521], [³H]GlySar [457, 475, 562, 636, 671, 691], [³H]mirogabalin [817]

Comments

Although most di/tripeptides can bind PEPT1, not all of them are substrates. The uptake depends on the structural features (charge, hydrophobicity, size, side chain flexibility, etc.) of the di/tripeptide. A variety of dipeptides and drugs interact with PEPT1, including D-Phe-Ala [179, 412], D-Phe-Gln [22], cyclo(L-Hyp-L-Ser) (*i.e.* JBP485) [103, 468], nateglinide [715], glibenclamide [642] and penicillin G (benzylpenicillin) [63]. Among many other molecules, PEPT1 has been shown to interact with L-Dopa-L-Phe [699, 734], D-Phe-Gly-L-Dopa [767], JBP485 prodrugs (*e.g.* JBP485-3-CH₂-O-valine, J3V) [376], 5-Aminosalicylic acid (5-ASA) derivatives (*i.e.* Gly-ASA, Glu-ASA, Val-ASA) [516, 832], cinnabar (*i.e.* α -HgS >96%) [800], doxorubicin-tripeptide (*i.e.* doxorubicin-Gly-Gly-Gly) [275], scutellarin methyl ester-4'-dipeptide conjugates (*e.g.* scutellarin methyl ester-4'-Val-homo-Leu) [459], curcumin (CUR)-peptide derivatives (*i.e.* CUR-Phe-Val, CUR-Ile-Val) [841], gemcitabine amino acid ester prodrugs (*i.e.* 5'-L-valyl-gemcitabine, V-Gem) [673, 720], decitabine amino acid ester prodrugs (*e.g.* 5'-O-L-valyl-decitabine, L-Val-DAC) [705, 706], didanosine amino acid ester prodrugs (*e.g.* 5'-O-L-valyl-didanosine, L-Val-DDI) [821], floxuridine amino acid ester prodrugs (*e.g.* 5'-L-isoleucyl and 5'-L-valyl amino acid ester prodrugs of floxuridine) [435, 436], floxuridine amino acid monoester prodrugs (*e.g.* 5'-O-D-valyl-floxuridine) [737], floxuridine dipeptide monoester prodrugs (*e.g.* 5'-L-phenylalanyl-L-tyrosyl-floxuridine, 5'-L-phenylalanyl-L-glycyl-floxuridine, and 5'-L-isoleucyl-L-glycyl-floxuridine) [736], amino acid acyloxy ester prodrugs of guanine oseltamivir carboxylate (GOC) (*e.g.* GOC-L-Val, the L-valyl acyloxy ethyl prodrug of GOC) [308] and the valyl amino acid prodrug of GOC with the isopropyl-methylene-dioxy linker (*i.e.* GOC-ISP-Val) [353], amino acid acyloxy ester prodrugs of zanamivir (Zan, *e.g.* Zan-L-Val, the L-valyl acyloxy ethyl prodrug of Zan) [310], peramivir-(CH₂)₂-L-Val and peramivir-L-Ile [684], thiodipeptide prodrugs of for example, ibuprofen and propofol [227], alanylpyrroline (Ala-Pyrr) and pyrrolalalanine (Pyrr-Ala) [257], dipeptide-bound derivatives of N⁶-(carboxymethyl)lysine (CML) and N⁶-(1-carboxyethyl)-lysine (CEL) (*i.e.* Ala-CML, CML-Ala, Ala-CEL, CEL-Ala) [329], *Flammulina velutipes* polysaccharide (FVP)-iron (III) complex [FVP-Fe (III) complex] [125], dipeptides of *p*-borono-L-phenylalanine (BPA) and tyrosine (*i.e.* L-Tyr-*p*-L-BPA (Tyr-BPA), *p*-L-BPA-L-tyrosine (BPA-Tyr)) [514] and Au^{III}-peptidodithiocarbamate complexes of the type [Au^{III}Br₂(dtc-AA₁-AA₂-OR)], in which AA₁ = N-methylglycine (Sar), L/D-Pro; AA₂ = L/D-Ala, α -aminoisobutyric acid (Aib); R = OtBu, triethylene glycol methyl ether (*e.g.* dtc-Pro-Aib-OtBu) [80]. In recent years, PEPT1 has been shown to interact with a large variety of specifically targeted (*i.e.* peptide- or amino acid-functionalized) nanoparticles [127, 147, 182, 279, 280, 804], (nano)micelles [377, 772, 799, 810] and nanocomposites [302, 779, 808, 809].

Although most di/tripeptides can bind PEPT2, not all of them are substrates. The uptake depends on the structural features (charge, hydrophobicity, size, side chain flexibility, etc.) of the di/tripeptide. Like PEPT1, PEPT2 interacts with dipeptides and drugs including D-Phe-Ala [179, 718], nateglinide [715], glibenclamide [642], penicillin G (benzylpenicillin) [551], polymyxins (*i.e.* polymyxin B and colistin) [475] and entecavir [807]. PEPT2 has been shown to interact with dipeptides of *p*-borono-L-phenylalanine (BPA) and tyrosine (*i.e.* L-Tyr-*p*-L-BPA (Tyr-BPA), *p*-L-BPA-L-tyrosine (BPA-Tyr)) [514] and with Au^{III}-peptidodithiocarbamate complexes of the type [Au^{III}Br₂(dtc-AA₁-AA₂-OR)], in which AA₁ = N-methylglycine (Sar), L/D-Pro; AA₂ = L/D-Ala, α -aminoisobutyric acid (Aib); R = OtBu, triethylene glycol methyl ether, *e.g.* dtc-Pro-Aib-OtBu) [80].

Nomenclature Peptide transporter 3

Systematic nomenclature SLC15A3

Common abbreviation PHT2

HGNC, UniProt [SLC15A3](#), [Q8IY34](#)

Substrates MDP-rhodamine [529], muramyl dipeptide [529, 777], glycyl-sarcosine [778], Tri-DAP [777], cefadroxil [778], valacyclovir [778]

Endogenous substrates L-histidine [634, 778], carnosine [559, 634], glycyl-glycyl-glycine [778]

Peptide transporter 4

SLC15A4

PHT1

[SLC15A4](#), [Q8N697](#)

muramyl dipeptide [529, 672], MDP-rhodamine [342, 529], Tri-DAP [444, 640, 672], C12-iE-DAP [444], His-Leu-lopinavir [491], glycyl-sarcosine [62, 343, 672, 691], valacyclovir [62]

L-histidine [62, 415, 491, 775, 820], carnosine [62, 559, 820], glycyl-glycyl-glycine [559]

Stoichiometry	PHT2 has not been analyzed systematically with respect to driving force, mode of transport, and substrate specificity. The pH dependence observed for transport of histidine [634] and the model peptides used, <i>i.e.</i> , carnosine [634] and histidyl-leucine [634], suggest a similar mode of operation as PEPT1 and PEPT2 proteins.	PHT1 has not been analyzed systematically with respect to driving force, mode of transport, and substrate specificity. The pH dependence observed for transport of histidine [62, 415, 491, 775, 820] and the model peptide used, <i>i.e.</i> , carnosine [62, 820], suggest a similar mode of operation as PEPT1 and PEPT2 proteins.
Labelled ligands	[¹⁴ C]histidine [634]	[¹⁴ C]histidine (Binding) [775, 776, 820], [³ H]histidine [62, 491, 691, 775]
Comments	Other PHT2 ligands include d ₃ -L-histidine [778] and [³ H]carnosine [634].	Other PHT1 ligands include d ₃ -L-histidine [672], [³ H]carnosine [62, 820], [¹⁴ C]GlySar [343], [³ H]GlySar [62, 691] and [³ H]valacyclovir [62]. Recently, PHT1 has been shown to interact with specifically targeted (<i>i.e.</i> peptide-functionalized) nanoparticles [805].

Comments: The members of the SLC15 family of peptide transporters are particularly promiscuous in the transport of di/tripeptides, and D-amino acid containing peptides are also transported. While SLC15A3 and SLC15A4 transport histidine, none of them transport tetrapeptides. In addition, many molecules, among which beta-lactam antibacterials, angiotensin-converting enzyme inhibitors and sartans, variably interact with the SLC15 family transporters. Known substrates include cefadroxil, valacyclovir, 5-aminolevulinic acid, L-Dopa prodrugs, gemcitabine prodrugs, floxuridine prodrugs, Maillard reaction products, JBP485 and JBP485 prodrugs, zanamivir prodrugs, oseltamivir

prodrugs, doxorubicin prodrugs, polymyxins, didanosine prodrugs, decitabine prodrugs, peramivir prodrugs, ibuprofen and propofol thiodipeptide prodrugs, curcumin-peptide derivatives, 5-aminosalicylic acid derivatives, cinnabar, dipeptide conjugates of scutellarin, *Flammulina velutipes* polysaccharide-iron (III) complex, *p*-borono-L-phenylalanine-containing dipeptides and Au^{III}-peptidodithiocarbamate complexes. Known substrates also include mirogabalin, javamide-I/-II esters, acetylated di/tripeptides, LY2140023, paclitaxel small molecule prodrugs, JBP923 enantiomers, fluorescein-labeled dipeptides and peptide-bound derivatives of carboxymethyllysine. Notably, PEPT1 interacts

with a variety of specifically PEPT1-targeted (*via* peptide- or amino acid-functionalization) nanoparticles, (nano)micelles and nanocomposites. Frequently used pharmaceutical excipients such as Tween 20, Tween 80, Solutol HS 15 and Cremophor EL strongly inhibit cellular uptake of Gly-Sar by SLC15A1 and/or SLC15A2 [562].

There is evidence to suggest the existence of a fifth member of this transporter family, *SLC15A5* (A6NIM6; ENSG00000188991), but to date there is no established biological function or reported pharmacology for this protein [674].

Further reading on SLC15 family of peptide transporters

Anderson CM *et al.* (2010) Hijacking solute carriers for proton-coupled drug transport. *Physiology (Bethesda)* **25**: 364-77 [PMID:21186281]
 Gyimesi G *et al.* (2023) Transporter-Mediated Drug Delivery. *Molecules* **28**: [PMID:36770817]
 Parker JL *et al.* (2021) Cryo-EM structure of PepT2 reveals structural basis for proton-coupled peptide and prodrug transport in mammals. *Sci Adv* **7**: [PMID:34433568]

Smith DE *et al.* (2013) Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. *Mol Aspects Med* **34**: 323-36 [PMID:23506874]
 Toyama-Sorimachi N *et al.* (2021) Lysosomal amino acid transporters as key players in inflammatory diseases. *Int Immunol* **33**: 853-858 [PMID:34508637]

SLC16 family of monocarboxylate transporters

Transporters → SLC superfamily of solute carriers → SLC16 family of monocarboxylate transporters

Overview: Members of the SLC16 family may be divided into subfamilies on the basis of substrate selectivities, particularly lactate (*e.g.* L-lactic acid), pyruvic acid and ketone bodies, as well as aromatic amino acids. Topology modelling suggests 12 TM domains, with intracellular termini and an extended loop at TM 6/7.

The proton-coupled monocarboxylate transporters (monocarboxylate transporters 1, 4, 2 and 3) allow transport of the products of cellular metabolism, principally lactate (*e.g.* L-lactic acid) and pyruvic acid.

Nomenclature	Monocarboxylate transporter 1	Monocarboxylate transporter 2	Monocarboxylate transporter 3	Monocarboxylate transporter 4	Monocarboxylate transporter 6	Monocarboxylate transporter 8	Monocarboxylate transporter 10
Systematic nomenclature	SLC16A1	SLC16A7	SLC16A8	SLC16A3	SLC16A5	SLC16A2	SLC16A10
Common abbreviation	MCT1	MCT2	MCT3	MCT4	MCT6	MCT8	TAT1
HGNC, UniProt	SLC16A1 , P53985	SLC16A7 , O60669	SLC16A8 , O95907	SLC16A3 , O15427	SLC16A5 , O15375	SLC16A2 , P36021	SLC16A10 , Q8TF71
Substrates	γ-hydroxybutyric acid [774]	–	–	–	–	–	–
Endogenous substrates	β-D-hydroxybutyric acid , L-lactic acid , pyruvic acid	L-lactic acid , pyruvic acid	L-lactic acid	L-lactic acid , pyruvic acid	–	triiodothyronine [235], T₄ [235]	L-tryptophan , L-phenylalanine , levodopa , L-tyrosine
Stoichiometry	1 H ⁺ : 1 monocarboxylate ⁻ (out)	1 H ⁺ : 1 monocarboxylate ⁻ (out)	1 H ⁺ : 1 monocarboxylate ⁻ (out)	1 H ⁺ : 1 monocarboxylate ⁻ (out)	Unknown	Unknown	Unknown
Inhibitors	BAY-8002 (pIC ₅₀ 9) [592], AZD3965 (pK _i 8.5) [146], compound 30 (Compound 30 is a channel blocker.) (pK _i 8.3) [305], BAY-8002 (pK _i 8.3) [592]	BAY-8002 (pIC ₅₀ 8.3) [592], 7ACC2 (pIC ₅₀ 8) [181], AZD3965 (pK _i 7.7) [146]	–	compound 18n (pIC ₅₀ 9) [327]	–	–	–
Comments	–	–	–	–	MCT6 has been reported to transport bumetanide , but not short chain fatty acids [523].	–	–

Comments: MCT1 and MCT2, but not MCT3 and MCT4, are inhibited by CHC, which also inhibits members of the mitochondrial transporter family, [SLC25](#).

MCT5-MCT7, MCT9 and MCT11-14 are regarded as orphan transporters.

Further reading on SLC16 family of monocarboxylate transporters

Bernal J *et al.* (2015) Thyroid hormone transporters-functions and clinical implications. *Nat Rev Endocrinol* **11**: 406-417 [PMID:25942657]

Bosshart PD *et al.* (2021) SLC16 Family: From Atomic Structure to Human Disease. *Trends Biochem Sci* **46**: 28-40 [PMID:32828650]

Felmlee MA *et al.* (2020) Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease. *Pharmacol Rev* **72**: 466-485 [PMID:32144120]

Halestrap AP. (2013) The SLC16 gene family - structure, role and regulation in health and disease. *Mol Aspects Med* **34**: 337-49 [PMID:23506875]

Jones RS *et al.* (2016) Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease. *Clin Pharmacol Ther* **100**: 454-463 [PMID:27351344]

SLC17 phosphate and organic anion transporter family

Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family

Overview: The SLC17 family are sometimes referred to as Type I sodium-phosphate co-transporters, alongside Type II (SLC34 family) and Type III (SLC20 family) transporters. Within the SLC17 family, however, further subgroups of organic anion transporters may be defined, allowing the accumulation of [sialic acid](#) in the endoplasmic reticulum and glutamate (*e.g.* [L-glutamic acid](#)) or nucleotides in synaptic and secretory vesicles. Topology modelling suggests 12 TM domains.

Type I sodium-phosphate co-transporters

Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family → Type I sodium-phosphate co-transporters

Overview: Type I sodium-phosphate co-transporters are expressed in the kidney and intestine.

Nomenclature	Sodium/phosphate cotransporter 1	Sodium/phosphate cotransporter 3	Sodium/phosphate cotransporter 4	Sodium/phosphate cotransporter homolog
Systematic nomenclature	SLC17A1	SLC17A2	SLC17A3	SLC17A4
Common abbreviation	NPT1	NPT3	NPT4	–
HGNC, UniProt	SLC17A1 , Q14916	SLC17A2 , O00624	SLC17A3 , O00476	SLC17A4 , Q9Y2C5
Substrates	probenecid [99], penicillin G [99], organic acids [351], Cl⁻ [351], uric acid [351], phosphate [351]	–	–	–
Stoichiometry	Unknown	Unknown	Unknown	Unknown

Sialic acid transporter

Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family → Sialic acid transporter

Overview: The sialic acid transporter is expressed on both lysosomes and synaptic vesicles, where it appears to allow export of [sialic acid](#) and accumulation of acidic amino acids, respectively [515], driven by proton gradients. In lysosomes, degradation of glycoproteins generates amino acids and sugar residues, which are metabolized further following export from the lysosome.

Nomenclature	Sialin
Systematic nomenclature	SLC17A5
Common abbreviation	AST
HGNC, UniProt	SLC17A5 , Q9NRA2
Endogenous substrates	L-glutamic acid (in) [515], L-aspartic acid [515], L-lactic acid , gluconate (out), sialic acid , glucuronic acid
Stoichiometry	1 H ⁺ : 1 sialic acid (out)

Comments: Loss-of-function mutations in sialin are associated with Salla disease (OMIM: 604369), an autosomal recessive neurodegenerative disorder associated with sialic acid storage disease [758].

Vesicular glutamate transporters (VGLUTs)

Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family → Vesicular glutamate transporters (VGLUTs)

Overview: Vesicular glutamate transporters (VGLUTs) allow accumulation of glutamate into synaptic vesicles, as well as secretory vesicles in endocrine tissues. The roles of VGLUTs in kidney and liver are unclear. These transporters appear to utilize the proton gradient and also express a chloride conductance [57].

	Vesicular glutamate transporter 1	Vesicular glutamate transporter 2	Vesicular glutamate transporter 3
Systematic nomenclature	SLC17A7	SLC17A6	SLC17A8
Common abbreviation	VGLUT1	VGLUT2	VGLUT3
HGNC, UniProt	SLC17A7 , Q9P2U7	SLC17A6 , Q9P2U8	SLC17A8 , Q8NDX2
Endogenous substrates	L-glutamic acid > D-glutamic acid	L-glutamic acid > D-glutamic acid	L-glutamic acid > D-glutamic acid
Stoichiometry	Unknown	Unknown	Unknown

Comments: Endogenous ketoacids produced during fasting have been proposed to regulate VGLUT function through blocking chloride ion-mediated allosteric enhancement of transporter function [381].

Vesicular nucleotide transporter

Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family → Vesicular nucleotide transporter

Overview: The vesicular nucleotide transporter is the most recent member of the SLC17 family to have an assigned function. Uptake of ATP was independent of pH, but dependent on chloride ions and membrane potential [641].

Nomenclature	Vesicular nucleotide transporter
Systematic nomenclature	SLC17A9
Common abbreviation	VNUT
HGNC, UniProt	SLC17A9, Q9BYT1
Endogenous substrates	ATP [641], guanosine-5'-triphosphate [641], guanosine 5'-diphosphate [641]
Stoichiometry	Unknown
Selective inhibitors	clodronic acid (pIC ₅₀ 7.8) [395]

Comments: VGLUTs and VNUT can be inhibited by DIDS and evans blue dye.

Further reading on SLC17 phosphate and organic anion transporter family

- Moriyama Y *et al.* (2017) Vesicular nucleotide transporter (VNUT): appearance of an actress on the stage of purinergic signaling. *Purinergic Signal* **13**: 387-404 [PMID:28616712]
- Omote H *et al.* (2016) Structure, Function, and Drug Interactions of Neurotransmitter Transporters in the Postgenomic Era. *Annu Rev Pharmacol Toxicol* **56**: 385-402 [PMID:26514205]
- Reimer RJ. (2013) SLC17: a functionally diverse family of organic anion transporters. *Mol Aspects Med* **34**: 350-9 [PMID:23506876]
- Takamori S. (2016) Vesicular glutamate transporters as anion channels? *Pflugers Arch* **468**: 513-8 [PMID:26577586]

SLC18 family of vesicular amine transporters

Transporters → SLC superfamily of solute carriers → SLC18 family of vesicular amine transporters

Overview: The vesicular amine transporters (VATs) are putative 12 TM domain proteins that function to transport singly positively charged amine neurotransmitters and hormones from the cytoplasm and concentrate them within secretory vesicles. They function as amine/proton antiporters driven by secondary active transport utilizing the proton gradient established by a multi-subunit vacuolar ATPase that acidifies secretory vesicles

(reviewed by [193]). The vesicular acetylcholine transporter (VAChT; [204]) localizes to cholinergic neurons, but non-neuronal expression has also been claimed [646]. Vesicular monoamine transporter 1 (VMAT1, [202]) is mainly expressed in peripheral neuroendocrine cells, but most likely not in the CNS, whereas VMAT2 [203] distributes between both central and peripheral sympathetic monoaminergic neurones [194].

The vesicular polyamine transporter (VPAT) is highly expressed in the lungs and placenta, with moderate expression in brain and testis, and with low expression in heart and skeletal muscle [334]. VPAT mediates vesicular accumulation of polyamines in mast cells [695].

Nomenclature	Vesicular monoamine transporter 1	Vesicular monoamine transporter 2	Vesicular acetylcholine transporter
Systematic nomenclature	SLC18A1	SLC18A2	SLC18A3
Common abbreviation	VMAT1	VMAT2	VAcHT
HGNC, UniProt	SLC18A1 , P54219	SLC18A2 , Q05940	SLC18A3 , Q16572
Substrates	β-phenylethylamine (K_i 3.4×10^{-5} M) [203], MPP+ (K_i 6.9×10^{-5} M) [203], MDMA (K_i 1.9×10^{-5} M) [203], fenfluramine (K_i 3.1×10^{-5} M) [203], dexamfetamine (K_i 4.7×10^{-5} M) [203]	β-phenylethylamine (K_i 3.7×10^{-6} M) [203], fenfluramine (K_i 5.1×10^{-6} M) [203], MDMA (K_i 6.9×10^{-6} M) [203], dexamfetamine (K_i 2.1×10^{-6} M) [203], MPP+ (K_i 8.9×10^{-6} M) [203]	TPP+ [84], ethidium [84], N-methyl-pyridinium-2-aldoxime [84], N-(4'-pentanonyl)-4-(4''-dimethylamino-styryl)pyridinium [84]
Endogenous substrates	(-)-adrenaline (K_i 5.5×10^{-6} M) [203], (-)-noradrenaline (K_i 1.3×10^{-5} M) [203], dopamine (K_i 3.8×10^{-6} M) [203], histamine (K_i 4.6×10^{-3} M) [203], 5-hydroxytryptamine (K_i 1.4×10^{-6} M) [203]	5-hydroxytryptamine (K_i 9×10^{-7} M) [203], (-)-adrenaline (K_i 1.9×10^{-6} M) [203], (-)-noradrenaline (K_i 3.4×10^{-6} M) [203], dopamine (K_i 1.4×10^{-6} M) [203], histamine (K_i 1.4×10^{-4} M) [203]	acetylcholine (K_i 7.9×10^{-4} M) [85, 401], choline (K_i 5×10^{-3} M) [85, 401]
Stoichiometry	1 amine (in): 2H ⁺ (out)	1 amine (in): 2H ⁺ (out)	1 amine (in): 2H ⁺ (out)
Inhibitors	reserpine (pK_i 7.5) [203], ketanserin (pK_i 5.8) [203], tetrabenazine (pK_i 4.7) [203]	reserpine (pK_i 7.9) [203], tetrabenazine (pK_i 7) [203], ketanserin (pK_i 6.3) [203]	aminobenzovesamicol (pK_i 10.9) [192], vesamicol (pK_i 8.7) [192]
Labelled ligands	–	[³H]TBZOH (Inhibitor) (pK_d 8.2) [754], [¹²⁵I]iodovinyl-TBZ (Inhibitor) (pK_d 8.1) [431], [¹¹C]DTBZ (Inhibitor), [¹²⁵I]7-azido-8-iodoketanserin (Inhibitor) [665]	[³H]vesamicol (pK_d 8.4) [754], [¹²³I]iodobenzovesamicol

Comments: pK_i values for endogenous and synthetic substrate inhibitors of human VMAT1 and VMAT2 are for inhibition of [³H]5-HT uptake in transfected and permeabilised CV-1 cells as detailed by [203]. In addition to the monoamines listed in the table, the trace amines [tyramine](#) and [β-phenylethylamine](#) are probable substrates for VMAT2 [194]. Probes listed in the table are those currently employed; additional agents have been synthesized (*e.g.* [854]).

Further reading on SLC18 family of vesicular amine transporters

German CL *et al.* (2015) Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. *Pharmacol Rev* **67**: 1005-24 [PMID:26408528]

Lohr KM *et al.* (2017) Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. *Eur J Neurosci* **45**: 20-33 [PMID:27520881]

Omote H *et al.* (2016) Structure, Function, and Drug Interactions of Neurotransmitter Transporters in the Postgenomic Era. *Annu Rev Pharmacol Toxicol* **56**: 385-402 [PMID:26514205]

Sitte HH *et al.* (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. *Trends Pharmacol Sci* **36**: 41-50 [PMID:25542076]

Wimalasena K. (2011) Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. *Med Res Rev* **31**: 483-519 [PMID:20135628]

SLC19 family of vitamin transporters

Transporters → SLC superfamily of solute carriers → SLC19 family of vitamin transporters

Overview: The B vitamins [folic acid](#) and [thiamine](#) are transported across the cell membrane, particularly in the intestine, kidneys and placenta, using pH differences as driving forces. Topological modelling suggests the transporters have 12 TM domains.

Nomenclature	Reduced folate transporter 1	Thiamine transporter 1	Thiamine transporter 2
Systematic nomenclature	SLC19A1	SLC19A2	SLC19A3
Common abbreviation	FOLT	ThTr1	ThTr2
HGNC, UniProt	SLC19A1 , P41440	SLC19A2 , O60779	SLC19A3 , Q9BZV2
Substrates	folic acid , methotrexate , folic acid [586], N ⁵ -formyltetrahydrofolate	–	–
Endogenous substrates	tetrahydrofolic acid [586], N ⁵ -methylfolate [586], thiamine monophosphate [846], Other tetrahydrofolate-cofactors, Organic phosphates; in particular, adenine nucleotides	thiamine	thiamine
Stoichiometry	Folate (in) : organic phosphate (out), precise stoichiometry unknown	A facilitative carrier not known to be coupled to an inorganic or organic ion gradient	A facilitative carrier not known to be coupled to an inorganic or organic ion gradient
Inhibitors	compound 9 (pK _i 6.6) [618], methotrexate (pK _i 5.3) [618]	–	–
Labelled ligands	[³H]folic acid [36], [³H]methotrexate [36]	[³H]thiamine [188]	[³H]thiamine [599]

Comments: Loss-of-function mutations in ThTr1 underlie thiamine-responsive megaloblastic anemia syndrome [168].

Further reading on SLC19 family of vitamin transporters

Matherly LH *et al.* (2014) The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. *Drug Metab Dispos* **42**: 632-49 [PMID:24396145]

Zhao R *et al.* (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. *Mol Aspects Med* **34**: 373-85 [PMID:23506878]

SLC20 family of sodium-dependent phosphate transporters

Transporters → SLC superfamily of solute carriers → SLC20 family of sodium-dependent phosphate transporters

Overview: The SLC20 family is looked upon not only as ion transporters, but also as retroviral receptors. As ion transporters, they are sometimes referred to as Type III sodium-phosphate co-transporters, alongside Type I (SLC17 family) and Type II (SLC34 family). PiTs are cell-surface transporters, composed of ten TM domains with extracellular C- and N-termini. PiT1 is a focus for dietary phosphate and vitamin D regulation of parathyroid hormone secretion from the parathyroid gland. PiT2 appears to be involved in intestinal absorption of dietary phosphate.

Nomenclature	Sodium-dependent phosphate transporter 1	Sodium-dependent phosphate transporter 2
Systematic nomenclature	SLC20A1	SLC20A2
Common abbreviation	PiT1	PiT2
HGNC, UniProt	SLC20A1, Q8WUM9	SLC20A2, Q08357
Substrates	AsO ₄ ³⁻ [600], phosphate [600]	phosphate [600]
Stoichiometry	>1 Na ⁺ : 1 HPO ₄ ²⁻ (in)	>1 Na ⁺ : 1 HPO ₄ ²⁻ (in)

Further reading on SLC20 family of sodium-dependent phosphate transporters

Biber J *et al.* (2013) Phosphate transporters and their function. *Annu Rev Physiol* **75**: 535-50
[PMID:23398154]

Forster IC *et al.* (2013) Phosphate transporters of the SLC20 and SLC34 families. *Mol Aspects Med* **34**: 386-95 [PMID:23506879]

Shobeiri N *et al.* (2014) Phosphate: an old bone molecule but new cardiovascular risk factor. *Br J Clin Pharmacol* **77**: 39-54 [PMID:23506202]

SLC22 family of organic cation and anion transporters

Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters

Overview: The SLC22 family of transporters is mostly composed of non-selective transporters, which are expressed highly in liver, kidney and intestine, playing a major role in drug disposition. The family may be divided into three subfamilies based on the nature of the substrate transported: organic cations (OCTs), organic anions (OATs) and organic zwitterion/cations (OCTN). Membrane topology is predicted to contain 12 TM domains with intracellular termini, and an extended extracellular loop at TM 1/2.

Organic cation transporters (OCT)

Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Organic cation transporters (OCT)

Overview: Organic cation transporters (OCT) are electrogenic, Na⁺-independent and reversible.

	Organic cation transporter 1	Organic cation transporter 2	Organic cation transporter 3
Nomenclature	Organic cation transporter 1	Organic cation transporter 2	Organic cation transporter 3
Systematic nomenclature	SLC22A1	SLC22A2	SLC22A3
Common abbreviation	OCT1	OCT2	OCT3
HGNC, UniProt	SLC22A1 , O15245	SLC22A2 , O15244	SLC22A3 , O75751
Substrates	tetraethylammonium, desipramine, MPP ⁺ , aciclovir, metformin [664]	tubocurarine [278], tetraethylammonium [278], pancuronium [278], MPP ⁺ [278], metformin [418], cisplatin [418]	quinidine, tetraethylammonium, MPP ⁺ , metformin [418]
Endogenous substrates	5-hydroxytryptamine, PGE ₂ , PGF ₂ α, choline	dopamine [297], histamine [297], PGE ₂ [405]	5-hydroxytryptamine [853], (-)-noradrenaline [853], dopamine [853]
Stoichiometry	Unknown	Unknown	Unknown
Inhibitors	clonidine (pK _i 6.3) [842]	decynium 22 (pK _i 7) [278]	disprocyinium24 (pK _i 7.8) [298]

Comments: Corticosterone and quinine are able to inhibit all three organic cation transporters.

Further reading on Organic cation transporters (OCT)

Koepsell H. (2020) Organic Cation Transporters in Health and Disease. *Pharmacol Rev* **72**: 253-319 [PMID:31852803]
 Lozano E *et al.* (2013) Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. *Biomed Res Int* **2013**: 692071 [PMID:23984399]
 Pelis RM *et al.* (2014) SLC22, SLC44, and SLC47 transporters—organic anion and cation transporters: molecular and cellular properties. *Curr Top Membr* **73**: 233-61 [PMID:24745985]

Samodelov SL *et al.* (2020) Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology. *Int J Mol Sci* **21**: [PMID:33114309]
 Yee SW *et al.* (2021) Emerging Roles of the Human Solute Carrier 22 Family. *Drug Metab Dispos* **50**: 1193-210 [PMID:34921098]
 Yin J *et al.* (2016) Renal drug transporters and their significance in drug-drug interactions. *Acta Pharm Sin B* **6**: 363-373 [PMID:27709005]

Organic zwitterions/cation transporters (OCTN)

Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Organic zwitterions/cation transporters (OCTN)

Overview: Organic zwitterions/cation transporters (OCTN) function as organic cation uniporters, organic cation/proton exchangers or sodium/L-carnitine co-transporters.

Nomenclature	Organic cation/carnitine transporter 1	Organic cation/carnitine transporter 2	Carnitine transporter 2
Systematic nomenclature	SLC22A4	SLC22A5	SLC22A16
Common abbreviation	OCTN1	OCTN2	CT2
HGNC, UniProt	SLC22A4, Q9H015	SLC22A5, O76082	SLC22A16, Q86VW1
Substrates	mepyramine, tetraethylammonium, verapamil, MPP ⁺	mepyramine, tetraethylammonium, verapamil, MPP ⁺	–
Endogenous substrates	L-carnitine	acetyl-L-carnitine, L-carnitine	L-carnitine
Stoichiometry	Unknown	Unknown	Unknown

Comments: Mutations in the *SLC22A5* gene lead to primary carnitine deficiency [470].

Further reading on Organic zwitterions/cation transporters (OCTN)

Matthaei J *et al.* (2016) OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. *Clin Pharmacol Ther* **99**: 633-41 [PMID:26659468]

Tamai I. (2013) Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and SLC22A21). *Biopharm Drug Dispos* **34**: 29-44 [PMID:22952014]

Yin J *et al.* (2016) Renal drug transporters and their significance in drug-drug interactions. *Acta Pharm Sin B* **6**: 363-373 [PMID:27709005]

Organic anion transporters (OATs)

Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Organic anion transporters (OATs)

Overview: Organic anion transporters (OATs) are non-selective transporters prominent in the kidney, placenta and blood-brain barrier.

Nomenclature	Organic anion transporter 1	Organic anion transporter 2	Organic anion transporter 3	Organic anion transporter 4	Organic anion transporter 7
Systematic nomenclature	SLC22A6	SLC22A7	SLC22A8	SLC22A11	SLC22A9
Common abbreviation	OAT1	OAT2	OAT3	–	OAT4
HGNC, UniProt	SLC22A6, Q4U2R8	SLC22A7, Q9Y694	SLC22A8, Q8TCC7	SLC22A11, Q9NSA0	SLC22A9, Q8IVM8

Searchable database: <https://www.guidetopharmacology.org/>

Full Contents of ConciseGuide: <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182/full>

Organic zwitterions/cation transporters (OCTN) S421

Substrates	non-steroidal anti-inflammatory drugs, aminohippuric acid	non-steroidal anti-inflammatory drugs, PGE_2 , aminohippuric acid	cimetidine [432], ochratoxin A [432], estrone-3-sulphate [432], aminohippuric acid [432], uric acid [542]	dehydroepiandrosterone sulphate [110], estrone-3-sulphate [110], ochratoxin A [110], uric acid [542]	–
Stoichiometry	Unknown	Unknown	Unknown	Unknown	Unknown
Inhibitors	probenecid (Inhibition of urate transport by human SCL22A6.) (pIC_{50} 4.9) [349]	–	–	–	–

Further reading on Organic anion transporters (OATs)

- Burckhardt G *et al.* (2011) In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. *Handb Exp Pharmacol* 29-104 [PMID:21103968]
- Koepsell H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. *Mol Aspects Med* 34: 413-35 [PMID:23506881]
- Nigam SK. (2018) The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease. *Annu Rev Pharmacol Toxicol* 58: 663-687 [PMID:29309257]
- Shen H *et al.* (2017) Organic Anion Transporter 2: An Enigmatic Human Solute Carrier. *Drug Metab Dispos* 45: 228-236 [PMID:27872146]
- Yee SW *et al.* (2021) Emerging Roles of the Human Solute Carrier 22 Family. *Drug Metab Dispos* 50: 1193-210 [PMID:34921098]
- Yin J *et al.* (2016) Renal drug transporters and their significance in drug-drug interactions. *Acta Pharm Sin B* 6: 363-373 [PMID:27709005]

Urate transporter

Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Urate transporter

Overview: URAT1, a member of the OAT (organic anion transporter) family, is an anion-exchanging uptake transporter localized to the apical (brush border) membrane of renal proximal tubular cells. It is an anion exchanger that selectively reabsorbs uric acid from the proximal tubule in exchange for monovalent anions such as lactate, nicotinoate, acetoacetate, and hydroxybutyrate [201].

Nomenclature	Urate anion exchanger 1
Systematic nomenclature	SLC22A12
Common abbreviation	URAT1
HGNC, UniProt	SLC22A12 , Q96S37
Endogenous substrates	orotic acid [201], uric acid [201]
Stoichiometry	Unknown
Selective inhibitors	dotinurad (pIC_{50} 6.4) [703], sufinpyrazone (pIC_{50} 4) [831], lesinurad [98]
Comments	URAT1 is expressed in the proximal tubule of the kidney and regulates uric acid excretion from the body. Inhibitors of this transporter, such as losartan , find clinical utility in managing hyperuricemia in patients with gout [98, 316].

Further reading on Urate transporter

Nigam SK *et al.* (2018) The systems biology of uric acid transporters: the role of remote sensing and signaling. *Curr Opin Nephrol Hypertens* **27**: 305-313 [PMID:29847376]

Atypical SLC22B subfamily

Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Atypical SLC22B subfamily

Overview: This family of transporters has previously been classified as part of the atypical major facilitator superfamily (MSF) protein superfamily [11, 568, 572, 573, 601]. The atypical SLCs share sequence similarities and phylogenetic ancestry with other SLCs, and they have historically been classified in to subfamilies (also referred to as atypical MFS transporter families (AMTF1-15)) based on phylogenetic, sequence and structural analyses [572].

Nomenclature	synaptic vesicle glycoprotein 2A
Systematic nomenclature	SLC22B1
HGNC, UniProt	SV2A , Q7L0J3
Substrates	Galactose [484]
Inhibitors	brivaracetam (pIC ₅₀ 7) [398] – Rat, levetiracetam (pK _i 5.8) [547] – Rat

Comments: There are three human synaptic vesicle glycoprotein 2 family members, SV2A, SV2B and SV2C. They have transmembrane transporter activity and can be classified in to the SLC superfamily of solute carriers in subfamily SLC22, as SCL22B1, B2 and B3 respectively. SV2A (SCL22B1) has been identified as the brain binding-site for the antiepileptic drugs levetiracetam [408, 472] and brivaracetam [540].

Further reading on Atypical SLC22B subfamily

Löscher W *et al.* (2016) Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. *CNS Drugs* **30**: 1055-1077 [PMID:27752944]

Mendoza-Torreblanca JG *et al.* (2013) Synaptic vesicle protein 2A: basic facts and role in synaptic function. *Eur J Neurosci* **38**: 3529-39 [PMID:24102679]

Further reading on SLC22 family of organic cation and anion transporters

Burckhardt G. (2012) Drug transport by Organic Anion Transporters (OATs). *Pharmacol Ther* **136**: 106-30 [PMID:22841915]

Nigam SK. (2018) The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease. *Annu Rev Pharmacol Toxicol* **58**: 663-687 [PMID:29309257]

Hillgren KM *et al.* (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. *Clin Pharmacol Ther* **94**: 52-63 [PMID:23588305]

Yee SW *et al.* (2021) **Emerging Roles of the Human Solute Carrier 22 Family**. *Drug Metab Dispos* **50**: 1193-210 [PMID:34921098]

Koepsell H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. *Mol Aspects Med* **34**: 413-35 [PMID:23506881]

Zamek-Gliszczynski MJ *et al.* (2018) Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. *Clin Pharmacol Ther* **104**: 890-899 [PMID:30091177]

SLC23 family of ascorbic acid transporters

Transporters → SLC superfamily of solute carriers → SLC23 family of ascorbic acid transporters

Overview: Predicted to be 12 TM segment proteins, members of this family transport the reduced form of ascorbic acid (while the oxidized form may be handled by members of the **SLC2 family** (GLUT1/SLC2A1, GLUT3/SLC2A3 and GLUT4/SLC2A4). **Phloretin** is considered a non-selective inhibitor of these transporters, with an affinity in the micromolar range [11].

Nomenclature	Sodium-dependent vitamin C transporter 1	Sodium-dependent vitamin C transporter 2	Sodium-dependent vitamin C transporter 3
Systematic nomenclature	SLC23A1	SLC23A2	SLC23A3
Common abbreviation	SVCT1	SVCT2	SVCT3
HGNC, UniProt	SLC23A1 , Q9UHI7	SLC23A2 , Q9UGH3	SLC23A3 , Q6PIS1
Endogenous substrates	L-ascorbic acid > D-ascorbic acid > dehydroascorbic acid [735]	L-ascorbic acid > D-ascorbic acid > dehydroascorbic acid [735]	–
Stoichiometry	2 Na ⁺ : 1 ascorbic acid (in) [735]	2 Na ⁺ : 1 ascorbic acid (in) [735]	–
Inhibitors	phloretin (pK _i 4.2) [735]	–	–
Labelled ligands	[¹⁴C]ascorbic acid (Binding) [480]	[¹⁴C]ascorbic acid	–
Comments	–	–	SLC23A3 does not transport ascorbic acid and remains an orphan transporter.

Nomenclature	Sodium-dependent nucleobase transporter
Systematic nomenclature	SLC23A4
Common abbreviation	SNBT1
HGNC, UniProt	SLC23A4P , –
Substrates	5-fluorouracil [815]
Endogenous substrates	uracil > thymine > guanine , hypoxanthine > xanthine , uridine [815]
Stoichiometry	1 Na ⁺ : 1 uracil (in) [815]
Comments	SLC23A4/SNBT1 is found in rodents and non-human primates, but the sequence is truncated in the human genome and named as a pseudogene, SLC23A4P

Further reading on SLC23 family of ascorbic acid transporters

Bürzle M *et al.* (2013) The sodium-dependent ascorbic acid transporter family SLC23. *Mol Aspects Med* **34**: 436-54 [PMID:23506882]

May JM. (2011) The SLC23 family of ascorbate transporters: ensuring that you get and keep your daily dose of vitamin C. *Br J Pharmacol* **164**: 1793-801 [PMID:21418192]

SLC24 family of sodium/potassium/calcium exchangers

Transporters → SLC superfamily of solute carriers → SLC24 family of sodium/potassium/calcium exchangers

Overview: The sodium/potassium/calcium exchange family of transporters utilize the extracellular sodium gradient to drive calcium and potassium co-transport out of the cell. As is the case for NCX transporters (SLC8A family), NKCX transporters are thought to be bidirectional, with the possibility of calcium influx following depolarization of the plasma membrane. Topological modeling suggests the presence of 10 TM domains, with a large intracellular loop between the fifth and sixth TM regions.

Nomenclature	Sodium/potassium/calcium exchanger 1	Sodium/potassium/calcium exchanger 6
Systematic nomenclature	SLC24A1	SLC24A6
Common abbreviation	NKCX1	NKCX6
HGNC, UniProt	SLC24A1, O60721	SLC8B1, Q6J4K2
Stoichiometry	4Na ⁺ :(1Ca ²⁺ + 1K ⁺)	–
Inhibitors	–	CGP-37157 (pIC ₅₀ 5.8) [494]

Comments: NKCX6 has been proposed to be the sole member of a CAX Na⁺/Ca²⁺ exchanger family, which may be the mitochondrial transporter responsible for calcium accumulation from the cytosol [652].

Further reading on SLC24 family of sodium/potassium/calcium exchangers

Schnetkamp PP. (2013) The SLC24 gene family of Na⁺/Ca²⁺-K⁺ exchangers: from sight and smell to memory consolidation and skin pigmentation. *Mol Aspects Med* **34**: 455-64 [PMID:23506883]

Schnetkamp PP *et al.* (2014) The SLC24 family of K⁺-dependent Na⁺-Ca²⁺ exchangers: structure-function relationships. *Curr Top Membr* **73**: 263-87 [PMID:24745986]

Sekler I. (2015) Standing of giants shoulders the story of the mitochondrial Na(+)Ca(2+) exchanger. *Biochem Biophys Res Commun* **460**: 50-2 [PMID:25998733]

SLC25 family of mitochondrial transporters

Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters

Overview: Mitochondrial carriers are nuclear-encoded proteins, which translocate solutes across the inner mitochondrial membrane. Mitochondrial carriers are functional as monomers and have six TM alpha-helices and the termini in the mitochondrial intermembrane space.

Mitochondrial di- and tri-carboxylic acid transporter subfamily

Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial di- and tri-carboxylic acid transporter subfamily

Overview: Mitochondrial di- and tri-carboxylic acid transporters are grouped on the basis of commonality of substrates and include the citrate transporter which facilitates **citric acid** export from the mitochondria to allow the generation of **oxalacetic acid** and **acetyl CoA** through the action of ATP:citrate lyase.

Nomenclature	Mitochondrial citrate transporter	Mitochondrial dicarboxylate transporter	Mitochondrial oxoglutarate carrier	Mitochondrial oxodicarboxylate carrier
Systematic nomenclature	SLC25A1	SLC25A10	SLC25A11	SLC25A21
Common abbreviation	CIC	DIC	OGC	ODC
HGNC, UniProt	SLC25A1 , P53007	SLC25A10 , Q9UBX3	SLC25A11 , Q02978	SLC25A21 , Q9BQT8
Substrates	citric acid , phosphoenolpyruvic acid , malic acid	succinic acid , malic acid , $S_2O_3^{2-}$, SO_4^{2-} , phosphate	α-ketoglutaric acid , malic acid	α-ketoglutaric acid , α-oxoadipic acid
Stoichiometry	Malate ²⁻ (in) : H-citrate ²⁻ (out)	PO ₃ ⁴⁻ (in) : malate ²⁻ (out)	Malate ²⁻ (in) : oxoglutarate ²⁻ (out)	Oxoadipate (in) : oxoglutarate (out)
Inhibitors	1,2,3-benzenetricarboxylic acid	–	–	–

Mitochondrial amino acid transporter subfamily

Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial amino acid transporter subfamily

Overview: Mitochondrial amino acid transporters can be subdivided on the basis of their substrates. Mitochondrial ornithine transporters play a role in the **urea** cycle by exchanging cytosolic ornithine (**L-ornithine** and **D-ornithine**) for mitochondrial citrulline (**L-citrulline** and **D-citrulline**) in equimolar amounts. Further members of the family include transporters of S-adenosylmethionine and carnitine.

Nomenclature	AGC1	AGC2	Mitochondrial glutamate carrier 2	Mitochondrial glutamate carrier 1	Mitochondrial ornithine transporter 2	Mitochondrial ornithine transporter 1	Carnitine/acylcarnitine carrier
Systematic nomenclature	SLC25A12	SLC25A13	SLC25A18	SLC25A22	SLC25A2	SLC25A15	SLC25A20
Common abbreviation	–	–	GC2	GC1	ORC2	ORC1	CAC
HGNC, UniProt	SLC25A12 , O75746	SLC25A13 , Q9UJS0	SLC25A18 , Q9H1K4	SLC25A22 , Q9H936	SLC25A2 , Q9BXI2	SLC25A15 , Q9Y619	SLC25A20 , O43772

Substrates	L-glutamic acid, L-aspartic acid, 2-amino-3-sulfinopropanoic acid	L-glutamic acid, L-aspartic acid, 2-amino-3-sulfinopropanoic acid	L-glutamic acid	L-glutamic acid	L-arginine [223], L-citrulline [223], L-lysine [223], L-ornithine [223], L-histidine [223], D-histidine [223], D-arginine [223], D-lysine [223], D-ornithine [223], D-citrulline [223]	L-arginine [223], L-citrulline [223], L-lysine [223], L-ornithine [223]	–
Stoichiometry	Aspartate : glutamate H ⁺ (bidirectional)	Aspartate : glutamate H ⁺ (bidirectional)	Glutamate : H ⁺ (bidirectional)	Glutamate : H ⁺ (bidirectional)	1 Ornithine (in) : 1 citrulline : 1 H ⁺ (out)	1 Ornithine (in) : 1 citrulline : 1 H ⁺ (out)	–
Comments	–	–	–	–	–	–	Exchanges cytosolic acylcarnitine for mitochondrial carnitine

Comments: Both ornithine transporters are inhibited by the polyamine [spermine](#) [224]. Loss-of-function mutations in these genes are associated with hyperornithinemia-hyperammonemia-homocitrullinuria.

Further reading on Mitochondrial amino acid transporter subfamily

Hewton KG *et al.* (2021) Transporters at the Interface between Cytosolic and Mitochondrial Amino Acid Metabolism. *Metabolites* **11**: [PMID:33669382]

Mitochondrial phosphate transporters

Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial phosphate transporters

Overview: Mitochondrial phosphate transporters allow the import of inorganic phosphate for ATP production.

Nomenclature	Mitochondrial phosphate carrier
Systematic nomenclature	SLC25A3
Common abbreviation	PHC
HGNC, UniProt	SLC25A3 , Q00325
Stoichiometry	PO ₃ ⁴⁻ (in) : OH ⁻ (out) or PO ₃ ⁴⁻ : H ⁺ (in)

Mitochondrial nucleotide transporter subfamily

Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial nucleotide transporter subfamily

Overview: Mitochondrial nucleotide transporters, defined by structural similarities, include the adenine nucleotide translocator family (SLC25A4, SLC25A5, SLC25A6 and SLC25A31), which under conditions of aerobic metabolism, allow coupling between mitochondrial oxidative phosphorylation and cytosolic energy consumption by exchanging cytosolic ADP for mitochondrial ATP. Further members of the mitochondrial nucleotide transporter subfamily convey diverse substrates including CoA, although not all members have had substrates identified.

Nomenclature	Mitochondrial adenine nucleotide translocator 1	Mitochondrial adenine nucleotide translocator 2	Mitochondrial adenine nucleotide translocator 3	Mitochondrial adenine nucleotide translocator 4	Graves disease carrier	Peroxisomal membrane protein
Systematic nomenclature	SLC25A4	SLC25A5	SLC25A6	SLC25A31	SLC25A16	SLC25A17
Common abbreviation	ANT1	ANT2	ANT3	ANT4	GDC	PMP34
HGNC, UniProt	SLC25A4 , P12235	SLC25A5 , P05141	SLC25A6 , P12236	SLC25A31 , Q9H0C2	SLC25A16 , P16260	SLC25A17 , O43808
Substrates	–	–	–	–	CoA and congeners	ADP, ATP, adenosine 5'-monophosphate
Stoichiometry	ADP ³⁻ (in) : ATP ⁴⁻ (out)	ADP ³⁻ (in) : ATP ⁴⁻ (out)	ADP ³⁻ (in) : ATP ⁴⁻ (out)	ADP ³⁻ (in) : ATP ⁴⁻ (out)	CoA (in)	ATP (in)
Inhibitors	bongkrek acid , carboxyatractyloside	–	–	–	–	–

Nomenclature	Deoxynucleotide carrier 1	S-Adenosylmethionine carrier	Mitochondrial phosphate carrier 1	Mitochondrial phosphate carrier 2	Mitochondrial phosphate carrier 3
Systematic nomenclature	SLC25A19	SLC25A26	SLC25A24	SLC25A23	SLC25A25
Common abbreviation	DNC	SAMC1	APC1	APC2	APC3
HGNC, UniProt	SLC25A19 , Q9HC21	SLC25A26 , Q70HW3	SLC25A24 , Q6NUK1	SLC25A23 , Q9BV35	SLC25A25 , Q6KCM7
Substrates	Deoxynucleotide Triphosphates (dNTPs), Deoxynucleotide Diphosphates (dNDPs), Nucleotide Diphosphates (NDPs), Dideoxynucleotide Triphosphates (ddNTPs)	S-adenosyl methionine	–	–	–
Stoichiometry	dNDP (in) : ATP (out)	–	–	–	–

Further reading on Mitochondrial nucleotide transporter subfamily

Ruprecht JJ *et al.* (2019) Structural changes in the transport cycle of the mitochondrial ADP/ATP carrier. *Curr Opin Struct Biol* **57**: 135-144 [PMID:31039524]

Ruprecht JJ *et al.* (2021) Structural Mechanism of Transport of Mitochondrial Carriers. *Annu Rev Biochem* **90**: 535-558 [PMID:33556281]

Mitochondrial uncoupling proteins

Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial uncoupling proteins

Overview: Mitochondrial uncoupling proteins allow dissipation of the mitochondrial proton gradient associated with thermogenesis and regulation of radical formation.

Nomenclature	Uncoupling protein 1	Uncoupling protein 2	Uncoupling protein 3	Uncoupling protein 4	Uncoupling protein 5	KMCP1
Systematic nomenclature	SLC25A7	SLC25A8	SLC25A9	SLC25A27	SLC25A14	SLC25A30
Common abbreviation	UCP1	UCP2	UCP3	UCP4	UCP5	–
HGNC, UniProt	UCP1 , P25874	UCP2 , P55851	UCP3 , P55916	SLC25A27 , O95847	SLC25A14 , O95258	SLC25A30 , Q5SVS4
Stoichiometry	H ⁺ (in)	H ⁺ (in)	H ⁺ (in)	H ⁺ (in)	H ⁺ (in)	–

Miscellaneous SLC25 mitochondrial transporters

Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Miscellaneous SLC25 mitochondrial transporters

Overview: Many of the transporters identified below have yet to be assigned functions and are currently regarded as orphans.

Information on members of this family may be found in the [online database](#).

Further reading on SLC25 family of mitochondrial transporters

- Baffy G. (2017) Mitochondrial uncoupling in cancer cells: Liabilities and opportunities. *Biochim Biophys Acta* **1858**: 655-664 [PMID:28088333]
- Crichton PG *et al.* (2017) The molecular features of uncoupling protein 1 support a conventional mitochondrial carrier-like mechanism. *Biochimie* **134**: 35-50 [PMID:28057583]
- Dolce V *et al.* (2014) Mitochondrial tricarboxylate and dicarboxylate-tricarboxylate carriers: from animals to plants. *IUBMB Life* **66**: 462-71 [PMID:25045044]
- Klingenberg M. (2017) UCP1 - A sophisticated energy valve. *Biochimie* **134**: 19-27 [PMID:27794497]
- Kunji ERS *et al.* (2020) The SLC25 Carrier Family: Important Transport Proteins in Mitochondrial Physiology and Pathology. *Physiology (Bethesda)* **35**: 302-327 [PMID:32783608]
- Lytovchenko O *et al.* (2017) Expression and putative role of mitochondrial transport proteins in cancer. *Biochim Biophys Acta Bioenerg* **1858**: 641-654 [PMID:28342810]
- Nicholls DG. (2017) The hunt for the molecular mechanism of brown fat thermogenesis. *Biochimie* **134**: 9-18 [PMID:27621145]
- Palmieri F *et al.* (2022) Mitochondrial transport and metabolism of the vitamin B-derived cofactors thiamine pyrophosphate, coenzyme A, FAD and NAD⁺, and related diseases: A review. *IUBMB Life* **74**: 592-617 [PMID:35304818]
- Palmieri F *et al.* (2020) Diseases Caused by Mutations in Mitochondrial Carrier Genes SLC25: A Review. *Biomolecules* **10**: [PMID:32340404]
- Ruprecht JJ *et al.* (2020) The SLC25 Mitochondrial Carrier Family: Structure and Mechanism. *Trends Biochem Sci* **45**: 244-258 [PMID:31787485]

SLC26 family of anion exchangers

Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers

Overview: Along with the SLC4 family, the SLC26 family acts to allow movement of monovalent and divalent anions across cell membranes. The predicted topology is of 10-14 TM domains with intracellular C- and N-termini, probably existing as dimers. Within the family, subgroups may be identified on the basis of functional differences, which appear to function as anion exchangers and anion channels (SLC26A7 and SLC26A9).

Selective sulphate transporters

Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers → Selective sulphate transporters

Nomenclature	Sat-1	DTDST
Systematic nomenclature	SLC26A1	SLC26A2
HGNC, UniProt	SLC26A1 , Q9H2B4	SLC26A2 , P50443
Substrates	oxalate, SO_4^{2-}	SO_4^{2-}
Stoichiometry	SO_4^{2-} (in) : anion (out)	1 SO_4^{2-} (in) : 2 Cl^- (out)

Chloride/bicarbonate exchangers

Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers → Chloride/bicarbonate exchangers

Nomenclature	DRA	Pendrin	PAT-1
Systematic nomenclature	SLC26A3	SLC26A4	SLC26A6
HGNC, UniProt	SLC26A3 , P40879	SLC26A4 , O43511	SLC26A6 , Q9BX59
Substrates	Cl^-	Cl^- , formate, OH^- , I^- , HCO_3^-	Cl^- , oxalate, formate, OH^- , SO_4^{2-} , I^- , HCO_3^-
Stoichiometry	2 Cl^- (in) : 1 HCO_3^- (out) or 2 Cl^- (in) : 1 OH^- (out)	Unknown	1 SO_4^{2-} (in) : 2 HCO_3^- (out) or 1 Cl^- (in) : 2 HCO_3^- (out)

Anion channels

Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers → Anion channels

Nomenclature	SLC26A7	SLC26A9
HGNC, UniProt	SLC26A7 , Q8TE54	SLC26A9 , Q7LBE3
Substrates	$\text{NO}_3^- \gg \text{Cl}^- = \text{Br}^- = \text{I}^- > \text{SO}_4^{2-} = \text{L-glutamic acid}$	$\text{I}^- > \text{Br}^- > \text{NO}_3^- > \text{Cl}^- > \text{L-glutamic acid}$
Functional Characteristics	Voltage- and time-independent current, linear I-V relationship [403]	Voltage- and time-independent current, linear I-V relationship [180]
Comments	–	SLC26A9 has been suggested to operate in two additional modes as a $\text{Cl}^-/\text{HCO}_3^-$ exchanger and as a Na^+ -anion cotransporter [112].

Other SLC26 anion exchangers

Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers → Other SLC26 anion exchangers

Nomenclature	Prestin
Systematic nomenclature	SLC26A5
HGNC, UniProt	SLC26A5 , P58743
Substrates	Cl^- [511], HCO_3^- [511]
Stoichiometry	Unknown
Comments	Prestin has been suggested to function as a molecular motor, rather than a transporter

Further reading on SLC26 family of anion exchangers

Alper SL *et al.* (2013) The SLC26 gene family of anion transporters and channels. *Mol Aspects Med* **34**: 494-515 [PMID:23506885]
 Kato A *et al.* (2011) Regulation of electroneutral NaCl absorption by the small intestine. *Annu Rev Physiol* **73**: 261-81 [PMID:21054167]

Nofziger C *et al.* (2011) Pendrin function in airway epithelia. *Cell Physiol Biochem* **28**: 571-8 [PMID:22116372]

Soleimani M. (2013) SLC26 $\text{Cl}^-/\text{HCO}_3^-$ exchangers in the kidney: roles in health and disease. *Kidney Int* **84**: 657-66 [PMID:23636174]

SLC27 family of fatty acid transporters

Transporters → SLC superfamily of solute carriers → SLC27 family of fatty acid transporters

Overview: Fatty acid transporter proteins (FATPs) are a family (SLC27) of six transporters (FATP1-6). They have at least one, and possibly six [455, 643], transmembrane segments, and are predicted on the basis of structural similarities to form dimers. SLC27 members have several structural domains: integral membrane associated domain, peripheral membrane associat-

ed domain, FATP signature, intracellular AMP binding motif, dimerization domain, lipocalin motif, and an ER localization domain (identified in FATP4 only) [210, 507, 560]. These transporters are unusual in that they appear to express intrinsic very long-chain acyl-CoA synthetase (EC 6.2.1.-, EC 6.2.1.7) enzyme activity. Within the cell, these transporters may associate with

plasma and peroxisomal membranes. FATP1-4 and -6 transport long- and very long-chain fatty acids, while FATP5 transports long-chain fatty acids as well as bile acids [11, 506, 643].

Nomenclature	Fatty acid transport protein 1	Fatty acid transport protein 2	Fatty acid transport protein 3	Fatty acid transport protein 4	Fatty acid transport protein 5	Fatty acid transport protein 6
Systematic nomenclature	SLC27A1	SLC27A2	SLC27A3	SLC27A4	SLC27A5	SLC27A6
Common abbreviation	FATP1	FATP2	FATP3	FATP4	FATP5	FATP6
HGNC, UniProt	SLC27A1 , Q6PCB7	SLC27A2 , O14975	SLC27A3 , Q5K4L6	SLC27A4 , Q6P1M0	SLC27A5 , Q9Y2P5	SLC27A6 , Q9Y2P4
Endogenous substrates	arachidonic acid > palmitic acid > oleic acid > butyric acid [643] palmitic acid > oleic acid > γ -linolenic acid > octanoic acid [266]	–	–	palmitic acid > oleic acid > butyric acid, γ -linolenic acid > arachidonic acid [675] palmitic acid, oleic acid > γ -linolenic acid > octanoic acid [266]	–	palmitic acid > oleic acid > γ -linolenic acid > octanoic acid [266]
Inhibitors	–	–	–	compound 11 (pIC ₅₀ 7.1) [70]	–	–
Comments	–	–	–	FATP4 is genetically linked to restrictive dermatopathy	–	–

Comments: Although the stoichiometry of fatty acid transport is unclear, it has been proposed to be facilitated by the coupling of fatty acid transport to conjugation with coenzyme A to form fatty acyl CoA esters. Small molecule inhibitors of FATP2 [456, 639] and FATP4 [70, 852], as well as bile acid inhibitors of FATP5 [852], have been described; analysis of the mechanism of action

of some of these inhibitors suggests that transport may be selectively inhibited without altering enzymatic activity of the FATP.

C1-BODIPY-C12 accumulation has been used as a non-selective index of fatty acid transporter activity.

FATP2 has two variants: Variant 1 encodes the full-length protein,

while Variant 2 encodes a shorter isoform missing an internal protein segment. FATP6 also has two variants: Variant 2 encodes the same protein as Variant 1 but has an additional segment in the 5' UTR.

Further reading on SLC27 family of fatty acid transporters

Anderson CM *et al.* (2013) SLC27 fatty acid transport proteins. *Mol Aspects Med* **34**: 516-28 [PMID:23506886]

Dourlen P *et al.* (2015) Fatty acid transport proteins in disease: New insights from invertebrate models. *Prog Lipid Res* **60**: 30-40 [PMID:26416577]

Schwenk RW *et al.* (2010) Fatty acid transport across the cell membrane: regulation by fatty acid transporters. *Prostaglandins Leukot Essent Fatty Acids* **82**: 149-54 [PMID:20206486]

SLC28 and SLC29 families of nucleoside transporters

Transporters → SLC superfamily of solute carriers → SLC28 and SLC29 families of nucleoside transporters

Overview: Nucleoside transporters are divided into two families, the sodium-dependent, concentrative solute carrier family 28 (SLC28) and the equilibrative, solute carrier family 29 (SLC29). The endogenous substrates are typically nucleosides, although some family members can also transport nucleobases and organic cations [11].

SLC28 family

Transporters → SLC superfamily of solute carriers → SLC28 and SLC29 families of nucleoside transporters → SLC28 family

Overview: SLC28 family members appear to have 13 TM segments with cytoplasmic N-termini and extracellular C-termini, and function as concentrative nucleoside transporters.

Nomenclature	Sodium/nucleoside cotransporter 1	Sodium/nucleoside cotransporter 2	Solute carrier family 28 member 3
Systematic nomenclature	SLC28A1	SLC28A2	SLC28A3
Common abbreviation	CNT1	CNT2	CNT3
HGNC, UniProt	SLC28A1 , O00337	SLC28A2 , O43868	SLC28A3 , Q9HAS3
Substrates	gemcitabine [129], zidovudine , zalcitabine , ribavirin [130]	formycin B [438], cladribine [564], vidarabine , didanosine , fludarabine [438]	zalcitabine , 5-fluorouridine , zebularine , formycin B , gemcitabine , cladribine , floxuridine , didanosine , zidovudine
Endogenous substrates	adenosine , uridine , thymidine , cytidine	adenosine , inosine , guanosine , thymidine	adenosine , inosine , uridine , guanosine , thymidine , cytidine
Stoichiometry	1 Na ⁺ : 1 nucleoside (in)	1 Na ⁺ : 1 nucleoside (in)	2 Na ⁺ /H ⁺
Inhibitors	–	–	compound 16 (pK _i 5.5) [311]
Comments	–	–	CNT3 forms cyclic homotrimers [678]. Genetic variants of SLC28A3 are associated with increased risk of anthracycline-induced cardiomyopathy [676].

Further reading on SLC28 family

Johnson ZL *et al.* (2014) Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters. *Elife* **3**: e03604 [PMID:25082345]

Pastor-Anglada M *et al.* (2008) SLC28 genes and concentrative nucleoside transporter (CNT) proteins. *Xenobiotica* **38**: 972-94 [PMID:18668436]

Pastor-Anglada M *et al.* (2018) Who Is Who in Adenosine Transport. *Front Pharmacol* **9**: 627 [PMID:29962948]

Pastor-Anglada M *et al.* (2015) Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. *Front Pharmacol* **6**: 13 [PMID:25713533]

Young JD *et al.* (2013) The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. *Mol Aspects Med* **34**: 529-47 [PMID:23506887]

SLC29 family

Transporters → SLC superfamily of solute carriers → SLC28 and SLC29 families of nucleoside transporters → SLC29 family

Overview: SLC29 family members are composed of 11 TM segments with cytoplasmic N-termini and extracellular C-termini. ENT1, ENT2 and ENT4 are primarily cell-surface transporters, while ENT3 is intracellular, possibly lysosomal [45]. ENT2 isoforms may also play a role in the nucleolar transport of nucleosides [288]. ENT1-3 are described as broad-spectrum equilibrative nucleoside transporters. ENT4 is primarily a polyspecific organic cation transporter at neutral pH [337], but transports adenosine and analogues such as 2-chloroadenosine, with affinities similar to other members of the SLC29 family, at acidic pH [701].

Nomenclature	Equilibrative nucleoside transporter 1	Equilibrative nucleoside transporter 2
Systematic nomenclature	SLC29A1	SLC29A2
Common abbreviation	ENT1	ENT2
HGNC, UniProt	SLC29A1 , Q99808	SLC29A2 , Q14542
Endogenous substrates in order of increasing Km:	adenosine < inosine < uridine < guanosine < cytidine < hypoxanthine < adenine < thymine	–
Substrates	formycin B , tubercidin , gemcitabine , cladribine , floxuridine , pentostatin , vidarabine , 2-chloroadenosine , cytarabine , zalcitabine , didanosine , ribavirin [130], abacavir [109], atenolol [508]	formycin B , tubercidin , gemcitabine , cladribine , vidarabine , zidovudine , cytarabine , 2-chloroadenosine
Endogenous substrates	adenosine [823], inosine [823], guanosine [823], thymidine [823], cytidine [823], adenine [823], uridine [823], hypoxanthine [823], thymine [823]	adenosine , inosine , hypoxanthine , uridine , guanosine , thymidine , guanine , thymine , cytosine
Stoichiometry	Equilibrative	Equilibrative
Inhibitors	nitrobenzylmercaptapurine ribonucleoside (pK _i 9.7), draflazine (pK _i 9.6) [317], KF24345 (pK _i 9.4) [318], NBTGR (pK _i 9.3), dilazep (pK _i 9), dipyridamole (pK _i 8.8) [318], ticagrelor (pK _i 7.3) [33]	–
Labelled ligands	[³H]nitrobenzylmercaptapurine ribonucleoside (pK _d 9.3)	–
Comments	SLC29A1 (ENT1) has 100-1000-fold lower affinity for nucleobases as compared with nucleosides [823]. The affinities of draflazine , dilazep , KF24345 and dipyridamole at SLC29A1 transporters are species dependent, exhibiting lower affinity at rat transporters than at human transporters [318, 685]. Dilazep and nitrobenzylmercaptapurine ribonucleoside have distinct but overlapping binding domains in the SLC29A1 crystal structure [797]. The loss of SLC29A1 activity in SLC29A1-null mice has been associated with a hypermineralization disorder similar to human diffuse idiopathic skeletal hyperostosis [781]. Lack of SLC29A1 also results in the Augustine-null blood type [150]. SLC29A1 forms homodimers and heterodimers (with SLC29A2) [289].	–

Nomenclature	Equilibrative nucleoside transporter 3	Plasma membrane monoamine transporter
Systematic nomenclature	SLC29A3	SLC29A4
Common abbreviation	ENT3	PMAT
HGNC, UniProt	SLC29A3 , Q9BZD2	SLC29A4 , Q7RTT9
Substrates	didanosine [45], cordycepin [45], zebularine [45], tubercidin [45], cladribine [45], fludarabine [45], zalcitabine [45], floxuridine [45], zidovudine [45]	tetraethylammonium [200, 770], MPP⁺ [200, 770], metformin [851], atenolol [508]
Endogenous substrates	adenosine [45], inosine [45], uridine [45], guanosine [45], thymidine [45], adenine [45]	dopamine [200, 770], 5-hydroxytryptamine [200, 770], histamine [200, 770], tyramine [200, 770], adenosine [850]
Stoichiometry	Equilibrative	Equilibrative
Inhibitors	–	decynium 22 (pK _i 7) [200, 770], rhodamine123 (pK _i 6) [200, 770], dipyridamole (pK _i 5.9) [766], verapamil (pK _i 4.7) [200, 770], fluoxetine (pK _i 4.6) [200, 770], quinidine (pK _i 4.6) [200, 770], quinine (pK _i 4.6) [200, 770], desipramine (pK _i 4.5) [200, 770], cimetidine (pK _i <3.3) [200, 770]
Comments	Defects in <i>SLC29A3</i> have been implicated in histiocytosis-lymphadenopathy plus syndrome (OMIM:602782) and lysosomal storage diseases [341, 391].	Uptake of substrates by PMAT is pH dependent, with greater uptake observed at acidic extracellular pH [51, 851].

Further reading on SLC29 family

Boswell-Casteel RC *et al.* (2017) Equilibrative nucleoside transporters-A review. *Nucleosides Nucleotides Nucleic Acids* **36**: 7-30 [[PMID:27759477](#)]
 Pastor-Anglada M *et al.* (2018) Who Is Who in Adenosine Transport. *Front Pharmacol* **9**: 627 [[PMID:29962948](#)]

Wang J. (2016) The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition. *Clin Pharmacol Ther* **100**: 489-499 [[PMID:27506881](#)]

Further reading on SLC28 and SLC29 families of nucleoside transporters

Boswell-Casteel RC *et al.* (2017) Equilibrative nucleoside transporters-A review. *Nucleosides Nucleotides Nucleic Acids* **36**: 7-30 [[PMID:27759477](#)]
 Pastor-Anglada M *et al.* (2015) Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. *Front Pharmacol* **6**: 13 [[PMID:25713533](#)]

Young JD. (2016) The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey. *Biochem Soc Trans* **44**: 869-76 [[PMID:27284054](#)]

Young JD *et al.* (2013) The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. *Mol Aspects Med* **34**: 529-47 [[PMID:23506887](#)]

SLC30 zinc transporter family

Transporters → SLC superfamily of solute carriers → SLC30 zinc transporter family

Overview: Along with the [SLC39 family](#), SLC30 transporters regulate the movement of zinc ions around the cell. In particular, these transporters remove zinc ions from the cytosol, allowing accumulation into intracellular compartments or efflux through the plasma membrane. ZnT1 is thought to be

placed on the plasma membrane extruding zinc, while ZnT3 is associated with synaptic vesicles and ZnT4 and ZnT5 are linked with secretory granules. Membrane topology predictions suggest a multimeric assembly, potentially heteromultimeric [688], with subunits having six TM domains, and both termini being

cytoplasmic. Dityrosine covalent linking has been suggested as a mechanism for dimerisation, particularly for ZnT3 [637]. The mechanism for zinc transport is unknown.

Information on members of this family may be found in the [online database](#).

Comments: ZnT8/SLC30A8 is described as a type 1 diabetes susceptibility gene.

Zinc fluxes may be monitored through the use of radioisotopic Zn-65 or the fluorescent dye FluoZin 3.

Further reading on SLC30 zinc transporter family

Bouron A *et al.* (2014) Contribution of calcium-conducting channels to the transport of zinc ions. *Pflugers Arch* **466**: 381-7 [PMID:23719866]

Hojyo S *et al.* (2016) Zinc transporters and signaling in physiology and pathogenesis. *Arch Biochem Biophys* **611**: 43-50 [PMID:27394923]

Huang L *et al.* (2013) The SLC30 family of zinc transporters - a review of current understanding of their biological and pathophysiological roles. *Mol Aspects Med* **34**: 548-60 [PMID:23506888]

Kambe T *et al.* (2014) Current understanding of ZIP and ZnT zinc transporters in human health and diseases. *Cell Mol Life Sci* **71**: 3281-95 [PMID:24710731]

Kambe T *et al.* (2015) The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in Zinc Homeostasis and Metabolism. *Physiol Rev* **95**: 749-784 [PMID:26084690]

SLC31 family of copper transporters

Transporters → SLC superfamily of solute carriers → SLC31 family of copper transporters

Overview: SLC31 family members, alongside the [Cu-ATPases](#) are involved in the regulation of cellular copper levels. The CTR1 transporter is a cell-surface transporter to allow monovalent copper accumulation into cells, while CTR2 appears to be a vacuolar/vesicular transporter [602]. Functional copper transporters appear to be trimeric with each subunit having three TM regions and an extracellular N-terminus. CTR1 is considered to be a higher affinity copper transporter compared to CTR2. The stoichiometry of copper accumulation is unclear, but appears to be energy-independent [443].

Nomenclature	Copper transporter 1	Copper transporter 2
Systematic nomenclature	SLC31A1	SLC31A2
Common abbreviation	CTR1	CTR2
HGNC, UniProt	SLC31A1 , O15431	SLC31A2 , O15432
Substrates	cisplatin [362]	cisplatin [71]
Endogenous substrates	copper [443]	copper
Stoichiometry	Unknown	Unknown

Comments: Copper accumulation through CTR1 is sensitive to silver ions, but not divalent cations [443].

Further reading on SLC31 family of copper transporters

Howell SB *et al.* (2010) Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. *Mol Pharmacol* **77**: 887-94 [PMID:20159940]

Kaplan JH *et al.* (2016) How Mammalian Cells Acquire Copper: An Essential but Potentially Toxic Metal. *Biophys J* **110**: 7-13 [PMID:26745404]

Kim H *et al.* (2013) SLC31 (CTR) family of copper transporters in health and disease. *Mol Aspects Med* **34**: 561-70 [PMID:23506889]

Monné M *et al.* (2014) Antiporters of the mitochondrial carrier family. *Curr Top Membr* **73**: 289-320 [PMID:24745987]

SLC32 vesicular inhibitory amino acid transporter

Transporters → SLC superfamily of solute carriers → SLC32 vesicular inhibitory amino acid transporter

Overview: The vesicular inhibitory amino acid transporter, VIAAT (also termed the vesicular GABA transporter VGAT), which is the sole representative of the SLC32 family, transports GABA, or glycine, into synaptic vesicles [254, 255], and is a member of the structurally-defined amino acid-polyamine-organocation/APC clan composed of SLC32, SLC36 and SLC38 transporter families (see [645]). VIAAT was originally suggested to be composed of 10 TM segments with cytoplasmic N- and C-termini [496]. However, an alternative 9TM structure with the

N terminus facing the cytoplasm and the C terminus residing in the synaptic vesicle lumen has subsequently been reported [493]. VIAAT acts as an antiporter for inhibitory amino acids and protons. The accumulation of GABA and glycine within vesicles is driven by both the chemical (ΔpH) and electrical ($\Delta\psi$) components of the proton electrochemical gradient ($\Delta\mu_{\text{H}^+}$) established by a vacuolar H^+ -ATPase [496]. However, one study, [382], presented evidence that VIAAT is instead a Cl^- /GABA co-transporter. VIAAT co-exists with VGLUT1 (SLC17A7),

or VGLUT2 (SLC17A6), in the synaptic vesicles of selected nerve terminals [214, 834]. VIAAT knock out mice die between embryonic day 18.5 and birth [791]. In cultures of spinal cord neurones established from earlier embryos, the co-release of GABA and glycine from synaptic vesicles is drastically reduced, providing direct evidence for the role of VIAAT in the sequestration of both transmitters [633, 791].

Nomenclature	Vesicular inhibitory amino acid transporter
Systematic nomenclature	SLC32A1
Common abbreviation	VIAAT
HGNC, UniProt	SLC32A1, Q9H598
Endogenous substrates	GABA (K_m 5×10^{-3} M) [496], glycine, β -alanine, γ -hydroxybutyric acid
Stoichiometry	1 amino acid (in): 1 H^+ (out) [255] or 1 amino acid: 2 Cl^- (in) [382]
Inhibitors	vigabatrin (pIC_{50} 2.1) [496]

Further reading on SLC32 vesicular inhibitory amino acid transporter

Anne C *et al.* (2014) Vesicular neurotransmitter transporters: mechanistic aspects. *Curr Top Membr* **73**: 149-74 [PMID:24745982]

Schiöth HB *et al.* (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects. *Mol Aspects Med* **34**: 571-85 [PMID:23506890]

SLC33 acetylCoA transporter

Transporters → SLC superfamily of solute carriers → SLC33 acetylCoA transporter

Overview: Acetylation of proteins is a post-translational modification mediated by specific acetyltransferases, using the donor **acetyl CoA**. SLC33A1/AT1 is a putative 11 TM transporter present on the endoplasmic reticulum, expressed in all tissues, but particularly abundant in the pancreas [390], which imports cytosolic **acetyl CoA** into these intracellular organelles.

Nomenclature	AcetylCoA transporter
Systematic nomenclature	SLC33A1
Common abbreviation	ACATN1
HGNC, UniProt	SLC33A1, O00400
Endogenous substrates	acetyl CoA
Stoichiometry	Unknown
Labelled ligands	[¹⁴ C]acetylCoA (Binding)

Comments: In heterologous expression studies, **acetyl CoA** transport through AT1 was inhibited by **coenzyme A**, but not **acetic acid**, **ATP** or **UDP-galactose** [378]. A loss-of-function mutation in ACATN1/SLC33A1 has been associated with spastic paraplegia (SPG42, [460]), although this observation could not be replicated in a subsequent study [647].

Further reading on SLC33 acetylCoA transporter

Hirabayashi Y *et al.* (2004) The acetyl-CoA transporter family SLC33. *Pflugers Arch* **447**: 760-2
[PMID:12739170]

Hirabayashi Y *et al.* (2013) The acetyl-CoA transporter family SLC33. *Mol Aspects Med* **34**: 586-9
[PMID:23506891]

SLC34 family of sodium phosphate co-transporters

Transporters → SLC superfamily of solute carriers → SLC34 family of sodium phosphate co-transporters

Overview: The SLC34 family are sometimes referred to as Type II sodium-phosphate co-transporters, alongside Type I (SLC17 family) and Type III (SLC20 family) transporters. Topological modelling suggests eight TM domains with C- and N- termini in the cytoplasm, and a re-entrant loop at TM7/8. SLC34 family members are expressed on the apical surfaces of epithelia in the intestine and kidneys to regulate body phosphate levels, principally NaPi-IIa and NaPi-IIb, respectively. NaPi-IIa and NaPi-IIb are electrogenic, while NaPiIIc is electroneutral [24].

Nomenclature	Sodium phosphate 1	Sodium phosphate 2	Sodium phosphate 3
Systematic nomenclature	SLC34A1	SLC34A2	SLC34A3
Common abbreviation	NaPi-IIa	NaPi-IIb	NaPi-IIc
HGNC, UniProt	SLC34A1 , Q06495	SLC34A2 , O95436	SLC34A3 , Q8N130
Stoichiometry	3 Na ⁺ : 1 HPO ₄ ²⁻ (in) [232]	3 Na ⁺ : 1 HPO ₄ ²⁻ (in) [24]	2 Na ⁺ : 1 HPO ₄ ²⁻ (in) [24]
Inhibitors	–	compound 15 (pIC ₅₀ 7.2) [486]	–
Antibodies	–	lifastuzumab vedotin (Binding) [163]	–
Comments	–	NaPi2b is highly expressed by ovarian and non-small cell lung cancer (NSCLC) carcinomas, and is being actively pursued as a drug target for these tumours. XMT-1536 (Mersana Therapeutics) has entered Phase 1 proof-of-concept trial NCT03319628. Lifastuzumab vedotin (Genentech) reached Phase 2 evaluation, but trial NCT01991210 was terminated as the test agent failed to increase progression-free survival compared to standard-of-care pegylated liposomal doxorubicin, in ovarian cancer patients [50]. XMT-1536 and lifastuzumab vedotin are NaPi2b-directed monoclonal antibody-drug conjugates (ADCs).	

Comments: These transporters can be inhibited by [foscarnet](#), in contrast to type III sodium-phosphate cotransporters, the [SLC20 family](#).

Further reading on SLC34 family of sodium phosphate co-transporters

Biber J *et al.* (2013) Phosphate transporters and their function. *Annu Rev Physiol* **75**: 535-50
[PMID:23398154]

Forster IC *et al.* (2013) Phosphate transporters of the SLC20 and SLC34 families. *Mol Aspects Med* **34**: 386-95 [PMID:23506879]

Shobeiri N *et al.* (2014) Phosphate: an old bone molecule but new cardiovascular risk factor. *Br J Clin Pharmacol* **77**: 39-54 [PMID:23506202]

Wagner CA *et al.* (2014) The SLC34 family of sodium-dependent phosphate transporters. *Pflugers Arch* **466**: 139-53 [PMID:24352629]

SLC35 family of nucleotide sugar transporters

Transporters → [SLC superfamily of solute carriers](#) → [SLC35 family of nucleotide sugar transporters](#)

Overview: Glycoprotein formation in the Golgi and endoplasmic reticulum relies on the accumulation of nucleotide-conjugated sugars via the SLC35 family of transporters. These transporters have a predicted topology of 10 TM domains, with cytoplasmic termini, and function as exchangers, swapping nucleoside monophosphates for the corresponding nucleoside diphosphate conjugated sugar. Five subfamilies of transporters have been identified on the basis of sequence similarity, namely SLC35A1, SLC35A2, SLC35A3, SLC35A4 and SLC35A5; SLC35B1, SLC35B2, SLC35B3 and SLC35B4; SLC35C1 and SLC35C2; SLC35D1, SLC35D2 and SLC35D3, and the subfamily of orphan SLC35 transporters, SLC35E1-4 and SLC35F1-5.

Nomenclature	CMP-sialic acid transporter	UDP-galactose transporter	UDP-N-acetylglucosamine transporter	PAPS transporter 1	PAPS transporter 2
Systematic nomenclature	SLC35A1	SLC35A2	SLC35A3	SLC35B2	SLC35B3
HGNC, UniProt	SLC35A1 , P78382	SLC35A2 , P78381	SLC35A3 , Q9Y2D2	SLC35B2 , Q8TB61	SLC35B3 , Q9H1N7
Substrates	CMP-sialic acid [358]	UDP-N-acetyl-glucosamine [360, 513], UDP-galactose [360, 513]	UDP-N-acetyl-glucosamine [361]	A3P5PS [385]	A3P5PS [384]

Searchable database: <https://www.guidetopharmacology.org/>

Full Contents of ConciseGuide: <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182/full>

SSLC35 family of nucleotide sugar transporters S439

Nomenclature	YEA	GDP-Fucose transporter	UDP-glucuronic acid/UDP-N-acetylgalactosamine dual transporter	HFRC1
Systematic nomenclature	SLC35B4	SLC35C1	SLC35D1	SLC35D2
HGNC, UniProt	SLC35B4 , Q969S0	SLC35C1 , Q96A29	SLC35D1 , Q9NTN3	SLC35D2 , Q76EJ3
Substrates	UDP N-acetyl-glucosamine [35], UDP-xylose [35]	GDP-fucose [477]	UDP-glucuronic acid [524], UDP-N-acetylgalactosamine [524]	UDP-N-acetylgalactosamine [359]

Further reading on SLC35 family of nucleotide sugar transporters

Ishida N *et al.* (2004) Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35). *Pflugers Arch* **447**: 768-75 [PMID:12759756]

Orellana A *et al.* (2016) Overview of Nucleotide Sugar Transporter Gene Family Functions Across Multiple Species. *J Mol Biol* **428**: 3150-3165 [PMID:27261257]

Song Z. (2013) Roles of the nucleotide sugar transporters (SLC35 family) in health and disease. *Mol Aspects Med* **34**: 590-600 [PMID:23506892]

SLC36 family of proton-coupled amino acid transporters

Transporters → SLC superfamily of solute carriers → SLC36 family of proton-coupled amino acid transporters

Overview: Members of the SLC36 family of proton-coupled amino acid transporters are involved in membrane transport of amino acids and derivatives [722, 723]. The four transporters show variable tissue expression patterns and are expressed in various cell types at the plasma-membrane and in intracellular

organelles. PAT1 is expressed at the luminal surface of the small intestine and absorbs amino acids and derivatives [20]. In lysosomes, PAT1 functions as an efflux mechanism for amino acids produced during intralysosomal proteolysis [6, 628]. PAT2 is expressed at the apical membrane of the renal proximal tubule

[94] and at the plasma-membrane in brown/beige adipocytes [742]. PAT1 and PAT4 are involved in regulation of the mTORC1 pathway [211, 656]. More comprehensive lists of substrates can be found within the reviews under Further Reading and in the references [11].

Nomenclature	Proton-coupled Amino acid Transporter 1	Proton-coupled Amino acid Transporter 2
Systematic nomenclature	SLC36A1	SLC36A2
Common abbreviation	PAT1	PAT2
HGNC, UniProt	SLC36A1 , Q7Z2H8	SLC36A2 , Q495M3
Substrates	MeAIB [723], vigabatrin [1, 723], L-azetidine-2-carboxylate [723], gaboxadol [439, 723], THPO [723], betaine [723], β -guanidinopropionic acid [723], 5-aminolevulinic acid [723], L-cycloserine [723], muscimol [723], arecaidine [723], D-cycloserine [723], nicotianamine-Fe (II) complex [525]	MeAIB [122], L-azetidine-2-carboxylate [399], L-cycloserine, D-cycloserine
Endogenous substrates	taurine [723], β -alanine [723], GABA [723], D-serine [723], D-alanine [723], sarcosine [723], L-alanine [723], D-cysteine [723], glycine [723], trans-4-hydroxy-proline [723], D-proline [723]	glycine, L-proline, trans-4-hydroxy-proline, L-alanine, sarcosine
Stoichiometry	1 H ⁺ : 1 amino acid (symport)	1 H ⁺ : 1 amino acid (symport)

Inhibitors	17β-estradiol (pIC ₅₀ 5–5.2) [541], ethinylestradiol (pIC ₅₀ 4.3–4.6) [541], 5-hydroxy-L-tryptophan (pK _i 3) [501], L-tryptophan (pK _i 2.3) [501], indole-3-propionic acid (pK _i 2.3) [501], 5-hydroxytryptamine (pK _i 2.2) [501]	5-hydroxy-L-tryptophan (pIC ₅₀ 2.8) [190], α-methyl-D,L-tryptophan (pIC ₅₀ 2.5) [190]
Comments	[³ H] or [¹⁴ C] labelled substrates as listed above are used as probes. PAT1 can also function as an electroneutral transport system for protons and short chain fatty acids including acetic acid, propanoic acid and butyric acid [228]. In addition, forskolin, phosphodiesterase inhibitors, amiloride analogues and SLC9A3 (NHE3) selective inhibitors all reduce PAT1 activity indirectly (in intact mammalian intestinal epithelia such as human intestinal Caco-2 cells) by inhibiting the Na ⁺ /H ⁺ exchanger NHE3 which is required to maintain the H ⁺ -electrochemical gradient driving force for H ⁺ /amino acid cotransport [20, 23, 723].	[³ H] or [¹⁴ C] labelled substrates as listed above are used as probes. Loss-of-function mutations in PAT2 lead to iminoglycinuria and hyperglycinuria in man [94]. PAT2 can also function as an electroneutral transport system for protons and fatty acids including acetic acid, propanoic acid and butyric acid [228]. Replacement of a Phe residue in transmembrane domain 3 with Cys (that has a smaller side-chain) broadens substrate specificity to include larger substrates (<i>e.g.</i> methionine, leucine) [191].

Nomenclature	Proton-coupled Amino acid Transporter 3	Proton-coupled Amino acid Transporter 4
Systematic nomenclature	SLC36A3	SLC36A4
Common abbreviation	PAT3	PAT4
HGNC, UniProt	SLC36A3 , Q495N2	SLC36A4 , Q6YBV0
Endogenous substrates	–	L-tryptophan [578], L-proline [578]
Stoichiometry	Unknown	Unknown
Comments	The function of the testes-specific PAT3 remains unknown.	PAT4 is not proton-coupled and functions by facilitated diffusion in an electroneutral, Na ⁺ -independent, manner [578]. PAT4 is expressed ubiquitously and is predominantly associated with the Golgi [212]. High PAT4 expression is associated with reduced relapse-free survival after colorectal cancer surgery [212].

Comments: The SLC36 transporters are part of the Amino Acid Auxin Permease (AAP) family within the Amino Acid-Polyamine-Organocation (APC) superfamily [645, 755]. In neuronal tissues, PAT1 is found predominantly in lysosomal membranes and to a lesser extent on neuronal plasma membranes [6, 628, 794]. PAT1 acts as a driver of mTORC1 signalling, contributing

CDK4/6 inhibitor resistance in melanoma [829]. PAT2 is found in myelinated fibres and in the endoplasmic reticulum in spinal cord and brain [60, 622]. In brown adipocytes, PAT2 acts as an extracellular amino acid sensor and regulates lysosomal acidification [771]. PAT4 is found in lysosomes in neurones and the plasma membrane of epithelial cells lining the lateral ventricles

[617]. High PAT4 expression is associated with reduced relapse-free survival after colorectal cancer surgery [212]. Inhibition of SLC36 transporters by indole-3-propionic acid suppresses proline-dependent tumour growth in *Drosophila melanogaster* [537]. In *C. elegans*, a SLC36 transporter is involved in lysosome reformation pathways [216, 244].

Further reading on SLC36 family of proton-coupled amino acid transporters

Schiöth HB *et al.* (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects. *Mol Aspects Med* **34**: 571-85 [PMID:23506890]

Thwaites DT *et al.* (2007) Deciphering the mechanisms of intestinal imino (and amino) acid transport: the redemption of SLC36A1. *Biochim Biophys Acta* **1768**: 179-97 [PMID:17123464]

Thwaites DT *et al.* (2011) The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport. *Br J Pharmacol* **164**: 1802-16 [PMID:21501141]

SLC37 family of phosphosugar/phosphate exchangers

Transporters → SLC superfamily of solute carriers → SLC37 family of phosphosugar/phosphate exchangers

Overview: The family of sugar-phosphate exchangers pass particular phosphorylated sugars across intracellular membranes, exchanging for inorganic phosphate. Of the family of sugar phosphate transporters, most information is available on SPX4, the glucose-6-phosphate transporter. This is a 10 TM domain protein with cytoplasmic termini and is associated with the endoplasmic reticulum, with tissue-specific splice variation.

Nomenclature	Glycerol-3-phosphate transporter	Sugar phosphate exchanger 2	Glucose-6-phosphate transporter
Systematic nomenclature	SLC37A1	SLC37A2	SLC37A4
Common abbreviation	SPX1	SPX2	SPX4
HGNC, UniProt	SLC37A1 , P57057	SLC37A2 , Q8TED4	SLC37A4 , O43826
Endogenous substrates	glycerol 3-phosphate, glucose 6-phosphate	glucose 6-phosphate	glucose 6-phosphate
Stoichiometry	Glucose 6-phosphate (in): phosphate (out) [567].	Glucose 6-phosphate (in): phosphate (out) [567].	Glucose 6-phosphate (in): phosphate (out) [120].
Inhibitors	–	–	S-4048 (pIC ₅₀ 8.7) [114] – Rat
Comments	–	–	Multiple polymorphisms have been described for the SLC37A4 gene, some of which associate with a glycogen storage disease [14].

Further reading on SLC37 family of phosphosugar/phosphate exchangers

Chou JY *et al.* (2014) The SLC37 family of sugar-phosphate/phosphate exchangers. *Curr Top Membr* **73**: 357-82 [PMID:24745989] Chou JY *et al.* (2013) The SLC37 family of phosphate-linked sugar phosphate antiporters. *Mol Aspects Med* **34**: 601-11 [PMID:23506893]

SLC38 family of sodium-dependent neutral amino acid transporters

Transporters → SLC superfamily of solute carriers → SLC38 family of sodium-dependent neutral amino acid transporters

Overview: The SLC38 family of transporters appears to be responsible for the functionally-defined system A and system N mechanisms of amino acid transport and are mostly expressed in the CNS. Two distinct subfamilies are identifiable within the SLC38 transporters. SNAT1, SNAT2 and SNAT4 appear to resemble system A transporters in accumulating neutral amino acids under the influence of the sodium gradient. SNAT3 and SNAT5 appear to resemble system N transporters in utilizing proton co-transport to accumulate amino acids. The predicted membrane topology is of 11 TM domains with an extracellular C-terminus and intracellular N-terminus [645].

System A-like transporters

Transporters → SLC superfamily of solute carriers → SLC38 family of sodium-dependent neutral amino acid transporters → System A-like transporters

Nomenclature	sodium-coupled neutral amino acid transporter 1	sodium-coupled neutral amino acid transporter 2	sodium-coupled neutral amino acid transporter 4
Systematic nomenclature	SLC38A1	SLC38A2	SLC38A4
Common abbreviation	SNAT1	SNAT2	SNAT4
HGNC, UniProt	SLC38A1 , Q9H2H9	SLC38A2 , Q96QD8	SLC38A4 , Q969I6
Substrates	MeAIB L-alanine > L-serine, L-glutamine, L-asparagine, L-histidine, L-cysteine, L-methionine > glycine, L-threonine, L-proline, L-tyrosine, L-valine [8]	MeAIB L-alanine, L-methionine > L-asparagine, L-glutamine, L-serine, L-proline, glycine > L-threonine, L-leucine, L-phenylalanine [325]	MeAIB L-histidine > L-arginine, L-alanine, L-asparagine, L-lysine > glycine, L-glutamine, L-serine, L-proline, L-leucine, L-phenylalanine [324]
Stoichiometry	1 Na ⁺ : 1 amino acid (in) [8]	1 Na ⁺ : 1 amino acid (in) [325]	1 Na ⁺ : 1 neutral amino acid (in) [324]
Labelled ligands	[¹⁴ C]alanine, [³ H]alanine	[¹⁴ C]alanine, [³ H]alanine	[¹⁴ C]alanine, [¹⁴ C]glycine, [³ H]alanine, [³ H]glycine
Comments	–	–	Transport of cationic amino acids by SNAT4 was sodium-independent [324].

System N-like transporters

Transporters → SLC superfamily of solute carriers → SLC38 family of sodium-dependent neutral amino acid transporters → System N-like transporters

Nomenclature	Sodium-coupled neutral amino acid transporter 3	Sodium-coupled neutral amino acid transporter 5
Systematic nomenclature	SLC38A3	SLC38A5
Common abbreviation	SNAT3	SNAT5
HGNC, UniProt	SLC38A3 , Q99624	SLC38A5 , Q8WUX1
Substrates	MeAIB L-histidine, L-glutamine > L-asparagine, L-alanine > L-glutamic acid [218]	MeAIB L-asparagine, L-serine, L-histidine, L-glutamine > glycine, L-alanine [532]
Stoichiometry	1 Na ⁺ : 1 amino acid (in) : 1 H ⁺ (out) [87]	1 Na ⁺ : 1 amino acid (in) : 1 H ⁺ (out) [532]
Labelled ligands	[¹⁴ C]glutamine, [³ H]glutamine	[¹⁴ C]histidine, [³ H]histidine

Orphan SLC38 transporters

Transporters → SLC superfamily of solute carriers → SLC38 family of sodium-dependent neutral amino acid transporters → Orphan SLC38 transporters

Nomenclature	Putative sodium-coupled neutral amino acid transporter 7
Systematic nomenclature	SLC38A7
Common abbreviation	SNAT7
HGNC, UniProt	SLC38A7, Q9NVC3
Comments	SNAT7/SLC38A7 has been described to be a system N-like transporter allowing preferential accumulation of glutamine (e.g. L-glutamine), histidine (e.g. L-histidine) and asparagine (e.g. L-asparagine) [313].

Further reading on SLC38 family of sodium-dependent neutral amino acid transporters

- Bhutia YD *et al.* (2016) Glutamine transporters in mammalian cells and their functions in physiology and cancer. *Biochim Biophys Acta* **1863**: 2531-9 [PMID:26724577]
- Bröer S. (2014) The SLC38 family of sodium-amino acid co-transporters. *Pflugers Arch* **466**: 155-72 [PMID:24193407]
- Bröer S *et al.* (2011) The role of amino acid transporters in inherited and acquired diseases. *Biochem J* **436**: 193-211 [PMID:21568940]
- Häggglund MG *et al.* (2011) Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. *J Biol Chem* **286**: 20500-11 [PMID:21511949]
- Schiöth HB *et al.* (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects. *Mol Aspects Med* **34**: 571-85 [PMID:23506890]

SLC39 family of metal ion transporters

Transporters → SLC superfamily of solute carriers → SLC39 family of metal ion transporters

Overview: Along with the SLC30 family, SLC39 family members regulate zinc movement in cells. SLC39 metal ion transporters accumulate zinc into the cytosol. Membrane topology modelling suggests the presence of eight TM regions with both termini extracellular or in the lumen of intracellular organelles. The mechanism for zinc transport for many members is unknown but appears to involve co-transport of bicarbonate ions [268, 467].

Nomenclature	Zinc transporter 8	Zinc transporter 14
Systematic nomenclature	SLC39A8	SLC39A14
Common abbreviation	ZIP8	ZIP14
HGNC, UniProt	SLC39A8, Q9C0K1	SLC39A14, Q15043
Substrates	Cd ²⁺ [149, 467]	Cd ²⁺ [268], Mn ²⁺ [268], Fe ²⁺ [469]
Stoichiometry	1 Zn ²⁺ (in) : 2 HCO ₃ ⁻ (in) [467]	–

Comments: Zinc fluxes may be monitored through the use of radioisotopic Zn-65 or the fluorescent dye FluoZin 3.

The bicarbonate transport inhibitor [DIDS](#) has been reported to inhibit cation accumulation through ZIP14 [\[268\]](#).

Further reading on SLC39 family of metal ion transporters

Hojyo S *et al.* (2016) Zinc transporters and signaling in physiology and pathogenesis. *Arch Biochem Biophys* **611**: 43-50 [\[PMID:27394923\]](#)

Jeong J *et al.* (2013) The SLC39 family of zinc transporters. *Mol Aspects Med* **34**: 612-9 [\[PMID:23506894\]](#)

Kambe T *et al.* (2014) Current understanding of ZIP and ZnT zinc transporters in human health and diseases. *Cell Mol Life Sci* **71**: 3281-95 [\[PMID:24710731\]](#)

Kambe T *et al.* (2015) The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in Zinc Homeostasis and Metabolism. *Physiol Rev* **95**: 749-784 [\[PMID:26084690\]](#)

Marger L *et al.* (2014) Zinc: an underappreciated modulatory factor of brain function. *Biochem Pharmacol* **91**: 426-35 [\[PMID:25130547\]](#)

SLC40 iron transporter

Transporters → SLC superfamily of solute carriers → SLC40 iron transporter

Overview: Alongside the [SLC11 family](#) of proton-coupled metal transporters, ferroportin allows the accumulation of iron from the diet. Whilst SLC11A2 functions on the apical membrane, ferroportin acts on the basolateral side of the enterocyte, as well as regulating macrophage and placental iron levels. The predicted topology is of 12 TM domains, with intracellular termini [\[608\]](#), with the functional transporter potentially a

dimeric arrangement [\[5, 157\]](#). Ferroportin is essential for iron homeostasis [\[178\]](#). Ferroportin is expressed on the surface of cells that store and transport iron, such as duodenal enterocytes, hepatocytes, adipocytes and reticuloendothelial macrophages. Levels of ferroportin are regulated by its association with (binding to) hepcidin, a 25 amino acid hormone responsive to circulating iron levels (amongst other signals). Hepcidin binding

targets ferroportin for internalisation and degradation, lowering the levels of iron export to the blood. Novel therapeutic agents which stabilise ferroportin or protect it from hepcidin-induced degradation are being developed as anti-anemia agents. Anti-ferroportin monoclonal antibodies are such an agent.

Nomenclature	Ferroportin
Systematic nomenclature	SLC40A1
Common abbreviation	IREG1
HGNC, UniProt	SLC40A1 , Q9NP59
Endogenous substrates	Fe ²⁺
Stoichiometry	Unknown
Antibodies	LY2928057 (Binding) [453]

Comments: Hepcidin ([HAMP](#), [P81172](#)), cleaved into [hepcidin-25](#) ([HAMP](#), [P81172](#)) and [hepcidin-20](#) ([HAMP](#), [P81172](#)), is a small protein that increases upon inflammation, binds to ferroportin to regulate its cellular distribution and degradation. Gene disruption in mice results in embryonic lethality [\[178\]](#), while loss-of-function mutations in man are associated with haemochromatosis [\[158\]](#).

Further reading on SLC40 iron transporter

McKie AT *et al.* (2004) The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1). *Pflugers Arch* **447**: 801-6 [\[PMID:12836025\]](#)

Montalbetti N *et al.* (2013) Mammalian iron transporters: families SLC11 and SLC40. *Mol Aspects Med* **34**: 270-87 [\[PMID:23506870\]](#)

Searchable database: <https://www.guidetopharmacology.org/>

Full Contents of ConciseGuide: <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182/full>

SLC40 iron transporter S445

SLC41 family of divalent cation transporters

Transporters → SLC superfamily of solute carriers → SLC41 family of divalent cation transporters

Overview: By analogy with bacterial orthologues, this family is probably magnesium transporters. The prokaryote orthologue, MgtE, is responsible for uptake of divalent cations, while the heterologous expression studies of mammalian proteins suggest Mg²⁺ efflux [420], possibly as a result of co-expression of particular protein partners (see [629]). Topological modelling suggests 10 TM domains with cytoplasmic C- and N- termini.

Nomenclature	Solute carrier family 41 member 1	Solute carrier family 41 member 2
Systematic nomenclature	SLC41A1	SLC41A2
Common abbreviation	MgtE	–
HGNC, UniProt	SLC41A1 , Q8IVJ1	SLC41A2 , Q96JW4
Substrates	Zn²⁺ [284] , Mg²⁺ [284] , Ba²⁺ [284] , Cd²⁺ [284] , Co²⁺ [284] , Cu²⁺ [284] , Sr²⁺ [284] , Fe²⁺ [284]	Mg²⁺ [285] , Ba²⁺ [285] , Ni²⁺ [285] , Co²⁺ [285] , Mn²⁺ [285] , Fe²⁺ [285]
Stoichiometry	Unknown	Unknown

Further reading on SLC41 family of divalent cation transporters

Payandeh J *et al.* (2013) The structure and regulation of magnesium selective ion channels. *Biochim Biophys Acta* **1828**: 2778-92 [PMID:23954807]

Sahni J *et al.* (2013) The SLC41 family of MgtE-like magnesium transporters. *Mol Aspects Med* **34**: 620-8 [PMID:23506895]

Schweigel-Röntgen M *et al.* (2014) SLC41 transporters—molecular identification and functional role. *Curr Top Membr* **73**: 383-410 [PMID:24745990]

SLC42 family of Rhesus glycoprotein ammonium transporters

Transporters → SLC superfamily of solute carriers → SLC42 family of Rhesus glycoprotein ammonium transporters

Overview: Rhesus is commonly defined as a 'factor' that determines, in part, blood type, and whether neonates suffer from haemolytic disease of the newborn. These glycoprotein antigens derive from two genes, [RHCE \(P18577\)](#) and [RHD \(Q02161\)](#), expressed on the surface of erythrocytes. On erythrocytes, RhAG

associates with these antigens and functions as an ammonium transporter. RhBG and RhBG are non-erythroid related sequences associated with epithelia. Topological modelling suggests the presence of 12TM with cytoplasmic N- and C- termini. The majority of information on these transporters derives from

orthologues in yeast, plants and bacteria. More recent evidence points to family members being permeable to carbon dioxide, leading to the term gas channels.

Nomenclature	Ammonium transporter Rh type A	Ammonium transporter Rh type B	Ammonium transporter Rh type C
Systematic nomenclature	SLC42A1	SLC42A2	SLC42A3
Common abbreviation	RhAG	RhBG	RhCG
HGNC, UniProt	RHAG , Q02094	RHBG , Q9H310	RHCG , Q9UBD6
Substrates	CO ₂ [199], NH ₃ [609], NH ₄ ⁺ [785]	–	NH ₃ [855]
Stoichiometry	Unknown	Unknown	Unknown
Labelled ligands	[¹⁴ C]methylamine (Binding) [330]	–	[¹⁴ C]methylamine (Binding) [487] – Mouse

Further reading on SLC42 family of Rhesus glycoprotein ammonium transporters

- Nakhoul NL *et al.* (2013) Characteristics of mammalian Rh glycoproteins (SLC42 transporters) and their role in acid-base transport. *Mol Aspects Med* **34**: 629-37 [PMID:23506896]
- Weiner ID *et al.* (2011) Role of NH₃ and NH₄⁺ transporters in renal acid-base transport. *Am J Physiol Renal Physiol* **300**: F11-23 [PMID:21048022]
- Weiner ID *et al.* (2014) Ammonia transport in the kidney by Rhesus glycoproteins. *Am J Physiol Renal Physiol* **306**: F1107-20 [PMID:24647713]

SLC43 family of large neutral amino acid transporters

Transporters → SLC superfamily of solute carriers → SLC43 family of large neutral amino acid transporters

Overview: LAT3 (SLC43A1) and LAT4 (SLC43A2) are transporters with system L amino acid transporter activity, along with the structurally and functionally distinct transporters LAT1 and LAT2 that are members of the [SLC7 family](#). LAT3 and LAT4 contain 12 putative TM domains with both N and C termini

located intracellularly. They transport neutral amino acids in a manner independent of Na⁺ and Cl⁻ and with two kinetic components [40, 74]. LAT3/SLC43A1 is expressed in human tissues at high levels in the pancreas, liver, skeletal muscle and fetal liver [40] whereas LAT4/SLC43A2 is primarily expressed in the

placenta, kidney and peripheral blood leukocytes [74]. SLC43A3 is expressed in vascular endothelial cells [765] but remains to be characterised.

Nomenclature	L-type amino acid transporter 3	L-type amino acid transporter 4
Systematic nomenclature	SLC43A1	SLC43A2
Common abbreviation	LAT3	LAT4
HGNC, UniProt	SLC43A1 , O75387	SLC43A2 , Q8N370
Substrates	L-leucine [40], L-isoleucine [40], L-phenylalanine [40], L-valine [40], L-valinol [40], L-phenylalaninol [40], L-methionine [40], L-leucinol [40]	L-isoleucine, L-leucine, L-phenylalanine, L-valinol, L-leucinol, L-valine, L-methionine
Stoichiometry	Operates by facilitative diffusion	Operates by facilitative diffusion

Comments: Covalent modification of LAT3 by [N-ethylmaleimide](#) inhibits its function [40] and at LAT4 inhibits the low-, but not high-affinity component of transport [74].

Further reading on SLC43 family of large neutral amino acid transporters

Bodoy S *et al.* (2013) The small SLC43 family: facilitator system I amino acid transporters and the orphan EEG1. *Mol Aspects Med* **34**: 638-45 [PMID:23268354]

SLC44 choline transporter-like family

Transporters → SLC superfamily of solute carriers → SLC44 choline transporter-like family

Overview: Members of the choline transporter-like family are encoded by five genes (CTL1-CTL5) with further diversity occurring through alternative splicing of CTL1, 4 and 5 [728]. CTL family members are putative 10TM domain proteins with extracellular termini that mediate Na⁺-independent transport of **choline** with an affinity that is intermediate to that of the

high affinity choline transporter CHT1 (SLC5A7) and the low affinity organic-cation transporters [OCT1 (SLC22A1) and OCT2 (SLC22A2)] [505]. CTL1 is expressed almost ubiquitously in human tissues [789] and mediates **choline** transport across the plasma and mitochondrial membranes [504]. Transport of **choline** by CTL2, which in rodents is expressed as two isoforms

(CTL2P1 and CLTP2; [421]) in lung, colon, inner ear and spleen and to a lesser extent in brain, tongue, liver, and kidney, has only recently been demonstrated [421, 531]. CTL3-5 remain to be characterized functionally.

Nomenclature	Choline transporter-like 1
Systematic nomenclature	SLC44A1
Common abbreviation	CTL1
HGNC, UniProt	SLC44A1, Q8WW15
Substrates	choline
Stoichiometry	Unknown: uptake enhanced in the absence of extracellular Na ⁺ , reduced by membrane depolarization, extracellular acidification and collapse of plasma membrane H ⁺ electrochemical gradient
Inhibitors	hemicholinium-3 (pK _i 3.5–4.5)

Comments: Data tabulated are features observed for CLT1 endogenous to: rat astrocytes [352]; rat renal tubule epithelial cells [812]; human colon carcinoma cells [424]; human keratinocytes [738] and human neuroblastoma cells [814]. Choline uptake by CLT1 is inhibited by numerous organic cations (*e.g.* [352, 812, 814]). In the guinea-pig, CTL2 is a target for antibody-induced hearing loss [527] and in man, a polymorphism in CTL2 constitutes the human neutrophil alloantigen-3a (HNA-3a; [291]).

Further reading on SLC44 choline transporter-like family

Inazu M. (2014) Choline transporter-like proteins CTLs/SLC44 family as a novel molecular target for cancer therapy. *Biopharm Drug Dispos* **35**: 431-49 [PMID:24532461]

Traiffort E *et al.* (2013) The choline transporter-like family SLC44: properties and roles in human diseases. *Mol Aspects Med* **34**: 646-54 [PMID:23506897]

SLC45 family of putative sugar transporters

Transporters → SLC superfamily of solute carriers → SLC45 family of putative sugar transporters

Overview: Members of the SLC45 family remain to be fully characterised. SLC45A1 was initially identified in the rat brain, particularly predominant in the hindbrain, as a proton-associated sugar transport, induced by hypercapnia [662]. The protein is predicted to have 12TM domains, with intracellular termini. The *SLC45A2* gene is thought to encode a transporter protein that mediates melanin synthesis. Mutations in *SLC45A2* are a cause of oculocutaneous albinism type 4 (e.g. [538]), and polymorphisms in this gene are associated with variations in skin and hair color (e.g. [287]).

Nomenclature	Proton-associated sugar transporter A
Systematic nomenclature	SLC45A1
HGNC, UniProt	<i>SLC45A1</i> , Q9Y2W3
Substrates	L-glucose [662], Galactose [662]
Stoichiometry	Unknown; increased at acid pH [662].

Further reading on SLC45 family of putative sugar transporters

Bartölke R *et al.* (2014) Proton-associated sucrose transport of mammalian solute carrier family 45: an analysis in *Saccharomyces cerevisiae*. *Biochem J* **464**: 193-201 [PMID:25164149] Vitavska O *et al.* (2013) The SLC45 gene family of putative sugar transporters. *Mol Aspects Med* **34**: 655-60 [PMID:23506898]

SLC46 family of folate transporters

Transporters → SLC superfamily of solute carriers → SLC46 family of folate transporters

Overview: Based on the prototypical member of this family, PCFT, this family includes proton-driven transporters with 11 TM segments. SLC46A1 has been described to act as an intestinal proton-coupled high-affinity folic acid transporter [590], with lower affinity for heme. Folic acid accumulation is independent of Na⁺ or K⁺ ion concentrations, but driven by extracellular protons with an as yet undefined stoichiometry.

Nomenclature	Proton-coupled folate transporter
Systematic nomenclature	SLC46A1
Common abbreviation	PCFT
HGNC, UniProt	SLC46A1 , Q96NT5
Substrates	methotrexate [590], N-formyltetrahydrofolate, pemetrexed folic acid (1.3 μM) > heme (>100 μM) [528]
Endogenous substrates	N ⁵ -methyltetrafolate [590]
Labelled ligands	[³ H]N ⁵ -methylfolate (Binding), [³ H]folic acid, [³ H]folinic acid (Binding), [³ H]methotrexate, [³ H]pemetrexed (Binding)
Comments	Loss-of-function mutations in PCFT (SLC46A1) are the molecular basis for hereditary folate malabsorption [638].

Further reading on SLC46 family of folate transporters

- Hou Z *et al.* (2014) Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. *Curr Top Membr* **73**: 175-204 [PMID:24745983]
- Matherly LH *et al.* (2014) The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. *Drug Metab Dispos* **42**: 632-49 [PMID:24396145]
- Wilson MR *et al.* (2015) Structural determinants of human proton-coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6. *Biochem J* **469**: 33-44 [PMID:25877470]
- Zhao R *et al.* (2011) Mechanisms of membrane transport of folates into cells and across epithelia. *Annu Rev Nutr* **31**: 177-201 [PMID:21568705]
- Zhao R *et al.* (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. *Mol Aspects Med* **34**: 373-85 [PMID:23506878]

SLC47 family of multidrug and toxin extrusion transporters

Transporters → SLC superfamily of solute carriers → SLC47 family of multidrug and toxin extrusion transporters

Overview: Human multidrug and toxin extrusion MATE1 and MATE2-K are H⁺/organic cation antiporters [10]. They are predominantly expressed in the kidney and play a role in renal tubular secretion of cationic drugs.

Nomenclature	Multidrug and toxin extrusion	MATE2
Systematic nomenclature	SLC47A1	SLC47A2
Common abbreviation	MATE1	MATE2-K
HGNC, UniProt	SLC47A1 , Q96FL8	SLC47A2 , Q86VL8
Substrates	paraquat [121], quinidine [704], cephradine [704], cephalexin [704], cimetidine (K _m 1.7 × 10 ⁻⁴ M) [554, 704], metformin (K _m 7.8 × 10 ⁻⁴ M) [704]	MPP⁺ [495], N¹-methylnicotinamide [495], procainamide [495], guanidine [704], aciclovir [704], cimetidine (K _m 1.2 × 10 ⁻⁴ M) [495, 704], metformin (K _m 1.9 × 10 ⁻³ M) [495, 704]

Endogenous substrates	thiamine [704], creatine [704]	creatine [704], thiamine [704]
Sub/family-selective inhibitors	pyrimethamine (pK _i 7.1) [365], cimetidine (pK _i 6) [733]	pyrimethamine (pK _i 6.3) [365] – Mouse, cimetidine (pK _i 5.1) [733]
Labelled ligands	[¹⁴ C]TEA [561, 712], [¹⁴ C]metformin [704, 712]	[¹⁴ C]TEA [704], [¹⁴ C]metformin [704]

Comments: DAPI has been used to allow quantification of MATE1 and MATE2-mediated transport activity [825]. MATE2 and MATE2-B are inactive splice variants of MATE2-K [495].

Further reading on SLC47 family of multidrug and toxin extrusion transporters

Damme K *et al.* (2011) Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. *Drug Metab Rev* **43**: 499-523 [PMID:21923552]
 Koepsell H. (2020) Organic Cation Transporters in Health and Disease. *Pharmacol Rev* **72**: 253-319 [PMID:31852803]
 Krishnan S *et al.* (2022) Challenges and Opportunities for Improved Drug-Drug Interaction Predictions for Renal OCT2 and MATE1/2-K Transporters. *Clin Pharmacol Ther* **112**: 562-572 [PMID:35598119]

Motohashi H *et al.* (2013) Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. *Mol Aspects Med* **34**: 661-8 [PMID:23506899]
 Yonezawa A *et al.* (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. *Br J Pharmacol* **164**: 1817-25 [PMID:21457222]

SLC48 heme transporter

Transporters → SLC superfamily of solute carriers → SLC48 heme transporter

Overview: HRG1 has been identified as a cell surface and lysosomal heme transporter [598]. In addition, evidence suggests this 4TM-containing protein associates with the V-ATPase in lysosomes [550]. Recent studies confirm its lysosomal location and demonstrate that it has an important physiological function in macrophages ingesting senescent red blood cells (erythrophagocytosis), recycling heme (released from the red cell hemoglobin) from the phagolysosome into the cytosol, where the heme is subsequently catabolized to recycle the iron [786].

Nomenclature	Heme transporter
Systematic nomenclature	SLC48A1
Common abbreviation	HRG1
HGNC, UniProt	SLC48A1, Q6P1K1

Further reading on SLC48 heme transporter

Khan AA *et al.* (2013) Heme and FLVCR-related transporter families SLC48 and SLC49. *Mol Aspects Med* **34**: 669-82 [PMID:23506900]

SLC49 family of FLVCR-related heme transporters

Transporters → SLC superfamily of solute carriers → SLC49 family of FLVCR-related heme transporters

Overview: FLVCR1 was initially identified as a cell-surface attachment site for feline leukemia virus subgroup C [693], and later identified as a cell surface accumulation which exports heme from the cytosol [594]. A recent study indicates that an isoform of FLVCR1 is located in the mitochondria, the site of the final steps of heme synthesis, and appears to transport heme into the cytosol [128]. FLVCR-mediated heme transport

is essential for erythropoiesis. Flvcr1 gene mutations have been identified as the cause of PCARP (**posterior column ataxia with retinitis pigmentosa**) (PCARP) [597]. There are three paralogs of FLVCR1 in the human genome.

FLVCR2, most similar to FLVCR1 [462], has been reported to function as a heme importer [183]. In addition, a congenital

syndrome of proliferative vasculopathy and hydranencephaly, also known as Fowler's syndrome, is associated with a loss-of-function mutation in FLVCR2 [502].

The functions of the other two members of the SLC49 family, MFSD7 and DIRC2, are unknown, although DIRC2 has been implicated in hereditary renal carcinomas [73].

Nomenclature	Feline leukemia virus subgroup C cellular receptor family, member 1	Feline leukemia virus subgroup C cellular receptor family, member 2
Systematic nomenclature	SLC49A1	SLC49A2
Common abbreviation	FLVCR1	FLVCR2
HGNC, UniProt	FLVCR1 , Q9YSY0	FLVCR2 , Q9UPI3
Substrates	heme [594]	heme [183]
Stoichiometry	Unknown	Unknown

Comments: Non-functional splice alternatives of FLVCR1 have been implicated as a cause of a congenital red cell aplasia, [Diamond Blackfan anemia](#) [606].

Further reading on SLC49 family of FLVCR-related heme transporters

Khan AA *et al.* (2011) Control of intracellular heme levels: heme transporters and heme oxygenases. *Biochim Biophys Acta* **1813**: 668-82 [PMID:21238504]

Khan AA *et al.* (2013) Heme and FLVCR-related transporter families SLC48 and SLC49. *Mol Aspects Med* **34**: 669-82 [PMID:23506900]

SLC50 sugar transporter

Transporters → SLC superfamily of solute carriers → SLC50 sugar transporter

Overview: A mouse stromal cell cDNA library was used to clone C2.3 [690], later termed Rag1-activating protein 1, with a sequence homology predictive of a 4TM topology. The plant orthologues, termed SWEETs, appear to be 7 TM proteins, with extracellular N-termini, and the capacity for bidirectional flux of [D-glucose](#) [118]. Expression of mouse SWEET in the mammary gland was suggestive of a role in Golgi lactose synthesis [118].

Nomenclature	SLC50 sugar exporter
Systematic nomenclature	SLC50A1
Common abbreviation	RAG1AP1
HGNC, UniProt	SLC50A1 , Q9BRV3

Further reading on SLC50 sugar transporter

Wright EM. (2013) Glucose transport families SLC5 and SLC50. *Mol Aspects Med* **34**: 183-96 [PMID:23506865]

Wright EM *et al.* (2011) Biology of human sodium glucose transporters. *Physiol Rev* **91**: 733-94 [PMID:21527736]

SLC51 family of steroid-derived molecule transporters

Transporters → SLC superfamily of solute carriers → SLC51 family of steroid-derived molecule transporters

Overview: The SLC51 organic solute transporter family of transporters is a pair of heterodimeric proteins which regulate bile salt movements in the small intestine, bile duct, and liver, as part of the enterohepatic circulation [11, 48, 154]. OST α /OST β is also expressed in steroidogenic cells of the brain and adrenal gland, where it may contribute to steroid sulphate movement [213]. Bile acid and steroid sulphate transport is suggested to be

facilitative and independent of sodium, potassium, chloride ions or protons [48, 154]. OST α /OST β heterodimers have been shown to transport [³H]taurocholic acid, [³H]dehydroepiandrosterone sulphate, [³H]estrone-3-sulphate, [³H]pregnenolone sulphate and [³H]dehydroepiandrosterone sulphate [48, 154, 213]. OST α /OST β -mediated transport is inhibited by [clofazimine](#) and [fidaxomicin](#) [488, 744]. OST α is suggested to be a seven TMprotein,

while OST β is a single TM 'ancillary' protein, both of which are thought to have intracellular C-termini [458]. Both proteins function in solute transport [132, 458]. Inherited mutations in OST α and OST β are associated with liver disease and congenital diarrhea in children [251, 682].

Nomenclature	Organic solute transporter subunit α	Organic solute transporter subunit β
Systematic nomenclature	SLC51A1	SLC51B
Common abbreviation	OST α	OST β
HGNC, UniProt	SLC51A , Q86UW1	SLC51B , Q86UW2

Further reading on SLC51 family of steroid-derived molecule transporters

Ballatori N. (2011) Pleiotropic functions of the organic solute transporter Ost α -Ost β . *Dig Dis* **29**: 13-7 [PMID:21691099]

Ballatori N *et al.* (2013) The heteromeric organic solute transporter, OST α -OST β /SLC51: a transporter for steroid-derived molecules. *Mol Aspects Med* **34**: 683-92 [PMID:23506901]

Beaudoin JJ *et al.* (2020) Role of Organic Solute Transporter Alpha/Beta in Hepatotoxic Bile Acid Transport and Drug Interactions. *Toxicol Sci* **176**: 34-35 [PMID:32294204]

Dawson PA. (2011) Role of the intestinal bile acid transporters in bile acid and drug disposition. *Handb Exp Pharmacol* 169-203 [PMID:21103970]

Malinen MM *et al.* (2018) Organic solute transporter OST α / β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury. *Am J Physiol Gastrointest Liver Physiol* **314**: G597-G609 [PMID:29420067]

SLC52 family of riboflavin transporters

Transporters → SLC superfamily of solute carriers → SLC52 family of riboflavin transporters

Overview: Riboflavin, also known as vitamin B2, is a precursor of the enzyme cofactors **flavin mononucleotide** (FMN) and **flavin adenine dinucleotide** (FAD). Riboflavin transporters are predicted to possess 10 or 11 TM segments.

Nomenclature	solute carrier family 52 member 1	solute carrier family 52 member 2	solute carrier family 52 member 3
Systematic nomenclature	SLC52A1	SLC52A2	SLC52A3
Common abbreviation	RFVT1	RFVT2	RFVT3
HGNC, UniProt	SLC52A1 , Q9NWF4	SLC52A2 , Q9HAB3	SLC52A3 , Q9NQ40
Endogenous substrates	riboflavin (K_m 1.3×10^{-3} M) [824]	riboflavin (K_m 9.8×10^{-4} M) [824]	riboflavin (K_m 3.3×10^{-4} M) [824]
Stoichiometry	Unknown	Unknown	H ⁺ -dependent

Comments: Although expressed elsewhere, RFVT3 is found on the luminal surface of intestinal epithelium and is thought to mediate uptake of dietary riboflavin, while RFVT1 and RFVT2 are thought to allow movement from the epithelium into the blood.

Further reading on SLC52 family of riboflavin transporters

Yonezawa A *et al.* (2013) Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. *Mol Aspects Med* **34**: 693-701 [PMID:23506902]

SLC53 Phosphate carriers

Transporters → SLC superfamily of solute carriers → SLC53 Phosphate carriers

Nomenclature	xenotropic and polytropic retrovirus receptor 1
Systematic nomenclature	SLC53A1
HGNC, UniProt	XPR1 , Q9UBH6
Substrates	Phosphate [267]
Comments	XPR1/SLC53A1 is a phosphate carrier which appears to play a role in bone and tooth mineralization. It is ubiquitously expressed [52, 692]. The pathological consequences of defective SLC53A1 expression in the brain [450] and kidney [26] have been reported.

SLC54 Mitochondrial pyruvate carriers

Transporters → SLC superfamily of solute carriers → SLC54 Mitochondrial pyruvate carriers

Overview: Pyruvate is oxidized to acetyl-CoA by pyruvate dehydrogenase which is localized in the mitochondrial matrix. The mitochondrial pyruvate carrier (MPC) is composed of SLC54 family members (MPC1 and MPC2) [86, 333], which form functional hetero-dimers [708, 709]. The MPC is expressed in the

inner mitochondrial membrane and involved in the import of pyruvate into mitochondria [86, 333]. Ubiquitous disruption of either MPC1 or MPC2 expression results in embryonic lethality [752, 761]. Clinically relevant concentrations of the insulin sensitizers, thiazolidinediones, inhibit the MPC [172]. Other

clinically relevant inhibitors of the MPC complex are lonidamine [533, 708], quinolone antibacterials [338], entacapone and nitrofurantoin [708].

Nomenclature	mitochondrial pyruvate carrier 1	mitochondrial pyruvate carrier 2	mitochondrial pyruvate carrier 1 like
Systematic nomenclature	SLC54A1	SLC54A2	SLC54A3
HGNC, UniProt	MPC1 , Q9YSU8	MPC2 , O95563	MPC1L , P0DKB6
Substrates	Pyruvate [86, 333]	Pyruvate [86, 333]	Pyruvate [751]
Inhibitors	UK-5099 (pIC ₅₀ 7.3) [314] – Rat, α-Cyano-5-phenyl-2,4-pentadienic acid (pIC ₅₀ 6.7) [314] – Rat, α-cyanocinnamate (pIC ₅₀ 6.7) [314] – Rat, mitoglitazone (pIC ₅₀ 5.9) [172] – Mouse	UK-5099 (pIC ₅₀ 7.3) [314] – Rat, α-Cyano-5-phenyl-2,4-pentadienic acid (pIC ₅₀ 6.7) [314] – Rat, α-cyanocinnamate (pIC ₅₀ 6.7) [314] – Rat, zaprinast (pIC ₅₀ 6.5) [708], entacapone (pIC ₅₀ 6.2) [708], mitoglitazone (pIC ₅₀ 5.9) [172] – Mouse, nitrofurantoin (pIC ₅₀ 5.5) [708], lonidamine (pIC ₅₀ 5.3) [708]	entacapone [708], lonidamine [708], nitrofurantoin [708], zaprinast [708]
Comments	SLC54A1 is ubiquitously expressed [751].	SLC54A2 is ubiquitously expressed [751]. The inhibitory potency of UK5099 in human MPC1L/MPC2 proteoliposomes is 53 nM [708]. The potency of mitoglitazone (MSDC-0160) in the same system is 2.7 μM [708].	SLC54A3 is expressed in testis, postmeiotic spermatids and sperm cells [751]. The MPC1L/MPC2 hetero-dimer binds the same inhibitors/antagonists as the MPC1/MPC2 complex [708].

Comments: SLC54 family of transporters form hetero-dimers responsible for the accumulation of pyruvate into mitochondria, to link glycolysis with oxidative phosphorylation.

Further reading on SLC54 Mitochondrial pyruvate carriers

Bader DA *et al.* (2019) Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. *Nat Metab* **1**: 70-85 [PMID:31198906]
 Harrison SA *et al.* (2020) Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. *J Hepatol* **72**: 613-626 [PMID:31697972]
 McCommis KS *et al.* (2017) Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. *Hepatology* **65**: 1543-1556 [PMID:28027586]

Tompkins SC *et al.* (2019) Disrupting Mitochondrial Pyruvate Uptake Directs Glutamine into the TCA Cycle away from Glutathione Synthesis and Impairs Hepatocellular Tumorigenesis. *Cell Rep* **28**: 2608-2619.e6 [PMID:31484072]
 Yiew NKH *et al.* (2022) The mitochondrial pyruvate carrier at the crossroads of intermediary metabolism. *Am J Physiol Endocrinol Metab* **323**: E33-E52 [PMID:35635330]

SLC55 Mitochondrial cation/proton exchangers

Transporters → SLC superfamily of solute carriers → SLC55 Mitochondrial cation/proton exchangers

Nomenclature	leucine zipper and EF-hand containing transmembrane protein 1	leucine zipper and EF-hand containing transmembrane protein 2	LETM1 domain containing 1
Systematic nomenclature	SLC55A1	SLC55A2	SLC55A3
HGNC, UniProt	LETM1 , O95202	LETM2 , Q2VYF4	LETMD1 , Q6P1Q0
Transport type	Exchanger/Ca ²⁺ :H ⁺ [374 , 657] Exchanger/K ⁺ :H ⁺ [171 , 545]	–	–
Substrates	Ca ²⁺ , K ⁺ , H ⁺ [171 , 545 , 546 , 859]	–	–
Comments	SLC55A1 is ubiquitously expressed [198]. Arguments against SLC55A1's role as a Ca ²⁺ transporter are outlined by Zotova <i>et al.</i> (2010) [859].	–	–

Comments: The family of SLC55 mitochondrial transporters appear to regulate ion fluxes and to maintain tubular networks.

SLC56 Sideroflexins

Transporters → SLC superfamily of solute carriers → SLC56 Sideroflexins

Nomenclature	sideroflexin 1	sideroflexin 2	sideroflexin 3	sideroflexin 4	sideroflexin 5
Systematic nomenclature	SLC56A1	SLC56A2	SLC56A3	SLC56A4	SLC56A5
HGNC, UniProt	SFXN1 , Q9H9B4	SFXN2 , Q96NB2	SFXN3 , Q9BWM7	–	SFXN5 , Q8TD22
Comments	Sideroflexin 1 (SFXN1/SLC56A1) was probably falsely identified as a tricarboxylate carrier in the 1993 article by Azzi <i>et al.</i> [39], as discussed several years later in [226]. SFXN1 likely transports pyridoxin or another heme precursor or the 5'-aminolevulinate synthase 2 (<i>ALAS2</i> ; P22557) cofactor [226 , 826]. SFXN1 has recently been suggested to be a mitochondrial serine transporter [422]. It is mainly expressed in adult kidney and liver (mouse) [226].	In mice sideroflexin 2 expression is mainly detected in adult kidney and liver [226]. In human tissues it is detected at highest levels in kidney, liver and pancreas [826].	Sideroflexin 3 is ubiquitously expressed in mouse tissues [226].	Sideroflexin 4 is expressed in mouse kidney, brain and heart [226]. The SFXN4a isoform is most highly expressed in human kidney and pancreas, and the SFXN4b isoform is barely detectable in brain [847].	Sideroflexin 5 is expressed in mouse brain and liver [226].

Comments: These are a family of incompletely-characterised mitochondrial transporters.

SLC57 NiPA-like magnesium transporter family

Transporters → SLC superfamily of solute carriers → SLC57 NiPA-like magnesium transporter family

Nomenclature	NIPA magnesium transporter 1	NIPA magnesium transporter 2	NIPA like domain containing 1	NIPA like domain containing 3
Systematic nomenclature	SLC57A1	SLC57A2	SLC57A3	SLC57A5
HGNC, UniProt	NIPA1 , Q7RTP0	NIPA2 , Q8N8Q9	NIPAL1 , Q6NVV3	NIPAL3 , Q6P499
Substrates	Mg ²⁺ [282], Sr ²⁺ , Fe ²⁺ and Co ²⁺ to a lesser extent [283]	Mg ²⁺ [283]	Mg ²⁺ , Sr ²⁺ , Ba ²⁺ , Fe ²⁺ , Cu ²⁺ [283]	–
Comments	Human tissue expression: Constitutively expressed at low levels, with significant enrichment in the brain [596]. Mouse tissue expression: Widely expressed, including in the heart, kidney, liver, colon, less in the brain, and not in the small intestine [282].	–	–	–

SLC58 MagT-like magnesium transporter family

Transporters → SLC superfamily of solute carriers → SLC58 MagT-like magnesium transporter family

Nomenclature	magnesium transporter 1	tumor suppressor candidate 3
Systematic nomenclature	SLC58A1	SLC58A2
HGNC, UniProt	MAGT1 , Q9H0U3	TUSC3 , Q13454
Transport type	Channel-like [591]	–
Substrates	Mg ²⁺ [286]	Mg ²⁺ , Fe ²⁺ , Cu ²⁺ , Mn ²⁺ [283, 591]
Comments	Expressed in kidney, colon, heart and liver (the latter only at the mRNA level) [286]; universally expressed [848].	Expressed in placenta, pancreas, testis, ovary, heart, and prostate [481].

SLC59 Sodium-dependent lysophosphatidylcholine symporter family

Transporters → SLC superfamily of solute carriers → SLC59 Sodium-dependent lysophosphatidylcholine symporter family

Nomenclature	MFSD2 lysolipid transporter A, lysophospholipid	MFSD2 lysolipid transporter B, sphingolipid
Systematic nomenclature	SLC59A1	SLC59A2
HGNC, UniProt	MFSD2A, Q8NA29	MFSD2B, A6NFX1
Transport type	Co-transporter: LPC:Na ⁺ , uptake	–
Substrates	LPC (lysophosphatidylcholine) form of DHA (docosahexaenoic acid) [539]	–
Comments	MFSD2/SLC59A1 has been suggested to be a sphingosine 1-phosphate transporter in erythropoietic cells [414]. It is expressed in brain, intestine, kidney, liver, lung, mammary gland, and prostate [25]; relatively low expression in BAT (brown adipose tissue), but upregulated during cold-induced thermogenesis [25]. Subcellular locations: plasma membrane [773] and ER [25].	Expressed in the spleen, lung, testis and subcellularly in the ER [25].

SLC60 Glucose transporters

Transporters → SLC superfamily of solute carriers → SLC60 Glucose transporters

Nomenclature	major facilitator superfamily domain containing 4A	major facilitator superfamily domain containing 4B
Systematic nomenclature	SLC60A1	SLC60A2
HGNC, UniProt	MFSD4A, Q8N468	MFSD4B, Q5TF39
Transport type	–	Co-transporter/Na ⁺ (1:1) uptake (Rat) [340]
Substrates	–	α-Me-glucose, D-glucose [340]
Inhibitors	–	phloretin [340] – Rat, phlorizin [340] – Rat, urea [534] – Rat
Comments	–	Expressed in rat kidney (cortex and medulla), brain, liver and lung [340].

SLC61 Molybdate transporter family

Transporters → SLC superfamily of solute carriers → SLC61 Molybdate transporter family

Nomenclature	major facilitator superfamily domain containing 5
Systematic nomenclature	SLC61A1
HGNC, UniProt	MFSD5 , Q6N075
Substrates	molybdate [711]
Comments	MFSD5/SLC61 is a putative 12TM cell-surface protein which appears to allow the accumulation of molybdate, and where the neural expression appears to respond to changes in the diet. It is expressed in cervix, stomach, nerve and skin [711]; ubiquitous but higher in skeletal muscle, olfactory bulb [234]; blood, cortex, hypothalamus, cerebellum and spinal cord (mouse) [574].

SLC62 Pyrophosphate transporters

Transporters → SLC superfamily of solute carriers → SLC62 Pyrophosphate transporters

Nomenclature	ANKH inorganic pyrophosphate transport regulator
Systematic nomenclature	SLC62A1
HGNC, UniProt	ANKH , Q9HCJ1
Substrates	Pyrophosphate [336]
Comments	ANKH/SLC62 is a putative 8TM membrane protein, also known as progressive ankylosis protein homolog. Mutations in this protein are associated with bone and joint abnormalities. It is expressed in kidney and bone [105].

SLC63 Sphingosine phosphate transporters

Transporters → SLC superfamily of solute carriers → SLC63 Sphingosine phosphate transporters

Overview: The SLC63 family of transporters has roles inside the cell (SLC63A1/SPNS1) or on the cell surface (SLC63A2/SPNS2) in sphingolipid transport.

Nomenclature	SPNS lysolipid transporter 1, lysophospholipid
Systematic nomenclature	SLC63A1
HGNC, UniProt	SPNS1, Q9H2V7
Comments	Expressed in mitochondria [822].

SLC64 Golgi Ca²⁺/H⁺ exchangers

Transporters → SLC superfamily of solute carriers → SLC64 Golgi Ca²⁺/H⁺ exchangers

Nomenclature	transmembrane protein 165
Systematic nomenclature	SLC64A1
HGNC, UniProt	TMEM165, Q9HC07
Transport type	Exchanger/Ca ²⁺ :H ⁺
Substrates	Ca ²⁺ , H ⁺ [161], Mn ²⁺ [584, 585]
Comments	TMEM165/SLC64 is a putative 6TM intracellular membrane protein. Mutations in the protein are associated with congenital disorder of glycosylation. It has been suggested to be essential for milk production in the mammary gland [670]. TMEM165 deficiency (<i>via</i> siRNA knockdown) causes Golgi glycosylation defects in transfected HEK cells [233].

SLC65 NPC-type cholesterol transporters

Transporters → SLC superfamily of solute carriers → SLC65 NPC-type cholesterol transporters

Overview: The SLC65 family of intracellular cholesterol transporters are 13TM membrane proteins. NPC1/SLC65A1 is an intracellular cholesterol transporter, which together with NPC2 (Uniprot ID [P61916](#)), allows the accumulation into the cytosol of cholesterol acquired from low density lipoproteins.

Nomenclature	NPC intracellular cholesterol transporter 1	NPC1 like intracellular cholesterol transporter 1
Systematic nomenclature	SLC65A1	SLC65A2
HGNC, UniProt	NPC1 , O15118	NPC1L1 , Q9UHC9
Substrates	Cholesterol [354 , 355 , 577]	Cholesterol [15]
Selective antagonists	–	ezetimibe (Inhibition) (pK _d 6.7) [252]
Comments	Expression is ubiquitous [15], with highest levels detected in liver, lung, and pancreas [153]. NPC1 plays a critical role in the regulation of intracellular cholesterol trafficking [106]. Mutations in the NPC1 gene have been identified in patients with the lipid storage disorder Niemann-Pick disease type C1 [72 , 106 , 290 , 816].	Expressed in small intestine, gallbladder, liver, testis and stomach [15].

SLC66 Lysosomal amino acid transporters

Transporters → SLC superfamily of solute carriers → SLC66 Lysosomal amino acid transporters

Overview: This is a family of 5 evolutionarily related proteins. Their structural similarities suggest that they are transporters. Biochemical evidence supports transporter activity for SLC66A1 (LAAT1) and SLC66A4 (CTNS; Cystinosis), primarily exporting amino acids from the lysosome to the cytoplasm. The functions of the 3 remaining members of the family are undetermined.

Nomenclature	solute carrier family 66 member 1	solute carrier family 66 member 2
Systematic nomenclature	SLC66A1	SLC66A2
HGNC, UniProt	SLC66A1 , Q6ZP29	SLC66A2 , Q8N2U9
Comments	Responsible for lysine and arginine export from lysosomes [463]. Functions as a pH-sensitive uniporter [452]. Transports cysteamine-cysteine mixed disulfide, structurally similar to lysine, which is a chemical intermediate formed during cysteamine therapy of cystinosis [373]. Acts to recruit the C9orf72-SMCR8-WDR41 complex to the cytoplasmic side of the lysosome upon cationic amino acid starvation, as the initiator of the signaling cascade [17 , 696].	–

Nomenclature	solute carrier family 66 member 3	cystinosin, lysosomal cystine transporter	mannose-P-dolichol utilization defect 1
Systematic nomenclature	SLC66A3	SLC66A4	SLC66A5
HGNC, UniProt	SLC66A3, Q8N755	CTNS, O60931	MPDU1, O75352
Comments	–	Exports cystine (cysteine disulfide) from the lysosomes into the cytoplasm. Acts as a cystine/H ⁺ symporter at a 1:1 stoichiometry [624]. Loss of function causes the monogenic systemic disease cystinosis [383, 727], characterized by intra-lysosomal cystine accumulation in all body cells and organs [197].	MPDU1 mutations cause congenital disorder of glycosylation type If (CDG-If) [425, 644].

Further reading on SLC66 Lysosomal amino acid transporters

Jézégou A *et al.* (2012) Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. *Proc Natl Acad Sci U S A* **109**: E3434-43 [PMID:23169667]

Kalatzis V *et al.* (2001) Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. *EMBO J* **20**: 5940-9 [PMID:11689434]

Kandasamy P *et al.* (2018) Amino acid transporters revisited: New views in health and disease. *Trends Biochem Sci* **43**: 752-789 [PMID:30177408]

Liu B *et al.* (2012) LAAT-1 is the lysosomal lysine/arginine transporter that maintains amino acid homeostasis. *Science* **337**: 351-4 [PMID:22822152]

Ruivo R *et al.* (2012) Mechanism of proton/substrate coupling in the heptahelical lysosomal transporter cystinosin. *Proc Natl Acad Sci U S A* **109**: E210-7 [PMID:22232659]

SLCO family of organic anion transporting polypeptides

Transporters → SLC superfamily of solute carriers → SLCO family of organic anion transporting polypeptides

Overview: The SLCO superfamily is comprised of the organic anion transporting polypeptides (OATPs). The 11 human OATPs are divided into 6 families and ten subfamilies based on amino acid identity. These proteins are located on the plasma membrane of cells throughout the body. They have 12 TM domains and intracellular termini, with multiple putative glycosylation sites. OATPs mediate the sodium-independent uptake of a wide range of amphiphilic substrates, including many drugs and toxins. Due to the multispecificity of these proteins, this guide lists classes of substrates and inhibitors for each family member. More comprehensive lists of substrates, inhibitors, and their relative affinities may be found in the review articles listed below.

Nomenclature	OATP1A2	OATP1B1	OATP1B3	OATP1C1
Systematic nomenclature	SLCO1A2	SLCO1B1	SLCO1B3	SLCO1C1
HGNC, UniProt	SLCO1A2, P46721	SLCO1B1, Q9Y6L6	SLCO1B3, Q9NPDS	SLCO1C1, Q9NYB5
Substrates	antibacterials, anticancer drugs, beta blockers, fluoroquinolones, HIV protease inhibitors, deltorphan II , rosuvastatin , bromsulphthalein , talinalolol , microcystin-LR [225], fexofenadine , ouabain	β -lactam antibacterials, anticancer drugs, HIV protease inhibitors, ACE inhibitors, bile acid derivatives and conjugates, endothelin receptor antagonists, opioids, sartans, statins, rifampicin , bromsulphthalein , fexofenadine , antifungals	β -lactam antibacterials, anticancer drugs, bile acid derivatives and conjugates, opioids, sartans, statins, erythromycin , rifampicin , bromsulphthalein , amanitin , digoxin , phalloidin , saquinavir , fexofenadine , ouabain	statins, bromsulphthalein

Searchable database: <https://www.guidetopharmacology.org/>

Full Contents of ConciseGuide: <http://onlinelibrary.wiley.com/doi/10.1111/bph.16182/full>

SLCO family of organic anion transporting polypeptides S462

Endogenous substrates	bile acids, steroid conjugates, thyroid hormones, bilirubin , PGE₂	steroid conjugates, thyroid hormones, leukotrienes, bilirubin , bile acids, coproporphyrin I [55], coproporphyrin III [55]	CCK-8 (CCK , P06307), bile acids, steroid conjugates, thyroid hormones, LTC₄ , bilirubin , coproporphyrin I [55], coproporphyrin III [55]	steroid conjugates, thyroid hormones
Ligands	–	pravastatin (Binding)	–	–
Inhibitors	rifamycin SV (pK _i 5) [757], rifampicin (pK _i 4.3) [757], naringin [43]	cyclosporin A (pK _i 7.3) [217, 393], estrone-3-sulphate (pI _{C₅₀} 7.2) [304], rifampicin (pK _i 6) [393], rifamycin SV (pK _i 5.7) [757], gemfibrozil [543], glycyrrhizin , indocyanine green	cyclosporin A (pI _{C₅₀} 6.1) [393, 729], sildenafil (pI _{C₅₀} 6.1) [729], rifampicin (pI _{C₅₀} 5.8) [393, 729], gemfibrozil , glycyrrhizin , rifamycin SV	DPDPE , probenecid , taurocholic acid
Labelled ligands	[³H]BSP , [³H]DPDPE , [³H]estrone-3-sulphate	[³H]estradiol-17β-glucuronide , [³H]estrone-3-sulphate	[³H]BSP , [³H]CCK-8 (human, mouse, rat), [³H]estradiol-17β-glucuronide	[¹²⁵I]thyroxine , [³H]BSP , [³H]estrone-3-sulphate
Comments	Although rat and mouse OATP1A4 are considered the orthologs of human OATP1A2 we do not cross-link to gene or protein databases for these since in reality there are five genes in rodents that arose through gene duplication in this family and it is not clear which one of these is the "true" ortholog.	Other inhibitors include, fibrates, flavonoids, glitazones and macrolide antibacterials. Estrone-3-sulphate or the drug substrates atorvastatin , pravastatin and rosuvastatin are used as a probe.	Other inhibitors include, HIV protease inhibitors, glitazones and macrolide antibacterials. CCK-8 is used as an OATP1B3-selective probe.	–

Nomenclature	OATP2A1	OATP2B1	OATP3A1	OATP4A1	OATP4C1
Systematic nomenclature	SLCO2A1	SLCO2B1	SLCO3A1	SLCO4A1	SLCO4C1
HGNC, UniProt	SLCO2A1 , Q92959	SLCO2B1 , O94956	SLCO3A1 , Q9UIG8	SLCO4A1 , Q96BD0	SLCO4C1 , Q6ZQN7
Substrates	synthetic prostaglandin derivatives	statins, telmisartan , glibenclamide , amiodarone , bosentan , bromsulphthalein , talinalol , aliskiren , fexofenadine	–	penicillin G	anticancer drugs, cardiac glycosides, dipeptidyl peptidase-4 inhibitors
Endogenous substrates	prostaglandins, eicosanoids	T₄ , dehydroepiandrosterone sulphate , coproporphyrin III [55]	BQ123 , thyroid hormones, prostaglandins, vasopressin (AVP , P01185)	bile acids, steroid conjugates, thyroid hormones, prostaglandins	steroid conjugates, thyroid hormones, cyclic AMP
Inhibitors	bromocresol green (Inhibition of PGF _{2α} uptake in PGT-expressing HeLa cells) (pK _i 5.4) [386] – Rat, bromsulphthalein (Inhibition of PGF _{2α} uptake in PGT-expressing HeLa cells) (pK _i 5.2) [386] – Rat	erlotinib (pK _i 6.3) [393], verlukast (pK _i 5.6) [393], gemfibrozil , glibenclamide , rifamycin SV , sildenafil [729]	–	–	–
Labelled ligands	[³H]PGE₂ (Binding) [111]	[³H]BSP , [³H]estrone-3-sulphate	[³H]PGE₂ , [³H]estrone-3-sulphate	[³H]estrone-3-sulphate	[³H]digoxin
Comments	Other inhibitors include NSAIDs	Other inhibitors include glitazones and citrus juices	–	–	–

Further reading on SLCO family of organic anion transporting polypeptides

- Hagenbuch B *et al.* (2013) The SLCO (former SLC21) superfamily of transporters. *Mol Aspects Med* **34**: 396-412 [PMID:23506880]
- Hillgren KM *et al.* (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. *Clin Pharmacol Ther* **94**: 52-63 [PMID:23588305]
- International Transporter Consortium *et al.* (2010) Membrane transporters in drug development. *Nat Rev Drug Discov* **9**: 215-36 [PMID:20190787]

Further reading on SLC superfamily of solute carriers

- Al-Ali AAA *et al.* (2019) Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption. *Int J Pharm* **566**: 410-433 [PMID:31125713]
- Bhutia YD *et al.* (2016) SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. *Biochem J* **473**: 1113-24 [PMID:27118869]
- Colas C *et al.* (2016) SLC Transporters: Structure, Function, and Drug Discovery. *Medchemcomm* **7**: 1069-1081 [PMID:27672436]
- César-Razquin A *et al.* (2015) A Call for Systematic Research on Solute Carriers. *Cell* **162**: 478-87 [PMID:26232220]
- Lin L *et al.* (2015) SLC transporters as therapeutic targets: emerging opportunities. *Nat Rev Drug Discov* **14**: 543-60 [PMID:26111766]
- Minhas GS *et al.* (2020) Recent advances in understanding prodrug transport through the SLC15 family of proton-coupled transporters. *Biochem Soc Trans* **48**: 337-346 [PMID:32219385]
- Nałęcz KA. (2017) Solute Carriers in the Blood-Brain Barrier: Safety in Abundance. *Neurochem Res* **42**: 795-809 [PMID:27503090]

Further reading on Transporters

- Gyimesi G *et al.* (20225) Systematic in silico discovery of novel solute carrier-like proteins from proteomes *PLoS One* **17**: e0271062 [PMID:35901096]

- Lee HH *et al.* (2017) Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). *Br J Clin Pharmacol* **83**: 1176-1184 [PMID:27936281]
- Roth M *et al.* (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. *Br J Pharmacol* **165**: 1260-87 [PMID:22013971]
- Zamek-Gliszczyński MJ *et al.* (2018) Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. *Clin Pharmacol Ther* **104**: 890-899 [PMID:30091177]

- Neul C *et al.* (2016) Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. *Trends Pharmacol Sci* **37**: 904-932 [PMID:27659854]
- Nigam SK. (2015) What do drug transporters really do? *Nat Rev Drug Discov* **14**: 29-44 [PMID:25475361]
- Pedersen NB *et al.* (2016) Glycosylation of solute carriers: mechanisms and functional consequences. *Pflugers Arch* **468**: 159-76 [PMID:26383868]
- Perland E *et al.* (2017) Classification Systems of Secondary Active Transporters. *Trends Pharmacol Sci* **38**: 305-315 [PMID:27939446]
- Rives ML *et al.* (2017) Potentiating SLC transporter activity: Emerging drug discovery opportunities. *Biochem Pharmacol* **135**: 1-11 [PMID:28214518]
- Ural-Blimke Y *et al.* (2019) Structure of Prototypic Peptide Transporter DtpA from *E. coli* in Complex with Valganciclovir Provides Insights into Drug Binding of Human PepT1. *J Am Chem Soc* **141**: 2404-2412 [PMID:30644743]

References

1. Abbot EL *et al.* (2006) [16331283]
2. Abram M *et al.* (2022) [35984707]
3. Abramson J *et al.* (2009) [19631523]
4. Agu R *et al.* (2011) [21366347]
5. Aguirre P *et al.* (2005) [15667655]
6. Agulhon C *et al.* (2003) [12761825]
7. Akazawa T *et al.* (2018) [30135242]
8. Albers A *et al.* (2001) [11692272]
9. Albrecht C *et al.* (2007) [16586097]
10. Alexander SP *et al.* (2021) [34529826]
11. Alexander SPH *et al.* (2019) [31710713]
12. Alghamdi O *et al.* (2021) [33404911]
13. Alghamdi OA *et al.* (2022) [35386060]
14. Almqvist J *et al.* (2004) [15260472]
15. Altmann SW *et al.* (2004) [14976318]
16. Amara SG *et al.* (1993) [8103691]
17. Amick J *et al.* (2020) [31851326]
18. Anand BS *et al.* (2003) [12538834]
19. Anderson CM *et al.* (2008) [18599538]
20. Anderson CM *et al.* (2004) [15521011]
21. Anderson CM *et al.* (2009) [19074966]
22. Anderson CM *et al.* (2010) [19789362]
23. Anderson CM *et al.* (2005) [15754324]
24. Andrini O *et al.* (2008) [18989094]
25. Angers M *et al.* (2008) [18694395]
26. Ansermet C *et al.* (2017) [27799484]
27. Aouameur R *et al.* (2007) [17932225]
28. Apparsundaram S *et al.* (2000) [11027560]
29. Apricò K *et al.* (2007) [17590480]
30. Apricò K *et al.* (2004) [14994336]
31. Apricò K *et al.* (2001) [11389172]
32. Arakawa H *et al.* (2020) [32622809]
33. Armstrong D *et al.* (2014) [24414167]
34. Arriza JL *et al.* (1993) [8101838]
35. Ashikov A *et al.* (2005) [15911612]
36. Assaraf YG *et al.* (1998) [9525913]
37. Aubrey KR *et al.* (2000) [10860934]
38. Auerbach SS *et al.* **DrugMatrix**. Accessed on 02/05/2014.
39. Azzi A *et al.* (1993) [8132491]
40. Babu E *et al.* (2003) [12930836]
41. Bagrov AY *et al.* (2009) [19325075]
42. Bailey CG *et al.* (2011) [21123949]
43. Bailey DG *et al.* (2007) [17301733]
44. Bakos E *et al.* (2007) [17187268]
45. Baldwin SA *et al.* (2005) [15701636]
46. Balimane P *et al.* (2000) [11180195]
47. Balimane PV *et al.* (1998) [9753615]
48. Ballatori N *et al.* (2005) [16317684]
49. Banerjee A *et al.* (2006) [16411770]
50. Banerjee S *et al.* (2018) [29401246]
51. Barnes K *et al.* (2006) [16873718]
52. Battini JL *et al.* (1999) [9990033]
53. Bayeva M *et al.* (2013) [23720443]
54. Bear PM *et al.* (2007) [17088867]
55. Bednarczyk D *et al.* (2016) [26383540]
56. Belanger AM *et al.* (2018) [30046012]
57. Bellocchio EE *et al.* (2000) [10938000]
58. Ben-Daniel R *et al.* (2008) [18487050]
59. Bergeron R *et al.* (1998) [9861038]
60. Birmingham Jr JR *et al.* (2002) [12451123]
61. Betz H *et al.* (2006) [16417482]
62. Bhardwaj RK *et al.* (2006) [16289537]
63. Bhardwaj RK *et al.* (2005) [15901802]
64. Bhat BG *et al.* (2003) [12810816]
65. Bianchi J *et al.* (1986) [3945643]
66. Biegel A *et al.* (2005) [15974593]
67. Biegel A *et al.* (2006) [16868651]
68. Bissonnette P *et al.* (2004) [15181167]
69. Bizhanova A *et al.* (2009) [19196800]
70. Blackburn C *et al.* (2006) [16644217]
71. Blair BG *et al.* (2009) [19509135]
72. Blom TS *et al.* (2003) [12554680]
73. Bodmer D *et al.* (2002) [11912179]
74. Boday S *et al.* (2005) [15659399]
75. Boehringer Ingelheim. **opnMe.com**. Accessed on 16/09/2020.
76. Böhmer C *et al.* (2005) [15804236]
77. Borden LA *et al.* (1994) [7874447]
78. Borden LA *et al.* (1994) [7851497]
79. Borst P *et al.* (2007) [16586096]
80. Boscutti G *et al.* (2018) [29570944]
81. Boudker O *et al.* (2007) [17230192]
82. Boulay D *et al.* (2008) [18621075]
83. Bourgeois F *et al.* (2005) [15613375]
84. Bravo DT *et al.* (2005) [15979764]
85. Bravo DT *et al.* (2004) [15485505]
86. Bricker DK *et al.* (2012) [22628558]
87. Bröer A *et al.* (2002) [11850497]
88. Bröer A *et al.* (2009) [19657969]
89. Bröer A *et al.* (1999) [10537079]
90. Bröer A *et al.* (2006) [16185194]
91. Bröer A *et al.* (2000) [10698697]
92. Bröer S. (2006) [16540203]
93. Bröer S. (2008) [18400692]
94. Bröer S *et al.* (2008) [19033659]
95. Brown A *et al.* (2001) [11454468]
96. Burant CF *et al.* (1992) [1634504]
97. Burger S *et al.* (2011) [21742018]
98. Burns CM *et al.* (2011) [20719377]
99. Busch AE *et al.* (1996) [8643577]
100. Buyse M *et al.* (2001) [11714740]
101. Buyse M *et al.* (2003) [14578196]
102. Byrne JA *et al.* (2002) [12404239]
103. Cang J *et al.* (2010) [20877133]
104. Carland JE *et al.* (2013) [22978602]
105. Carr G *et al.* (2009) [19910700]
106. Carstea ED *et al.* (1997) [9211849]
107. Caulfield MJ *et al.* (2008) [18842065]
108. Caulfield WL *et al.* (2001) [11495577]
109. Cervený L *et al.* (2018) [30097436]
110. Cha SH *et al.* (2000) [10660625]
111. Chan BS *et al.* (1998) [9506966]
112. Chang MH *et al.* (2009) [19365592]
113. Chao EC *et al.* (2010) [20508640]
114. Charkoudian LK *et al.* (2012) *Medchem-comm* **3**: 926-931
115. Charrier L *et al.* (2006) [16568107]
116. Chavan H *et al.* (2015) [25623066]
117. Cheeseman C. (2008) [18477702]
118. Chen LQ *et al.* (2010) [21107422]
119. Chen NH *et al.* (2004) [12719981]
120. Chen SY *et al.* (2008) [18337460]
121. Chen Y *et al.* (2007) [17495125]
122. Chen Z *et al.* (2003) [12727219]
123. Chen ZQ *et al.* (2006) [16421098]
124. Chen ZS *et al.* (1999) [10570049]
125. Cheng C *et al.* (2019) [30953722]
126. Cheng Q *et al.* (2017) [28176326]
127. Chi H *et al.* (2017) [28280329]
128. Chiabrande D *et al.* (2012) [23187127]
129. Choi MK. (2012) [22644860]
130. Choi MK *et al.* (2015) [25011570]
131. Chong X *et al.* (1992) [1417961]
132. Christian WV *et al.* (2012) [22535958]
133. Chu XY *et al.* (2001) [11602669]
134. Clausen RP *et al.* (2006) [17175818]
135. Coady MJ *et al.* (2007) [17526579]
136. Coady MJ *et al.* (2002) [12133831]
137. Coelho D *et al.* (2012) [22922874]
138. Cohen-Kfir E *et al.* (2005) [15829583]
139. Colleoni S *et al.* (2008) [18451317]
140. Colton CK *et al.* (2010) [20508255]
141. Coon *et al.* (2004) Society for Neuroscience:
142. Counillon L *et al.* (1993) [8246907]
143. Covitz KM *et al.* (1996) [8956326]
144. Craddock AL *et al.* (1998) [9458785]
145. Cuboni S *et al.* (2014) [25318072]
146. Curtis NJ *et al.* (2017) [2950199]
147. Dai T *et al.* (2016) [26811678]
148. Dai W *et al.* (1999) [9882430]
149. Dalton TP *et al.* (2005) [15722412]
150. Daniels G *et al.* (2015) [25896650]
151. Danthi SJ *et al.* (2019) [30589598]
152. Darcel NP *et al.* (2005) [15930458]
153. Davies JP *et al.* (2000) [10783261]
154. Dawson PA *et al.* (2005) [15563450]
155. Dawson PA *et al.* (2009) [19498215]
156. de Carvalho FD *et al.* (2011) [20980265]
157. De Domenico I *et al.* (2007) [17077321]
158. De Domenico I *et al.* (2005) [15956209]
159. Dean M *et al.* (2001) [11441126]
160. Delpire E *et al.* (2009) [19279215]
161. Demaegd D *et al.* (2013) [23569283]
162. Demirel Ö *et al.* (2012) [22641697]
163. Dennis M *et al.* (2013) Patent number: US8535675 B2.
164. DeStefano GM *et al.* (2014) [24831815]
165. Dhar TG *et al.* (1994) [8057281]
166. Dhar TGM *et al.* (1996) *Bioorg Med Chem Lett* **6**: 1535-1540
167. Di Daniel E *et al.* (2009) [19607714]
168. Diaz GA *et al.* (1999) [10391223]
169. Dieck ST *et al.* (1999) [9888294]
170. Diez-Sampedro A *et al.* (2003) [13130073]
171. Dimmer KS *et al.* (2008) [17925330]
172. Divakaruni AS *et al.* (2013) [23513224]
173. Dodd JR *et al.* (2007) [17400549]
174. Doerge H *et al.* (2001) [11583593]
175. Dohán O *et al.* (2007) [18077370]
176. Dong H *et al.* (2002) [11916852]
177. Dong Z *et al.* (2013) [23339484]
178. Donovan A *et al.* (2005) [16054062]
179. Döring F *et al.* (1998) [9637710]
180. Dorwart MR *et al.* (2007) [17673510]
181. Draoui N *et al.* (2013) [24095010]
182. Du Y *et al.* (2018) [29890854]
183. Duffy SP *et al.* (2010) [20823265]

184. Dunlop J. (2006) [16368269]
 185. Dunlop J *et al.* (2006) [17017964]
 186. Dunlop J *et al.* (2003) [14517179]
 187. Dunlop J *et al.* (2005) [16014807]
 188. Dutta B *et al.* (1999) [10542220]
 189. Edington AR *et al.* (2009) [19875446]
 190. Edwards N *et al.* (2011) [20691150]
 191. Edwards N *et al.* (2018) [29058016]
 192. Efang SM *et al.* (1995) [7702637]
 193. Eiden LE *et al.* (2004) [12827358]
 194. Eiden LE *et al.* (2011) [21272013]
 195. Eliasof S *et al.* (2001) [11299317]
 196. Elliott AM *et al.* (2009) [19147539]
 197. Elmonon MA *et al.* (2016) [27102039]
 198. Ende S *et al.* (1999) [10486213]
 199. Edward V *et al.* (2008) [17712059]
 200. Engel K *et al.* (2005) [16099839]
 201. Enomoto A *et al.* (2002) [12024214]
 202. Erickson JD *et al.* (1993) [8245983]
 203. Erickson JD *et al.* (1996) [8643547]
 204. Erickson JD *et al.* (1994) [8071310]
 205. Eskandari S *et al.* (1997) [9341168]
 206. Esslinger CS *et al.* (2005) [16183084]
 207. Esslinger CS *et al.* (2005) [15670919]
 208. Etoja JL *et al.* (2010) [20303751]
 209. Eulenburg V *et al.* (2005) [15950877]
 210. Faergeman NJ *et al.* (1997) [9079682]
 211. Fan SJ *et al.* (2018) [29971004]
 212. Fan SJ *et al.* (2016) [26434594]
 213. Fang F *et al.* (2010) [20649839]
 214. Fattorini G *et al.* (2009) [19627441]
 215. Favari E *et al.* (2004) [15514211]
 216. Fazeli G *et al.* (2023) [36652947]
 217. Fehrenbach T *et al.* (2003) [14530907]
 218. Fei YJ *et al.* (2000) [10823827]
 219. Ferdinandusse S *et al.* (2015) [25168382]
 220. Ferguson SM *et al.* (2004) [15173594]
 221. Ferguson SM *et al.* (2004) [14993474]
 222. Fernandes CF *et al.* (2007) [17632081]
 223. Fiermonte G *et al.* (2003) [12807890]
 224. Fiermonte G *et al.* (2009) [19429682]
 225. Fischer WJ *et al.* (2005) [15737679]
 226. Fleming MD *et al.* (2001) [11274051]
 227. Foley DW *et al.* (2018) [30006163]
 228. Foltz M *et al.* (2004) [15345686]
 229. Fontana AC *et al.* (2007) [17646426]
 230. Fontana AC *et al.* (2003) [12890709]
 231. Forrest LR *et al.* (2009) [19996368]
 232. Forster IC *et al.* (1999) [10198426]
 233. Foulquier F *et al.* (2012) [22683087]
 234. Fredriksson R *et al.* (2008) [18948099]
 235. Friesema EC *et al.* (2006) [16887882]
 236. Fromowitz M *et al.* (2007) [17228864]
 237. Fu Y *et al.* (2013) [23931754]
 238. Fujimoto Y *et al.* (1991) [1714740]
 239. Fujinami K *et al.* (2015) [25312043]
 240. Fujita T *et al.* (2004) [14715149]
 241. Fülep GH *et al.* (2006) [16766089]
 242. Gabernet L *et al.* (2005) [15555781]
 243. Gameiro A *et al.* (2011) [21641307]
 244. Gan Q *et al.* (2019) [31235480]
 245. Ganapathy ME *et al.* (1995) [7592745]
 246. Ganapathy ME *et al.* (1998) [9610386]
 247. Ganapathy ME *et al.* (1997) [9092716]
 248. Ganapathy V *et al.* (2008) [18446519]
 249. Ganapathy V *et al.* (2009) [18992769]
 250. Ganel R *et al.* (2006) [16274998]
 251. Gao E *et al.* (2020) [31863603]
 252. Garcia-Calvo M *et al.* (2005) [15928087]
 253. Garzel B *et al.* (2014) [24335466]
 254. Gasnier B. (2000) [10865121]
 255. Gasnier B. (2004) [12750892]
 256. Gebhardt FM *et al.* (2010) [20688910]
 257. Geissler S *et al.* (2010) [20104847]
 258. Geissler S *et al.* (2010) [20067523]
 259. Gendreau S *et al.* (2004) [15265858]
 260. Gengo PJ *et al.* (2005) *J Urol* **173**: Abstract 878
 261. Geyer J *et al.* (2007) [17491011]
 262. Geyer J *et al.* (2008) [18355966]
 263. Geyer J *et al.* (2004) [15020217]
 264. Gillberg P-G *et al.* (2017) Patent number: US9694018B1.
 265. Gillberg P-G *et al.* (2013) Patent number: US20130225511A1.
 266. Gimeno RE *et al.* (2003) [12556534]
 267. Giovannini D *et al.* (2013) [23791524]
 268. Girijashanker K *et al.* (2008) [18270315]
 269. Gleeson JP *et al.* (2017) [28315445]
 270. Gleeson JP *et al.* (2018) [29684535]
 271. Godoy JR *et al.* (2007) [17628207]
 272. Gomez J *et al.* (2006) [16722246]
 273. Gomez J *et al.* (2003) [14622582]
 274. Gomez J *et al.* (2003) [14622583]
 275. Gong Y *et al.* (2017) [28465466]
 276. Gong Y *et al.* (2017) [28943923]
 277. Gopal E *et al.* (2005) [15651982]
 278. Gorboulev V *et al.* (1997) [9260930]
 279. Gourdon B *et al.* (2017) [28705621]
 280. Gourdon B *et al.* (2018) [29803721]
 281. Goursaud S *et al.* (2011) [21730107]
 282. Goytain A *et al.* (2007) [17166836]
 283. Goytain A *et al.* (2008) [18667602]
 284. Goytain A *et al.* (2005) [15713785]
 285. Goytain A *et al.* (2005) [15809054]
 286. Goytain A *et al.* (2005) [15804357]
 287. Graf J *et al.* (2005) [15714523]
 288. Grañé-Boladeras N *et al.* (2016) [27271752]
 289. Grañé-Boladeras N *et al.* (2019) [30521377]
 290. Greer WL *et al.* (1999) [10521290]
 291. Greinacher A *et al.* (2010) [20037594]
 292. Grewer C *et al.* (2005) [16128593]
 293. Grewer C *et al.* (2004) [15107471]
 294. Grewer C *et al.* (2005) [15834685]
 295. Groneberg DA *et al.* (2001) [11518682]
 296. Grozio A *et al.* (2019) [31131364]
 297. Gründemann D *et al.* (1999) [10385678]
 298. Gründemann D *et al.* (1998) [10196521]
 299. Grunewald M *et al.* (2000) [10734120]
 300. Gu H *et al.* (1994) [8125921]
 301. Gu HH *et al.* (1996) [8636118]
 302. Gu Y *et al.* (2019) [31244219]
 303. Guha S *et al.* (2021) [33923345]
 304. Gui C *et al.* (2010) [20448812]
 305. Guile SD *et al.* (2006) [16455256]
 306. Gunshin H *et al.* (1997) [9242408]
 307. Guo A *et al.* (1999) [10087037]
 308. Gupta D *et al.* (2013) [23244438]
 309. Gupta N *et al.* (2006) [16375929]
 310. Gupta SV *et al.* (2011) [21905667]
 311. Gupte A *et al.* (2009) [19097778]
 312. Hager K *et al.* (1995) [7537337]
 313. Häggglund MG *et al.* (2011) [21511949]
 314. Halestrap AP. (1975) [1156402]
 315. Hallén S *et al.* (1999) [10471288]
 316. Hamada T *et al.* (2008) [18670416]
 317. Hammond JR. (2000) [10763851]
 318. Hammond JR *et al.* (2004) [14634039]
 319. Hamouda NN *et al.* (2020) [33310703]
 320. Han H *et al.* (1998) [9706043]
 321. Han X *et al.* (2006) [16734743]
 322. Hannaert P *et al.* (2002) [11882915]
 323. Harvey RJ *et al.* (2008) [18707791]
 324. Hatanaka T *et al.* (2001) [11342143]
 325. Hatanaka T *et al.* (2000) [10930503]
 326. Hatanaka T *et al.* (2001) [11306607]
 327. Heinrich T *et al.* (2021) [34382802]
 328. Helias V *et al.* (2012) [22246506]
 329. Hellwig M *et al.* (2011) [21538757]
 330. Hemker MB *et al.* (2003) [12846905]
 331. Herdon HJ *et al.* (2010) [20691713]
 332. Herrera-Ruiz D *et al.* (2004) [15832510]
 333. Herzog S *et al.* (2012) [22628554]
 334. Hiasa M *et al.* (2014) [25355561]
 335. Hirschfield GM *et al.* (2013) [23583734]
 336. Ho AM *et al.* (2000) [10894769]
 337. Ho HT *et al.* (2011) [21816955]
 338. Hodges WT *et al.* (2022) [34973337]
 339. Hollingworth P *et al.* (2011) [21460840]
 340. Horiba N *et al.* (2003) [12590146]
 341. Hsu CL *et al.* (2012) [22174130]
 342. Hu Y *et al.* (2018) [29784761]
 343. Hu Y *et al.* (2014) [24548120]
 344. Hu Z *et al.* (2000) [10615129]
 345. Huang HC *et al.* (2005) [16134951]
 346. Huang S *et al.* (2009) [19074430]
 347. Hummel CS *et al.* (2011) [20980548]
 348. Ibberson M *et al.* (2000) [10671487]
 349. Ichida K *et al.* (2003) [12472777]
 350. Ichikawa Y *et al.* (2012) [22375032]
 351. Iharada M *et al.* (2010) [20566650]
 352. Inazu M *et al.* (2005) [16000150]
 353. Incecayir T *et al.* (2016) [26869437]
 354. Infante RE *et al.* (2008) [17989073]
 355. Infante RE *et al.* (2008) [17989072]
 356. Inoue T *et al.* (2017) [28410751]
 357. Irie M *et al.* (2001) [11454935]
 358. Ishida N *et al.* (1998) [9644260]
 359. Ishida N *et al.* (2005) [15607426]
 360. Ishida N *et al.* (1996) [9010752]
 361. Ishida N *et al.* (1999) [10393322]
 362. Ishida S *et al.* (2002) [12370430]
 363. Ismair MG *et al.* (2006) [17487240]
 364. Itagaki S *et al.* (2006) [16729224]
 365. Ito S *et al.* (2010) [20065018]
 366. Ito Y *et al.* (2001) [11527541]
 367. Iwamoto H *et al.* (2006) [17005849]
 368. Iwamoto T *et al.* (2006) [16973719]
 369. Iwao T *et al.* (2014) [23822979]
 370. Jappard D *et al.* (2010) [20660104]
 371. Jensen AA *et al.* (2009) [19161278]
 372. Jeong HJ *et al.* (2010) [20860669]
 373. Jézégou A *et al.* (2012) [23169667]
 374. Jiang D *et al.* (2009) [19797662]
 375. Jiang J *et al.* (2011) [20708631]
 376. Jiang Q *et al.* (2019) [31393124]
 377. Jin Y *et al.* (2019) [31681915]
 378. Jonas MC *et al.* (2010) [20826464]
 379. Jost N *et al.* (2013) [23647096]
 380. Ju P *et al.* (2004) [15031290]

381. Juge N *et al.* (2010) [20920794]
 382. Juge N *et al.* (2009) [19843525]
 383. Kalatzis V *et al.* (2001) [11689434]
 384. Kamiyama S *et al.* (2006) [16492677]
 385. Kamiyama S *et al.* (2003) [12716889]
 386. Kanai N *et al.* (1995) [7754369]
 387. Kanai Y *et al.* (2003) [14612154]
 388. Kanai Y *et al.* (2004) [14530974]
 389. Kanai Y *et al.* (1994) [8282810]
 390. Kanamori A *et al.* (1997) [9096318]
 391. Kang N *et al.* (2010) [20595384]
 392. Kang SY *et al.* (2010) [20637636]
 393. Karlgren M *et al.* (2012) [22541068]
 394. Karunakaran S *et al.* (2008) [18522536]
 395. Kato Y *et al.* (2017) [28720702]
 396. Kemp S *et al.* (2016) [27312864]
 397. Kemp S *et al.* (2011) [21488864]
 398. Kenda BM *et al.* (2004) [14736235]
 399. Kennedy DJ *et al.* (2005) [15644866]
 400. Kerr ID *et al.* (2011) [21175590]
 401. Khare P *et al.* (2010) [20225888]
 402. Kim K *et al.* (2011) [21792905]
 403. Kim KH *et al.* (2005) [15591059]
 404. Kim RB *et al.* (1999) [10565843]
 405. Kimura H *et al.* (2002) [11907186]
 406. Kinoshita H *et al.* (2020) [32884434]
 407. Klaassen CD *et al.* (2010) [20103563]
 408. Klitgaard H *et al.* (2007) [23484603]
 409. Knutsen LJ *et al.* (1999) [10479278]
 410. Knütter I *et al.* (2004) [14706812]
 411. Knütter I *et al.* (2009) [18824524]
 412. Knütter I *et al.* (2001) [11284702]
 413. Knütter I *et al.* (2008) [18173951]
 414. Kobayashi N *et al.* (2018) [29563527]
 415. Kobayashi T *et al.* (2014) [25238095]
 416. Koch HP *et al.* (2007) [17360917]
 417. Koch HP *et al.* (1999) [10570036]
 418. Koepsell H. (2013) [23506881]
 419. Kohajda Z *et al.* (2016) [27832106]
 420. Kolisek M *et al.* (2012) [22031603]
 421. Kommareddi PK *et al.* (2010) [20665236]
 422. Kory N *et al.* (2018) [30442778]
 423. Kottra G *et al.* (2013) [24744852]
 424. Kouji H *et al.* (2009) [19135976]
 425. Kranz C *et al.* (2001) [11733556]
 426. Krishnamurthy PC *et al.* (2006) [17006453]
 427. Krishnaswamy A *et al.* (2009) [19186169]
 428. Kristensen AS *et al.* (2011) [21752877]
 429. Ksander BR *et al.* (2014) [25030174]
 430. Kudo M *et al.* (2020) [31757425]
 431. Kung MP *et al.* (1994) [7855735]
 432. Kusuhara H *et al.* (1999) [10224140]
 433. Kvist T *et al.* (2009) [19275529]
 434. Labib PL *et al.* (2021) [33059124]
 435. Landowski CP *et al.* (2005) [16132363]
 436. Landowski CP *et al.* (2005) [15827340]
 437. Lapinsky DJ *et al.* (2011) [21129986]
 438. Larráyoz IM *et al.* (2006) [16837649]
 439. Larsen M *et al.* (2009) [19594759]
 440. Lau CL *et al.* (2011) [21309758]
 441. Leary GP *et al.* (2007) [17360916]
 442. Lee A *et al.* (2010) [20883814]
 443. Lee J *et al.* (2002) [11734551]
 444. Lee J *et al.* (2009) [19570976]
 445. Lee JY *et al.* (2016) [27144356]
 446. Lee S *et al.* (2018) [29589443]
 447. Lee SG *et al.* (2008) [18326497]
 448. Lee SH *et al.* (2008) [18269914]
 449. Lee YC *et al.* (2010) [20639396]
 450. Legati A *et al.* (2015) [25938945]
 451. Leier I *et al.* (1994) [7961706]
 452. Leray X *et al.* (2021) [34344826]
 453. Leung DDM *et al.* (2010) Patent number: WO2010065496 A1.
 454. Levy LM *et al.* (1998) [9822723]
 455. Lewis SE *et al.* (2001) [11470793]
 456. Li H *et al.* (2008) [17928635]
 457. Li M *et al.* (2006) [16434549]
 458. Li N *et al.* (2007) [17650074]
 459. Li T *et al.* (2020) [32540782]
 460. Lin P *et al.* (2008) [19061983]
 461. Lin X *et al.* (2009) [19032932]
 462. Lipovich L *et al.* (2002) [11943475]
 463. Liu B *et al.* (2012) [22822152]
 464. Liu H *et al.* (2008) [18983139]
 465. Liu W *et al.* (1995) [7756356]
 466. Liu Y *et al.* (2013) [23597791]
 467. Liu Z *et al.* (2008) [18037372]
 468. Liu Z *et al.* (2011) [21262302]
 469. Luzzi JP *et al.* (2006) [16950869]
 470. Longo N *et al.* (2016) [26828774]
 471. Lopachev AV *et al.* (2022) [34694500]
 472. Löscher W *et al.* (2016) [27752944]
 473. Lowe 3rd JA *et al.* (2003) [12657266]
 474. Lowe 3rd JA *et al.* (2009) [19410451]
 475. Lu X *et al.* (2016) [26494147]
 476. Luckner P *et al.* (2005) [15567297]
 477. Lühn K *et al.* (2001) [11326279]
 478. Lytton J *et al.* (1991) [1832668]
 479. Ma GG *et al.* (2019) [31700909]
 480. MacDonald L *et al.* (2002) [11895172]
 481. MacGrogan D *et al.* (1996) [8661104]
 482. Machtens JP *et al.* (2011) [21572047]
 483. Maciver B *et al.* (2008) [18256317]
 484. Madeo M *et al.* (2014) [25326386]
 485. Madsen KK *et al.* (2010) [20026354]
 486. Maemoto M *et al.* (2022) [35034442]
 487. Mak DO *et al.* (2006) [16131648]
 488. Malinen MM *et al.* (2019) [30481467]
 489. Mallack EJ *et al.* (2022) [35053399]
 490. Mallorga PJ *et al.* (2003) [12941372]
 491. Mandal A *et al.* (2016) [27543355]
 492. Manolescu AR *et al.* (2007) [17710649]
 493. Martens H *et al.* (2008) [19052203]
 494. Martínez-Sanz FJ *et al.* (2016) [26774037]
 495. Masuda S *et al.* (2006) [16807400]
 496. McIntire SL *et al.* (1997) [9349821]
 497. Meier PJ *et al.* (1997) [9398014]
 498. Meredith D *et al.* (1998) [9882198]
 499. Merlin D *et al.* (2001) [11375948]
 500. Merlin D *et al.* (1998) [9835627]
 501. Metzner L *et al.* (2005) [16126914]
 502. Meyer E *et al.* (2010) [20206334]
 503. Mezler M *et al.* (2008) [18815213]
 504. Michel V *et al.* (2009) [19357133]
 505. Michel V *et al.* (2006) [16636297]
 506. Mihalik SJ *et al.* (2002) [11980911]
 507. Milgrom K *et al.* (2006) [17062637]
 508. Mimura Y *et al.* (2017) [28089688]
 509. Mingorance-Le Meur A *et al.* (2013) [23962079]
 510. Minhas GS *et al.* (2019) [30602453]
 511. Mistrik P *et al.* (2012) [22890707]
 512. Mitsuoka K *et al.* (2008) [18344442]
 513. Miura N *et al.* (1996) [8889805]
 514. Miyabe J *et al.* (2019) [30833090]
 515. Miyaji T *et al.* (2011) [21781115]
 516. Miyake M *et al.* (2017) [28867741]
 517. Miyauchi S *et al.* (2004) [14966140]
 518. Miyazaki E *et al.* (2001) [11641397]
 519. Mladenova G *et al.* (2012) [22420844]
 520. Molinaro P *et al.* (2013) [23066092]
 521. Molotkov A *et al.* (2020) [32024310]
 522. Morgan RE *et al.* (2010) [20829430]
 523. Murakami Y *et al.* (2005) [16174808]
 524. Muraoka M *et al.* (2001) [11322953]
 525. Murata Y *et al.* (2021) [33334885]
 526. Nabulsi NB *et al.* (2005) [15781409]
 527. Nair TS *et al.* (2004) [14973250]
 528. Nakai Y *et al.* (2007) [17475902]
 529. Nakamura N *et al.* (2014) [24695226]
 530. Nakamura N *et al.* (2005) [15522866]
 531. Nakamura T *et al.* (2010) [20410607]
 532. Nakanishi T *et al.* (2001) [11243884]
 533. Nancolas B *et al.* (2016) [26831515]
 534. Nawata CM *et al.* (2015) [26423860]
 535. Neumann J *et al.* (2003) [12649372]
 536. Neumann J *et al.* (2004) [15128310]
 537. Newton H *et al.* (2020) [32938923]
 538. Newton JM *et al.* (2001) [11574907]
 539. Nguyen LN *et al.* (2014) [24828044]
 540. Nicolas JM *et al.* (2016) [26663401]
 541. Nielsen CU *et al.* (2021) [32835702]
 542. Nigam SK *et al.* (2018) [29847376]
 543. Noé J *et al.* (2007) [17470528]
 544. Nothmann D *et al.* (2011) [21127051]
 545. Nowikovsky K *et al.* (2004) [15138253]
 546. Nowikovsky K *et al.* (2007) [17541427]
 547. Noyer M *et al.* (1995) [8605950]
 548. Noyon D *et al.* (2001) [11279194]
 549. Núñez E *et al.* (2000) [10694221]
 550. O'Callaghan KM *et al.* (2010) [19875448]
 551. Ocheltree SM *et al.* (2004) [14600253]
 552. Oda K *et al.* (2010) [19900191]
 553. Oh J *et al.* (2018) [28815639]
 554. Ohta KY *et al.* (2006) [16928787]
 555. Okuda T *et al.* (2003) [12675135]
 556. Okuda T *et al.* (2000) [11068039]
 557. Omori Y *et al.* (2015) [25837937]
 558. Oppedisano F *et al.* (2010) [20599776]
 559. Oppermann H *et al.* (2019) [31073693]
 560. Ordovás L *et al.* (2006) [17065791]
 561. Otsuka M *et al.* (2005) [16330770]
 562. Otter M *et al.* (2017) [27903454]
 563. Oude Elferink RP *et al.* (2007) [16622704]
 564. Owen RP *et al.* (2006) [16840788]
 565. Ozvegy C *et al.* (2001) [11437380]
 566. Palacín M *et al.* (1998) [9790568]
 567. Pan CJ *et al.* (2011) [21949678]
 568. Pao SS *et al.* (1998) [9529885]
 569. Paytubi S *et al.* (2009) [19570978]
 570. Pearlman RJ *et al.* (2003) [12558979]
 571. Pérez-Siles G *et al.* (2011) [21574997]
 572. Perland E *et al.* (2017) [28878041]
 573. Perland E *et al.* (2017) [27939446]
 574. Perland E *et al.* (2016) [27272503]
 575. Perry KW *et al.* (2008) [18602930]
 576. Pestov NB *et al.* (2006) [16525125]
 577. Pfeffer SR. (2016) [27410046]
 578. Pillai SM *et al.* (2011) [21097500]

579. Pinard E *et al.* (2010) [20491477]
 580. Pinilla-Tenas J *et al.* (2003) [14502423]
 581. Pochini L *et al.* (2014) [24704252]
 582. Pondarré C *et al.* (2006) [16467350]
 583. Pondarre C *et al.* (2007) [17192398]
 584. Potelle S *et al.* (2017) [28270545]
 585. Potelle S *et al.* (2016) [27008884]
 586. Prasad PD *et al.* (1995) [7826387]
 587. Prasad PD *et al.* (2000) [10772912]
 588. Priebe W *et al.* (1998) [9647783]
 589. Pristupa ZB *et al.* (1994) [8302271]
 590. Qiu A *et al.* (2006) [17129779]
 591. Quamme GA. (2010) [19940067]
 592. Quanz M *et al.* (2018) [30115664]
 593. Quazi F *et al.* (2014) [24707049]
 594. Quigley JG *et al.* (2004) [15369674]
 595. Raffel DM *et al.* (2004) [15300361]
 596. Rainier S *et al.* (2003) [14508710]
 597. Rajadhyaksha AM *et al.* (2010) [21070897]
 598. Rajagopal A *et al.* (2008) [18418376]
 599. Rajgopal A *et al.* (2001) [11731220]
 600. Ravera S *et al.* (2007) [17494632]
 601. Reddy VS *et al.* (2012) [22458847]
 602. Rees EM *et al.* (2004) [15494390]
 603. Rehmman H. (2012) [22260657]
 604. Reid G *et al.* (2003) [12835412]
 605. Reith ME *et al.* (1996) [8878059]
 606. Rey MA *et al.* (2008) [18815190]
 607. Reyes N *et al.* (2009) [19924125]
 608. Rice AE *et al.* (2009) [19150361]
 609. Ripoché P *et al.* (2004) [15572441]
 610. Roberson SW *et al.* (2021) [33830084]
 611. Rogers S *et al.* (2003) [12914765]
 612. Rohm F *et al.* (2019) [31394017]
 613. Rohm F *et al.* (2019) [30521147]
 614. Romano A *et al.* (2010) [19913073]
 615. Romera C *et al.* (2007) [17213861]
 616. Rose EM *et al.* (2009) [19553454]
 617. Roshanbin S *et al.* (2014) [24530433]
 618. Rosowsky A *et al.* (2004) [15615544]
 619. Rotella DP *et al.* (2009) [19720528]
 620. Rothstein JD *et al.* (2005) [15635412]
 621. Rousseau F *et al.* (2008) [18815261]
 622. Rubio-Aliaga I *et al.* (2004) [14600155]
 623. Rühl A *et al.* (2005) [16041713]
 624. Ruivo R *et al.* (2012) [22232659]
 625. Ryan RM *et al.* (2007) [17435767]
 626. Ryan RM *et al.* (2004) [14982939]
 627. Sager G *et al.* (2012) [22380603]
 628. Sagné C *et al.* (2001) [11390972]
 629. Sahni J *et al.* (2013) [23506895]
 630. Said HM. (2009) [19056639]
 631. Said HM *et al.* (1989) [2911998]
 632. Saier MH *et al.* (2009) [19022853]
 633. Saito K *et al.* (2010) [21190592]
 634. Sakata K *et al.* (2001) [11336635]
 635. Sala-Rabanal M *et al.* (2006) [16627568]
 636. Sala-Rabanal M *et al.* (2008) [18367661]
 637. Salazar G *et al.* (2009) [19521526]
 638. Salojin KV *et al.* (2011) [21346251]
 639. Sandoval A *et al.* (2010) [19913517]
 640. Sasawatari S *et al.* (2011) [21277849]
 641. Sawada K *et al.* (2008) [18375752]
 642. Sawada K *et al.* (1999) [10578127]
 643. Schaffer JE *et al.* (1994) [7954810]
 644. Schenk B *et al.* (2001) [11733564]
 645. Schiöth HB *et al.* (2013) [23506890]
 646. Schirmer SU *et al.* (2011) [21482687]
 647. Schlipf NA *et al.* (2010) [20461110]
 648. Schousboe A *et al.* (2011) [21428813]
 649. Schousboe A *et al.* (2004) [15451399]
 650. Secondo A *et al.* (2015) [25942323]
 651. Seidler NW *et al.* (1989) [2530215]
 652. Sekler I. (2015) [25998733]
 653. Semyanov A *et al.* (2004) [15111008]
 654. Sethi AA *et al.* (2008) [18805791]
 655. Seyffer F *et al.* (2015) [24923865]
 656. Shang P *et al.* (2017) [28083894]
 657. Shao J *et al.* (2016) [27669901]
 658. Shigeri Y *et al.* (2001) [11677257]
 659. Shimamoto K *et al.* (1998) [9463476]
 660. Shimamoto K *et al.* (2007) [17047096]
 661. Shimamoto K *et al.* (2000) [11078189]
 662. Shimokawa N *et al.* (2002) [12417639]
 663. Shintre CA *et al.* (2013) [23716676]
 664. Shu Y *et al.* (2007) [17476361]
 665. Sievert MK *et al.* (1997) [9325342]
 666. Singer D *et al.* (2009) [19478081]
 667. Singh N *et al.* (2010) [20601425]
 668. Singh SK *et al.* (2007) [17687333]
 669. Sloan JL *et al.* (1999) [10446133]
 670. Snyder NA *et al.* (2019) [30622138]
 671. Song F *et al.* (2017) [27836942]
 672. Song F *et al.* (2018) [29224352]
 673. Song X *et al.* (2005) [15804190]
 674. Sreedharan S *et al.* (2011) [21044875]
 675. Stahl A *et al.* (1999) [10518211]
 676. Stansberry WM *et al.* (2018) [30351207]
 677. Stauffer M *et al.* (2022) [36697632]
 678. Stecula A *et al.* (2017) [28661652]
 679. Stewart G. (2011) [21449978]
 680. Stieger B. (2009) [19684528]
 681. Sugawara M *et al.* (2000) [10824137]
 682. Sultan M *et al.* (2018) [28898457]
 683. Sun D *et al.* (2013) [23442152]
 684. Sun Y *et al.* (2018) [32104429]
 685. Sundaram M *et al.* (1998) [9705281]
 686. Supplisson S *et al.* (2002) [12354619]
 687. Suzuki H *et al.* (1998) [9875554]
 688. Suzuki T *et al.* (2005) [15994300]
 689. Swaan PW *et al.* (2008) [18474668]
 690. Tagoh H *et al.* (1996) [8630032]
 691. Tai W *et al.* (2013) [22950754]
 692. Tailor CS *et al.* (1999) [9927670]
 693. Tailor CS *et al.* (1999) [10400745]
 694. Takano M *et al.* (2022) [35110509]
 695. Takeuchi T *et al.* (2017) [28082679]
 696. Talaia G *et al.* (2021) [33597295]
 697. Talvenheimo J *et al.* (1983) [6853478]
 698. Tamai I *et al.* (1997) [9379359]
 699. Tamai I *et al.* (1998) [10189264]
 700. Tamarappoo BK *et al.* (1996) [8603078]
 701. Tandio D *et al.* (2019) [31537831]
 702. Tang L *et al.* (2012) [22085049]
 703. Taniguchi T *et al.* (2019) [31371478]
 704. Tanihara Y *et al.* (2007) [17509534]
 705. Tao W *et al.* (2017) [28070705]
 706. Tao W *et al.* (2018) [29471144]
 707. Tatsumi M *et al.* (1997) [9537821]
 708. Tavoulari S *et al.* (2022) [35278701]
 709. Tavoulari S *et al.* (2019) [30979775]
 710. Taylor NMI *et al.* (2017) [28554189]
 711. Tejada-Jiménez M *et al.* (2011) [21464289]
 712. Terada T *et al.* (2006) [16850272]
 713. Terada T *et al.* (1997) [9374833]
 714. Terada T *et al.* (1996) [8843163]
 715. Terada T *et al.* (2000) [10748266]
 716. Thangaraju M *et al.* (2006) [16873376]
 717. Thangaraju M *et al.* (2006) [17178845]
 718. Theis S *et al.* (2002) [11752223]
 719. Theis S *et al.* (2002) [11751927]
 720. Thompson BR *et al.* (2020) [32603666]
 721. Thomsen C *et al.* (1997) [9134205]
 722. Thwaites DT *et al.* (2007) [17123464]
 723. Thwaites DT *et al.* (2011) [21501141]
 724. Tollefson MB *et al.* (2003) [14552767]
 725. Torres-Salazar D *et al.* (2007) [17908688]
 726. Tóth A *et al.* (2002) [12054538]
 727. Town M *et al.* (1998) [9537412]
 728. Traiffort E *et al.* (2005) [15715662]
 729. Treiber A *et al.* (2007) [17496208]
 730. Tsai G *et al.* (2004) [15159536]
 731. Tse CM *et al.* (1993) [8415663]
 732. Tse CM *et al.* (1993) [7685025]
 733. Tsuda M *et al.* (2009) [19164462]
 734. Tsuji A. (1999) [10518656]
 735. Tsukaguchi H *et al.* (1999) [10331392]
 736. Tsume Y *et al.* (2008) [18652477]
 737. Tsume Y *et al.* (2008) [18719516]
 738. Uchida Y *et al.* (2009) [19122366]
 739. Uldry M *et al.* (2002) [12135767]
 740. Umapathy NS *et al.* (2004) [15290873]
 741. Ural-Blimke Y *et al.* (2019) [30644743]
 742. Ussar S *et al.* (2014) [25080478]
 743. Utsunomiya-Tate N *et al.* (1996) [8662767]
 744. van de Wiel SMW *et al.* (2018) [29675448]
 745. van Leeuwen EM *et al.* (2015) [25751400]
 746. van Roermund CW *et al.* (2008) [18757502]
 747. van Roermund CW *et al.* (2011) [21145416]
 748. Vandenberg RJ *et al.* (2004) [15324920]
 749. Vandenberg RJ *et al.* (1997) [9145919]
 750. Vandenberg RJ *et al.* (2007) [17383967]
 751. Vanderperre B *et al.* (2016) [27317664]
 752. Vanderperre B *et al.* (2016) [27176894]
 753. Vanslambrouck JM *et al.* (2010) [20377526]
 754. Varoqui H *et al.* (1996) [8910293]
 755. Vastermark A *et al.* (2014) [25043943]
 756. Vavricka SR *et al.* (2004) [15521010]
 757. Vavricka SR *et al.* (2002) [12085361]
 758. Verheijen FW *et al.* (1999) [10581036]
 759. Veruki ML *et al.* (2006) [17041592]
 760. Vig BS *et al.* (2006) [16759105]
 761. Vigueira PA *et al.* (2014) [24910426]
 762. Visser WE *et al.* (2010) [19682536]
 763. von Linde T *et al.* (2021) [34371711]
 764. Voss AA *et al.* (2007) [17110502]
 765. Wallgard E *et al.* (2008) [18483404]
 766. Wang C *et al.* (2013) [24021350]
 767. Wang CL *et al.* (2010) [20815935]
 768. Wang D *et al.* (2003) [14634667]
 769. Wang H *et al.* (1999) [10329687]
 770. Wang J. (2016) [27506881]
 771. Wang J *et al.* (2022) [35513259]
 772. Wang J *et al.* (2018) [30538473]
 773. Wang JZ *et al.* (2016) [26747400]
 774. Wang Q *et al.* (2006) [16707723]
 775. Wang XX *et al.* (2017) [27845049]
 776. Wang XX *et al.* (2018) [29305823]
 777. Wang Y *et al.* (2018) [29305856]
 778. Wang Y *et al.* (2019) [31254495]

779. Wang Y *et al.* (2020) [31931169]
780. Wängler B *et al.* (2004) [15380228]
781. Warraich S *et al.* (2013) [23184610]
782. Weinman SA *et al.* (1998) [9856990]
783. Wenzel U *et al.* (1998) [9843719]
784. Wenzel U *et al.* (1996) [8627565]
785. Westhoff CM *et al.* (2002) [11861637]
786. White C *et al.* (2013) [23395172]
787. White HS *et al.* (2005) [15550575]
788. Wiles AL *et al.* (2006) [16899062]
789. Wille S *et al.* (2001) [11698453]
790. Wilson BJ *et al.* (2014) [24934811]
791. Wojcik SM *et al.* (2006) [16701208]
792. Wolf S *et al.* (2002) [12049641]
793. Wong EH *et al.* (2000) [10812041]
794. Wreden CC *et al.* (2003) [12598615]
795. Wright EM *et al.* (2011) [21527736]
796. Wright EM *et al.* (2004) [12748858]
797. Wright NJ *et al.* (2019) [31235912]
798. Wu CA *et al.* (2004) [15140889]
799. Wu H *et al.* (2022) [35745853]
800. Wu Q *et al.* (2020) [31838184]
801. Wu SP *et al.* (2013) [23259992]
802. Wu X *et al.* (2002) [12504846]
803. Wu Y *et al.* (2013) [23678871]
804. Wu Y *et al.* (2019) [31408067]
805. Xi Z *et al.* (2022) [34864116]
806. Xiang J *et al.* (2006) [17034769]
807. Xu Q *et al.* (2014) [24184752]
808. Xu T *et al.* (2018) [29491707]
809. Xu T *et al.* (2016) [26940970]
810. Xu X *et al.* (2020) [31590850]
811. Xu X *et al.* (2018) [29615471]
812. Yabuki M *et al.* (2009) [19236841]
813. Yadav A *et al.* (2020) [32180718]
814. Yamada T *et al.* (2011) [21185344]
815. Yamamoto S *et al.* (2010) [20042597]
816. Yamamoto T *et al.* (1999) [10480349]
817. Yamamura N *et al.* (2022) [36170033]
818. Yamashita A *et al.* (2005) [16041361]
819. Yamashita K *et al.* (2016) [27480939]
820. Yamashita T *et al.* (1997) [9092568]
821. Yan Z *et al.* (2011) [21280612]
822. Yanagisawa H *et al.* (2003) [12815463]
823. Yao SY *et al.* (2011) [21795683]
824. Yao Y *et al.* (2010) [20463145]
825. Yasujima T *et al.* (2010) [20047987]
826. Ye X *et al.* (2003) [12670026]
827. Yee BK *et al.* (2006) [16554468]
828. Yernool D *et al.* (2004) [15483603]
829. Yoshida A *et al.* (2019) [31555743]
830. Yu XC *et al.* (2009) [19159658]
831. Yu Z *et al.* (2007) [17325024]
832. Yuri T *et al.* (2020) [32238712]
833. Zaia KA *et al.* (2009) [19147495]
834. Zander JF *et al.* (2010) [20519538]
835. Zelcer N *et al.* (2003) [12523936]
836. Zeng Z *et al.* (2008) [18355687]
837. Zerangue N *et al.* (1996) [8782106]
838. Zerangue N *et al.* (1996) [8857541]
839. Zerangue N *et al.* (1996) [8910405]
840. Zhang HX *et al.* (2009) [19433577]
841. Zhang J *et al.* (2019) [31450166]
842. Zhang L *et al.* (1998) [9655880]
843. Zhang Z *et al.* (2012) [22749870]
844. Zhao D *et al.* (2015) [26355221]
845. Zhao D *et al.* (2007) [17506977]
846. Zhao R *et al.* (2002) [11997266]
847. Zheng H *et al.* (2003) [14756423]
848. Zhou H *et al.* (2009) [19717468]
849. Zhou LM *et al.* (1997) [8996224]
850. Zhou M *et al.* (2010) [20592246]
851. Zhou M *et al.* (2007) [17600084]
852. Zhou W *et al.* (2010) [20448275]
853. Zhu HJ *et al.* (2010) [20402963]
854. Zhu L *et al.* (2009) [19632829]
855. Zidi-Yahiaoui N *et al.* (2009) [19553567]
856. Zimmermann M *et al.* (2010) [20868728]
857. Zimmermann M *et al.* (2010) [19612975]
858. Zipp GG *et al.* (2014) [25037917]
859. Zotova L *et al.* (2010) [20197279]
860. Zou S *et al.* (2011) [21426345]
861. Zuo Y *et al.* (2008) [18957418]